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Abstract 
Density Enhanced Protein Tyrosine Phosphatase-1 (DEP-1) is a receptor-like protein tyrosine 
phosphatase (PTP). It is also termed as HPTP, PTPRJ, PTP-RL9, rPTPRJ (rat homolog) and 
Byp or HPTP-like tyrosine phosphatase (murine homolog). The presence of the phosphatase 
domain on the intracytoplasmic tail of PTPRJ indicates its participation in signal transduction 
pathways, whereas the presence of fibronectin type III (FNIII) motifs in the structural 
arrangement of the extracellular domain, suggest its possible involvement in the process of 
cell adhesion.  
PTPRJ is widely expressed on the surfaces of haematopoietic cell lineages, vascular 
endothelial cells and duct epithelial cells. Growing evidence indicates that PTPRJ has a 
prominent role as a negative regulator of epithelial cell transformation and proliferation. 
Additionally, it was demonstrated that an antibody to PTPRJ inhibits monocyte chemotaxis in 
vitro implicating PTPRJ and its putative ligands in inflammation. A monoclonal antibody 
against the ectodomain sequence of PTPRJ inhibits endothelial-cell growth and blocks 
angiogenesis in mouse cornea in vivo. However, the mechanisms by which anti-PTPRJ 
inhibits monocyte chemotaxis and angiogenesis are largely unknown. Loss of heterozygosity 
of PTPRJ is observed frequently in the development of human meningioma, lung, breast and 
colon cancer, which further suggests a tumour suppressor function of this PTP.  
Since the availability of the monoclonal antibodies against the ECD region of PTPRRJ is 
very limited and due to the need for fully human or humanized antibodies that can have 
potential therapeutic applications, this project aims to isolate human and humanized 
monoclonal antibodies with high affinity and specificity to the extracellular domain motifs of 
mouse and human PTPRJ using phage display technology, and to use these antibodies as 
tools to investigate the function of PTPRJ in cell proliferation, differentiation, adhesion, 
spreading, wound healing and subsequently its role in inflammation. 
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CHAPTER 1 
 
Introduction 
 
1.1 Protein Tyrosine Phosphatases (PTPs):  
The protein tyrosine phosphatases (PTPs) represent a superfamily of enzymes that function in 
a coordinated manner in conjunction with protein tyrosine kinases (PTKs) to control signal 
transduction pathways in many physiological processes such as: cell growth and 
differentiation, cell cycle, metabolism, and cytoskeletal function. The extent of activation of 
kinases controls the magnitude of a signal, whereas regulated dephosphorylation by protein 
tyrosine phosphatases (PTPs) controls the rate and duration (Hornberg et al., 2005, Li and 
Dixon, 2000, Stoker, 2005, Tonks, 2006). Therefore, an imbalance between PTPs and PTKs, 
in the immune system, can have critical pathologic consequences, including diabetes, 
autoimmunity, malignancy and immunodeficiency (Hermiston et al., 2002). 
Recent estimates predict the presence of 107 PTPs that are encoded by the human genome 
(Figure 1.1) and they are well-defined by the active-site motif HC(X)5R, in which the 
cysteine residue works as a nucleophile and is vital for catalysis (Alonso et al., 2004, Tonks, 
2006). Of these 107 PTPs, 38 belong to the sub-group of ‗classical or tyrosine-specific PTPs‘ 
characterized by the prototypic member PTP1B in which the signature motif is ―(I/V) 
HCSxGxGR(S/T) G‖ .Other subgroups of PTPs includes: the Eya-family of PTPs, the dual-
specificity PTPs, low molecular weight PTP and cell division cycle 25 phosphatases  
(Soulsby and Bennett, 2009). 
Structurally, members of the classical PTPs family are classified broadly into two categories 
which consist of non-transmembrane PTPs that localize to the cytoplasm, or transmembrane 
receptor-like molecules (RPTPs) (Figure 1.2) (Moller, 2002). These can be further divided 
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into 17 major subtypes according to the amino acid sequence homology of their conserved 
PTP domains (Andersen et al., 2001). 
The function of PTPs can be regulated through the control of when and where they are 
expressed. Over the past decade, a variety of modification models of PTP regulation have 
been proposed including: Reversible oxidation; ligand binding; RPTP dimerisation; 
phosphorylation; cleavage and differential localization. 
 
 
Figure 1.1: The PTP superfamily. The figure shows some of the 107 members of the protein tyrosine 
phosphatase (PTP) superfamily, divided into four classes on the basis of the amino acid sequence of the 
catalytic domain. Obtained from (Julien et al., 2011). 
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Figure 1.2: Structure of classical PTPs. Schematic representation of the classical PTPs grouped as either 
receptor-like PTPs or non-transmembrane PTPs which contain various functional domains [BRO-1, 
BRO-1 homology; CAH, carbonic anhydrase-like; Cad, cadherin-like juxta membrane sequence; FERM, 
FERM (4.1/ezrin/radixin/moesin) domain; FN, fibronectin type III-like domain; Gly, glycosylated; HD, 
histidine domain; Ig, immunoglobulin domain; KIM, kinase-interacting motif; MAM, mephrin/A5/μ 
domain; Pro, proline-rich; RGDS, RGDS-adhesion recognition motif; SEC14, SEC14/cellular 
retinaldehyde-binding protein-like; SH2, Src homology 2]. Some of the receptor-like PTPs contain a 
membrane proximal PTP domain that is catalytically active and a membrane-distal PTP domain (PTP 
pseudo-phosphatase domain) that has residual activity. The non-transmembrane PTPs all contain a single 
PTP domain. Obtained from (Tiganis and Bennett, 2007).  
 
1.2 Catalytic mechanism of PTPs: 
PTPs have a highly conserved catalytic domain that comprises approximately 280 residues 
and is defined by the amino acid motif ―(I/V) HCXAGXGR(S/T)G‖ that presents near the 
carboxyl-terminus of the phosphatase domain in all PTPs sand functions as a phosphate 
binding loop at the active site. The cysteine and arginine residues within this motif are 
essential for the PTP activity (Andersen et al., 2001, Zhang and Dixon, 1993). The catalytic 
mechanism of PTPs has been obtained from the three-dimensional structural and kinetic 
studies of these enzymes. The active site cleft of the PTPs is surrounded by four loops, which 
contain residues essential for catalysis and substrate recognition. The catalytic mechanism is 
achieved in two steps and involves formation of a cysteinyl-phosphate intermediate followed 
by hydrolysis of the intermediate (Figure 1.3). In the first step, there is a nucleophilic attack 
on the phosphate by the sulphur atom of the thiolate ion of the catalytic cysteine residue 
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(Cys215 in PTP1B; Cys1240 in PTPRJ) to form the cysteinyl phosphate intermediate and an 
invariant protonated aspartic acid residue (Asp181 in PTP1B; Asp1205 in PTPRJ) in the 
flexible loop enhances cleavage of the P-O bond by acting as a general acid catalyst. This 
phosphor enzyme intermediate is then hydrolysed by a water molecule mediated by an 
invariant glutamine residue (Gln262 in PTP1B; Gln1283 in PTPRJ), and activated by the 
aspartic acid (Asp181 in PTP1B), which now functions as a general base, culminating in the 
release of phosphate (Tonks, 2006, Pannifer et al., 1998, Barford et al., 1998) 
Mutation in the catalytic residues that are involved in the catalytic steps causes a complete 
loss of the PTP activity and/or uniform reduction in the levels of tyrosine phosphorylation 
(Tiganis et al., 1997, Kuramochi et al., 1996). For instance, substrate trapping mutation of 
PTP1B (Asp 181Ala) turns the enzyme to the inactive form but allows the formation of stable 
phosphatase-substrate complexes, whereas substitution of glutamine for alanine (Glu262Ala) 
decreases the rate of cysteinyl-phosphate hydrolysis without affecting the rate of this 
formation. Moreover, substitution of the catalytic cystein residue for a serine (Cys215Ser) 
abolishes the formation of the cysteinyl-phosphate intermediate and the catalytic activity of 
the PTPs (Barford et al., 1998). 
 
 
Figure 1.3: Schematic representation of the catalytic mechanism of PTPs. The nucleophilic cysteine 
residue recognizes the phosphate of the target protein. The first step of the catalysis involves the 
nucleophilic attack on the phosphorylated target protein to form a phosphoenzyme intermediate. The 
second step involves the hydrolysis of the intermediate. Finally, the substrate is dephosphorylated and the 
nucleophilic cysteine restored for a new reaction. Adapted from (Tonks, 2006) 
 
. 
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1.3 Protein Tyrosine Phosphatase Receptor type J (PTPRJ): 
PTPRJ was the first tyrosine-specific PTP to be assigned a convincing role as a tumour 
suppressor in relation to the development of several human cancers. Positional cloning 
demonstrated that PTPRJ is the underlying mouse gene responsible for the susceptibility to 
colon cancer locus Scc1 (Ruivenkamp et al., 2002) and loss of heterozygosity at the human 
PTPRJ locus at 11p11-p12 was observed in 19 of the 39 human colorectal adenocarcinomas.  
PTPRJ is a Class III RPTP. It was first characterized in 1994 during the 6
th
 International 
Workshop and Conference on Human Leucocyte Differentiation Antigens (Ostman et al., 
1994) as a new membrane tyrosine phosphatase using the monoclonal antibodies 143.41 and 
A3 (Autschbach et al., 1999, Higashitsuji et al., 1995, Schraven, 2000). PTPRJ is the official 
gene name but it is also known as CD148, DEP-1 (Density Enhanced Protein Tyrosine 
Phosphatase-1), PTP-RL9, HPTP-η, Byp or HPTP -like tyrosine phosphatase (murine 
homolog) and rPTPRJ (rat homolog). Although the name ―DEP-1‖ has been used by many 
researchers, it is a misnomer since its expression is not always enhanced in all cell types as 
cell density increases and hence does not cause growth arrest (Ostman et al., 1994). 
The gene coding for this phosphatase was determined to be on the chromosome 11p11.2 in 
human (Honda et al., 1994) and region 2E of mouse chromosome 2 (Kuramochi et al., 1996, 
Borges et al., 1996). There is 95% amino acid sequence identity in the cytoplasmic regions of 
mouse and human PTPRJ, and 63% homology shared in the extracellular regions (Kuramochi 
et al., 1996). Immunoprecipitation and western blot experiments of PTPRJ from monocytes 
demonstrated an apparent molecular weight of 240 kDa, although minor differences have 
been observed depending on the type of cells that have been studied (Ostman et al., 1994). 
These differences could be due to a differential glycosylation of the molecules. 
Immunochemical characterization of PTPRJ confirmed that this molecule contains both O- 
and N-linked carbohydrates, with 34 potential sites for N-linked glycosylation as determined 
from its cDNA sequence (Ostman et al., 1994).  
This molecule contains an extracellular domain predicted to comprise eight to ten fibronectin 
type III repeats (FNIII), a transmembrane segment and an intra-cytoplasmic tail which 
contains a single PTP domain (Figure 1.4), making it unusual, since most receptor PTPs 
contain a tandem repeat of two cytoplasmic phosphatase domains. The presence of the 
phosphatase domain on the cytoplasmic tail of the protein indicates its involvement in signal 
transduction pathways, whereas the presence of the FNIII motifs in the extracellular domain 
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indicates a possible participation in cell adhesion processes (Gaya et al., 1999, Palou et al., 
1997).The PTP domain of PTPRJ contains a cysteine residue that is critical for its catalytic 
activity. When the cysteine residue is mutated to serine, the catalytic activity of PTPRJ is 
abolished (Sallee and Burridge, 2009). 
 
 
Figure 1.4: Schematic representation of human PTPRJ (CD148).  PTPRJ is a type III receptor-like PTP 
that consists of an extracellular region with a 36 amino acid leader sequence and eight fibronectin type III 
domains, a transmembrane domain, and a cytoplasmic tail consisting of a single PTP domain. Obtained 
from (Harrod and Justement, 2002). 
 
1.3.1 Expression of PTPRJ on haematopoietic and non-haematopoietic cells: 
PTPRJ is widely expressed in many cell types, including epithelial and endothelial cells, 
fibroblasts, and most haematopoietic cells. Outside the immune system, PTPRJ expression 
has been shown to be up-regulated in some cells when they are cultured at high cell density, 
as well as after cellular differentiation. In mice, PTPRJ is expressed primarily in platelets, B 
cells and myeloid lineage cells however, it is more restricted in the T cell lineage (Heddy, 
2007), as it is induced in peripheral T cells only after TCR activation. Transient expression 
has been noted in double-negative thymocytes as well.  By contrast, in humans, PTPRJ is 
widely expressed in mature thymocytes, peripheral T cells (with CD8+ T cells having higher 
levels than CD4+T cells), B cells, NK cells, granulocytes, macrophages, and certain DC 
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populations. The expression of PTPRJ on human peripheral T cells is further induced upon 
TCR stimulation (Lin et al., 2004, Acton, 2012). 
Evaluation of rat PTPRJ (rPTPRJ) expression by Northern blot revealed that rat PTPRJ 
transcripts are particularly high in the cerebellum, brain cortex, megakaryocytes and kidney 
cortex and somewhat less abundant in spleen, liver, placenta and lung, but are not present in 
all of the muscle tissues. Expression of rPTPRJ in endothelial cells is only detectable in 
vessels composed of both smooth muscular cells (SMC) and endothelium (Borges et al., 
1996). 
The Src family kinases (SFKs) play a critical role in ensuring communication between a cell 
and its extra-cellular environment in a haematopoietic cells. These non-receptor PTKs are 
located on the proximal position in numerous signaling transduction cascades including those 
transduced by the T and B cell antigen receptors, Fc receptors, growth factor receptors, 
cytokine receptors, and integrins. Additionally, SFKs function as negative regulators of 
cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) on inhibitory receptors, leading to the recruitment and activation of inhibitory 
molecules, which includes Src homology 2 (SH2) domain-containing phosphatase 1 (SHP-1) 
and SH2 containing 5‘- inositol phosphatase 1 (SHIP-1) (Holsinger et al., 2002). The ITIM-
containing inhibitory receptors G6b-B and PECAM-1 also become phosphorylated 
downstream of αIIbβ3 however, their exact contributions to αIIbβ3 signalling remain 
ambiguous. Both receptors associate with Shp1 and Shp2 following SFK-dependent 
phosphorylation of tyrosine residues within tandem ITIM/immunoreceptor tyrosine-based 
switch motif (Senis et al., 2014). 
1.3.2 Expression of PTPRJ in megakaryocyte lineage: 
Megakaryocytes are bone marrow-derived cells that produce blood platelets which are 
essential for normal blood clotting.  PTPRJ was identified as the only RPTP present on the 
platelet surface after global membrane proteomics analysis (Senis et al., 2007). A more recent 
study confirmed the expression of PTPRJ in human platelets by western blotting and flow 
cytometry (Senis et al., 2009). To investigate whether PTPRJ plays a role in regulating 
platelet function, PTPRJ loss-of-function transgenic and knock-out (KO) mice were 
generated. The study demonstrated that PTPRJ is responsible for platelet activation through 
major platelet surface receptors such as; ITAM, G protein–coupled receptors and integrin. In 
addition, PTPRJ is crucial in positive regulation of arterial thrombosis in vivo and 
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homeostasis. In vivo analysis of hemostasis and thrombosis indicate that PTPRJ plays an 
important physiologic function in preventing blood loss from sites of vascular injury. The 
structure of PTPRJ that includes the large extracellular domain and its unique function in 
platelets, make it an ideal target for development of a new class of antiplatelet agents (Acton, 
2012, Senis et al., 2009). 
1.3.3 PTPRJ as a marker for memory B cells: 
Naïve and memory B cells represent two important stages in the development of B 
lymphocytes and they are best described by the presence or absence of somatic hyper 
mutation in the IgV genes. There are no antigens on the surface of B cell that are able to 
make a distinction between these cell types. Recent studies nominated PTPRJ and CD27 as 
the possible memory B cell markers (Tangye et al., 1998, de la Fuente-Garcia et al., 1998, 
van Lier et al., 1987, Maurer et al., 1990). During B cell maturation to memory cells and Ig 
producing-cells and upon T cell activation, the expression of both PTPRJ and CD27 can be 
up-regulated (Maurer et al., 1992, Agematsu et al., 1999). Human splenic and circulated B 
cells could be separated into two subsets based on CD148 and CD27 expression (Tangye et 
al., 1998, Klein et al., 1998). CD148+ and CD27+ B cells in human spleen exhibit 
characteristics of memory B cells as assessed by their phenotype, localization within the 
marginal zone, their enhanced ability to differentiate into plasma cells and the presence of 
mutations in Ig V region gene. In contrast, CD27- and PTPRJ- cells had little or no IgV 
somatic hyper mutation and, thus, characteristically resembled naïve B cells. In agreement 
with these studies, both PTPRJ and/ or CD27 have been proposed as indicators of human 
normal memory B cells that are misrepresented in B cell malignancies such as non-Hodgkin‘s 
lymphomas B cell (Dong et al., 2002). 
1.3.4 PTPRJ positively and negatively regulates T-cell receptor signalling: 
In the hematopoietic lineage, PTPRJ inhibits signalling downstream of the T cell receptor.  
Similar to CD45, PTPRJ activates and inhibits the Src family kinases (SFKs) engaged in 
signalling of T-Cell Receptor (TCR). However, in the absence of CD45, stimulating effects 
exist, leading to functional complementation of CD45 deficiency in human T cell lines 
(Shirish, 2012). This is significantly independent of PTPRJ C-terminal tail tyrosines; 
conflicting the newly suggested phosphotyrosine displacement model as a mechanism of SFK 
activation by PTPRJ. Collectively, differential effects of PTPRJ in T cells and other 
leukocyte subsets are explained by its dual inhibitory/activatory function and specific 
expression pattern (Mak, 1998). 
9 
 
Analysis of PTPRJ expression on lymphoid cells demonstrates that PTPRJ is expressed at 
low levels in T cells and up regulated in response to activation. Several groups have observed 
that PTPRJ negatively controls T cell stimulation in response to cross linking of its antigen 
receptor, as an important factor in feedback inhibition of the T cell immune response  (Tonks 
(Tonks et al., 2006). In the B cell compartment, expression of PTPRJ is limited to the 
memory sub-population, increasing its likelihood to provide exclusive roles mainly in these 
cells. PTPRJ interacts with the PDZ domain-containing protein syntenin, suggesting that its 
function in T and B cells might involve interaction with PDZ domain-containing proteins 
(Heddy, 2007, Lin et al., 2004). 
T-cell antigen receptor (TCR) signalling resulting in T-cell stimulation includes regulation of 
several PTKs and phosphorylation of numerous substrates. Tyrosine phosphorylation is 
usually of extremely low stoichiometry in intact cells and is swiftly reversed because PTPs 
that eliminate phosphate from tyrosine-phosphorylated substrates have higher capacity than 
the PTKs (Holsinger et al., 2002). A moderate alteration in equilibrium between PTK/PTPase 
significantly impacts reversible tyrosine phosphorylation hence stimulating and propagating 
T-cells (Mak, 1998). 
The function of PTPRJ in leukocytes was initially analyzed by the expression of PTPRJ in a 
Jurkat T-cell line. These studies demonstrated that induced expression of PTPRJ led to 
selective dephosphorylation of phospholipase C gamma1 (PLCγ1) and linker for activation of 
T cells (LAT), resulting in down regulation of TCR-dependent signalling (Holsinger et al., 
2002, Lin and Weiss, 2003). However, it was not clear whether this was due to direct or 
indirect actions of the phosphatase, as it was also plausible that the phosphatase could 
activate a negative feedback loop resulting in activation of other phosphatases within the cell 
that then down-regulate the TCR response. Consistent with a potential role in termination of 
the immune response, immunofluorescence microscopy revealed that the extracellular 
domain of PTPRJ mediated its exclusion from the immunological synapse, sequestering it 
from potential substrates. It was proposed that upon T cell-antigen-presenting cell 
disengagement, PTPRJ could then access and dephosphorylate its relevant substrates, 
resulting in termination of prolonged TCR signalling (Lin, 2003). 
1.3.5 Role of PTPRJ in cells of the mononuclear phagocyte system: 
PTPRJ is expressed at high levels in macrophages and is further up-regulated by pro-
inflammatory stimuli (Osborne et al., 1998). Usually PTPRJ is restricted to the plasma 
membrane of macrophages and it regulates many signalling pathways leading to growth, 
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activation, differentiation, phagocytosis and adhesion cell function in these cells. (Nakamura 
et al., 2003).When stimulated by CSF-1 /LPS, there is accumulation and re-arrangement of 
PTPRJ in region of membrane ruffling. In addition, PTPRJ transcription is down-regulated in 
response to CSF-1whereas stimulating with LPS leads to an increase in its expression. 
Together, this suggested a role for PTPRJ in regulation of monocyte cell proliferation and/ or 
activation. Pre-treatment of bone marrow-derived macrophages (BMMs) with anti-PTPRJ 
monoclonal antibody repressed CSF-1-stimulated spreading of macrophage, chemotaxis and 
reorganization of the cytoskeletal without disturbing the total phosphotyrosine bands, the 
phospho-fms and phospho-Akt profile of PTPRJ antibody treated cells. These data suggested 
that PTPRJ is an important regulator of macrophage adhesion and spreading, which are the 
two key attributes important for inflammation. It also aids in regulation of several signalling 
pathways resulting to development, phagocytosis, differentiation and activation in 
macrophages (Dave et al., 2009). 
Src family kinases (SFKs) play a fundamental task in regulating the function of immune cells 
in disease because they are strategically located in several signal transduction cascades 
including those derived from cytokine receptors and integrin (Mak, 1998). PTPRJ functions 
redundantly with CD45 to regulate SFK activity in B cells and macrophages in 
immunoreceptor tyrosine-based activation motifs (ITAM) stimulation (Zhu et al., 2008). 
Whether CD45 and PTPRJ regulate other non-ITAM mediated signalling pathways such as 
GPCR-mediated responses have been investigated using neutrophil-responses to 
Staphylococcus aureus bacterial infection. It has been confirmed that CD45 and PTPRJ have 
critical and redundant functions in regulating neutrophil adhesion, phagocytosis, superoxide 
release and bacterial killing. Therefore, deficiency in either of these RPTPs influenced 
neutrophil-dependent bacterial clearance in the skin air pouch model (Zhu et al., 2011). 
1.3.6 Physiological functions of PTPRJ in non-haematopoietic cells: 
To date, a number of studies support the association between the expression of PTPRJ and 
cell density. In epithelial cell line, Ostman et al have observed that PTPRJ expression peaks 
at saturation cell density, therefore this phosphatase was originally named as DEP-1 (high 
cell Density Enhanced PTP 1) (Ostman et al., 1994). PTPRJ is known to regulate contact 
inhibition of cell growth that depends on hemophilic interaction with PTPRJ molecules on 
neighbouring cells. The expression of PTPRJ in migration and proliferating endothelial cells 
has found to be down-regulated following vascular injury and overexpression of PTPRJ in 
3T3 cells resulted in distinct morphological changes with a significant reduction in the ability 
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of the cells to adhere and spread. These findings further support the inhibitory role of PTPRJ 
in cell growth, signalling and propagation in non-hematopoietic cells (Borges et al., 1996, 
Kellie et al., 2004). 
PTPRJ was localized to regions of cell-cell contact and it was reported to interact with and 
dephosphorylate the prominent tight junction proteins (p120 catenin and β-catenin), occludin 
and ZO-1(Figure 1.5). In addition, decreasing the level of tyrosine phosphorylation by PTPRJ 
reduced the permeability of epithelial monolayers during the early stages of junction 
assembly. The action of PTPRJ on adherent and tight junctions suggests its role in protecting 
cells from oncogenic transformation and metastasis; controlling the stability and the strength 
of cell-cell interactions (Sallee and Burridge, 2009, Dejana, 2004). 
PTPRJ was investigated for its role in growth inhibition or induction of differentiation in 
breast cancer cells. It was demonstrated that overexpression of PTPRJ inhibits colony 
formation in three breast cancer cell lines (ZR57-1, SKBR-3 and MCF-7) and inhibits the 
growth of MCF-7 cells in vitro by 5-10 fold. However, the specific phosphotyrosines 
dephosphorylated by PTPRJ and the pathways through which it mediates the growth 
inhibitory effect remain to be characterized (Keane et al., 1996). In vitro and in vivo studies 
demonstrated that PTPRJ has a distinct apical localisation in mammary tissue and is regulated 
during murine mammary gland differentiation. Varying expression levels and patterns of 
intracellular distribution in oncogenic breast cell lines were identified. Additionally, over-
expression of PTPRJ in a mammary epithelial cell line inhibited in vitro differentiation which 
further suggests a role for PTPRJ in normal mammary gland development. These findings 
propose altered subcellular localisation of PTPRJ as an additional regulatory factor in normal 
breast biology and oncogenesis (Smart et al., 2012). To examine the role of PTPRJ in cell 
proliferation, ectopic expression of PTPRJ in NIH3T3 cells was performed and it was 
demonstrated that PTPRJ caused cell cycle arrest, with a dramatic reduction in the population 
of cells in the synthetic phase of the cell cycle under normal growth conditions. Quiesced 
NIH3T3 cells were stimulated with platelet derived-growth factor (PDGF) to further 
investigate the role of PTPRJ in proliferation responses and the results showed that induction 
of PTPRJ in fibroblasts did not increase cellular tyrosine phosphorylation in response to this 
stimulation compared to uninduced control cells (Kellie et al., 2004).  
Takahashi et al, and Trapasso et al, demonstrated using the antibody crosslinking that 
activation of PTPRJ was shown to inhibit cell cycle progression at G0/G1 phase. Inhibition of 
cell growth in this case was accompanied by an increase in p27kip1 protein levels, which is a 
cyclin dependent kinase (CDK) inhibitor, involved in the regulation of G1/S transition, a 
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decrease in ERK1/2 activity and induction of tyrosine dephosphorylation of PLCγ1 
(Takahashi et al., 2006, Trapasso et al., 2000, Iuliano et al., 2003). Another study by Brunner 
indicated that PTPRJ inhibited the VEGF-dependent activation of ERK1/2 in confluent 
endothelial cells, which in turn down-regulated the urokinase-type plasmingen activator 
(Herminghaus et al.), a central molecule for proangiogenic (Brunner et al., 2011). Paduano et 
al (Paduano et al., 2012) confirmed that binding of PTPRJ-interacting peptides to cell 
cultures significantly reduces the level of MAPK phosphorylation as well as total 
phosphotyrosine extent by inducing a significant increase of the cell cycle inhibitor 
p27kip1.Moreover, the physical interaction between EGFR and PTPRJ at the cell surface, 
maintains bidirectional enzyme-substrate interaction, which is relevant to their functions as 
monogenic and tumor suppressive (Tarcic et al., 2009). 
 
 
Figure 1.5: Inhibition of cell proliferation by PTPRJ. In confluent endothelial cells, vascular endothelial 
cadherin (VE-cadherin) is clustered at junctions and forms a complex with the vascular endothelial 
growth factor (VEGF) receptor-2 (VEGFR2). The phosphatase density enhanced protein-1 (DEP1; also 
known as CD148) associates with the complex, probably through p120 and beta-catenin, and 
dephosphorylates VEGFR2 (jagged arrow pointing towards VEGFR2). This phosphatase specifically 
targets tyrosine residues that, when phosphorylated, would recruit phospholipase Cγ (PLCγ; not shown) 
and signal proliferation through extracellular signal-regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK). Tyrosine residues in VEGFR2 that are required for activation of phosphatidylinositol 3-
kinase (PI3K) and AKT/protein kinase B (PKB) are not targeted. Obtained from (Dejana, 2004). 
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1.3.7 Ligand binding: 
Cellular adhesion to the extracellular matrix is an essential feature in developmental 
processes, inflammation, tissue repair and immune surveillance. The structural diversity of 
the extracellular domain of receptor-like PTPs suggests that it may be a target for binding of 
regulatory ligands. A mutant form of the extracellular domain of PTPRJ failed to respond to 
Matrigel
TM 
(a preparation of extracellular matrix proteins) stimulation, suggesting a possible 
role of the ligand for modulating PTPRJ activity (Sorby et al., 2001). The extracellular 
ligands of PTPRJ are still not well defined and to identify them, HA-tagged PTPRJ was 
introduced into cultured endothelial cells and its association with extracellular protein(s) was 
analysed using biotin surface tagging and successive purifications. Soluble thrombospondin-1 
(TSP1) was found to interact with the extracellular domain of PTPRJ with high affinity and 
specificity, and its binding enhanced PTPRJ catalytic activity. The study indicates that TSP1 
is a receptor for PTPRJ (Takahashi et al., 2012). Syndecan-4 (SD-4) is another ligand that 
mediates the inhibitory function of the highly-glycosylated dendritic antigen-presenting cells 
(DC-HIL) through the association with PTPRJ (Chung et al., 2011). A recent study proposed 
Syndecan-2 as a key novel ligand for PTPRJ (Whiteford et al., 2011). The pathway described 
in this study required PTPRJ signalling to β1 integrin via processes involving both 
dephosphorylation of the p85 subunit of phosphatidylinositol 3 kinase (PI3K) and the activity 
of the class II PI3K-C2β in a Src kinase–dependent process. This finding supports the role of 
PTPRJ in cytoskeletal organization and downstream β1 integrin-mediated adhesion 
(Whiteford et al., 2011). 
To date, several proteins have been identified as potential PTPRJ substrates. These include 
PDGFR, HGFR (c-Met), p120ctn, c-Src (C-terminal inhibitory tyrosine), VEGF receptor 2, 
EGF receptor, hepatocyte growth factor receptor (HGFR), FGF receptor, Erk1/2, 
phospholipase Cγ1 and P13K (Lunardi et al., 2002, Holsinger et al., 2002). Unfortunately, 
most of these putative substrates were identified using substrate trapping methodologies in 
vitro or overexpression approaches in cell lines and have not been validated in vivo (Lunardi 
et al., 2002). 
1.4 PTPRJ and diseases: 
Disturbance of the balance of PTK and PTP activities could lead to malignancy, 
immunodeficiency or autoimmunity, in view of the fact that joint regulation of tyrosine 
phosphorylation by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) 
is essential to normal immune cell function. 
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1.4.1 PTPRJ and cancer: 
PTPRJ is the first tyrosine-specific phosphatase to be identified as a tumour suppressor. Loss 
of PTPRJ expression was reported in human pancreatic tumours, human and rat thyroid 
tumours, colorectal cancer, lung cancer, breast cancer, hepatoblastoma, hepatocellular 
carcinoma and transitional cell carcinoma of the bladder (Table 1) (Borges et al., 1996, 
Keane et al., 1996, Lu et al., 1998, Luo et al., 2006, Trapasso et al., 2004, van der Bij et al., 
2005, Zhang et al., 1997). Frequent deletion, loss of heterozygosity (Troll et al.) and missense 
mutation in PTPRJ have been associated with development of carcinomas (Figure 1.6). 
 
PTP Cancer Type Alteration in cancer 
PTPRD 
Glioma, melanoma, CRC, head and 
neck 
Methylation, somatic mutation 
and micro-deletion in 5‘UTR 
PTPRG 
Head and neck 
Methylation, somatic mutation 
and LOH 
Breast, ovarian and lung Down-regulation 
PTPRJ 
Colon, breast and lung LOH and missense 
CRC SNP and LOH 
Thyroid SNP 
PTPRM Melanoma, glioma Down-regulation 
PTPRO Breast, lung, CRC Methylation 
 
Table 1.1: Receptor PTPs with potential tumour suppressor functions in cancer (Julien et al., 2011) 
 
r-PTPh gene (the rat homolog of human PTPRJ) is expressed in almost all normal mouse and 
rat tissues and cells. It was reported that r-PTPh gene expression was reduced in all 
oncogene-transformed cells and was absent from highly malignant thyroid cells. PTPRJ 
overexpression in a malignant rat thyroid cell line was found to induce dephosphorylation of 
the Src-inhibitory carboxyl phosphotyrosine and thus to increase Src activity. A further study 
on the thyroid cancer demonstrated that the expression of PTPRJ was dramatically reduced in 
a panel of human thyroid malignant neoplasias. This indicates that reduction in PTPRJ 
expression is a common event in human thyroid carcinogenesis. The r-PTPh gene was also 
found to suppress the malignant phenotype of rat thyroid cells transformed by retroviruses 
carrying the v-mos and the v-ras-Ki oncogenes, causing G1 growth arrest, by increasing the 
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cyclin-dependent kinase inhibitor p27Kip1 protein level. Therefore, it was proposed that r-
PTPh gene may act as a tumour suppressor gene (Trapasso et al., 2000). 
Positional cloning of a gene responsible for susceptibility to colon cancer (Scc1) in mice 
revealed PTPRJ orthologue as a major candidate gene. Sequence differences in PTPRJ 
between the cancer-susceptible and cancer-resistant strains were identified; supporting the 
theory that tumour-susceptibility is conferred by certain PTPRJ variants (Ruivenkamp et al., 
2003). Significant association between LOH of PTPRJ and loss of chromosome18q12–21 in 
progressed colorectal adenomas was reported. LOH of PTPRJ occurs early in progressed 
colorectal adenoma, whereas loss of chromosome 18q12–21 is a later event. Re-expression of 
active PTPRJ in a colon cancer cell line with suppressed PTPRJ highly inhibited cell 
propagation and relocation whereas; repression of PTPRJ in cell membrane of colon 
epithelial with endogenous levels of PTPRJ increased proliferation (Acton, 2012, 
Ruivenkamp et al., 2002, Ruivenkamp et al., 2003). The cancer resistance PTPRJ SNP 
(A1176C) is more frequently lost in tumours with PTPRJ LOH and it has been reported in 
breast tumours. This non-conservative substitution in the second fibronectin (FN III) repeat is 
assumed to prime a conformational change, possibly altering the normal protein function 
though, even with normal protein expression levels, a PTPRJ SNP could affect protein 
conformation, leading to altered PTPRJ normal function (Ruivenkamp et al., 2002, Smart et 
al., 2012). 
Sequence alignments, homology modelling and secondary structure prediction of PTPRJ 
indicate that the majority of amino acid substitutions are localized to the extracellular part of 
PTPRJ, which is potentially available for interactions with other proteins and ligands. 
Therefore, any amino acid polymorphisms may lead to alterations in the signalling events and 
hence predisposition to cancer (Ruivenkamp et al., 2002). The latest evidence reveals that 
PTPRJ could suppress tumours however; the tumour-suppressive function of PTPRJ remains 
incompletely understood. Answering how the PTPRJ enzyme normally functions may 
support the development of new anticancer drugs.   
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Figure 1.6: Schematic illustration of different mechanisms for protein-tyrosine phosphatase inactivation 
in cancer. a) Point mutations in the coding region of six different protein-tyrosine phosphatase (PTP) 
genes were found in coloncarcinoma and several other solid tumours. The most frequently affected gene 
is PTPRT, which encodes the receptor-like PTP PTPρ. Several of the PTPρ mutations have been 
predicted or shown to affect PTPρ-mediated cell–cell adhesion, or inhibition of cell proliferation, 
respectively. b) Allelic loss, but no point mutations, was found for PTPRJ — which encodes the receptor-
like PTP DEP1 — in different types of carcinoma. c) Promoter silencing of the SHP1-encoding gene, 
PTPN6, by methylation occurs frequently in lymphoma and leukaemia. In the figure, the promoter region 
and coding region of genes are indicated in yellow and blue, respectively. mRNA is symbolized in pink. At 
the PTP protein level, active states are in dark green and inactive states are in red. Obtained from 
(Ostman et al., 2006). 
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1.4.2 PTPRJ and inflammation: 
PTPRJ plays a significant regulatory role in the phosphorylation content of cells. PTPRJ is 
displayed on eosinophils and eosinophilic cell line EoL-3 and acts as a transduction molecule 
on these cells. PTPRJ is capable of stimulating degranulation and orientation of superoxide 
anion production triggered by vascular cell adhesion molecule 1 (VCAM-1) (Nagata et al., 
1995). Cross linking of PTPRJ is sufficient to stimulate the respiratory burst and release of 
cytotoxic proteins from eosinophil granules, for example, ECP and EPX. The significance of 
discharging these substances is supported by reality that these intermediaries are poisonous to 
tissues thus contributing to pathogenesis of asthma (Shirish, 2012). 
PTPRJ has been associated with an autoimmune disease, Cogan‘s syndrome which is a 
chronic inflammatory disease characterized by sensorineural hearing loss, keratitis and 
vasculitis (Lunardi et al., 2002). This was demonstrated by the presence of autoantibodies to 
PTPRJ in the patients, which inhibited proliferation of PTPRJ-expressing cells and replicated 
the features of Cogan‘s disease when infused into mice (Lunardi et al., 2002). 
1.5 Generation of antibodies by phage display 
Over the past few years, substantial effort has gone into manipulation of antibody molecules 
and genetic engineering. One importance of this research has been the use of filamentous 
phage as a vehicle on which to display antibody fragments. Since its introduction almost 20 
years ago by George P. Smith, phage display technology has revolutionized approaches to the 
analysis of biomedical problems, rapidly impacting the fields of immunology, pharmacology, 
cell biology, biotechnology, and drug discovery. 
Development of the technique made it possible for display of large protein and peptide 
libraries on the surface of the filamentous phage.  The presentation makes it possible to select 
proteins, peptides and antibodies, with high affinity and specificity to almost any target. The 
technology is grounded on genetic engineering of coat proteins of filamentous bacteriophages 
of E. coli such as M13, F1 or FD.  During the phage propagation, elongated phage particles 
assemble through polymerization of the major gene VIII coat protein, before being capped by 
the terminal gene III protein (Griffiths, 1993, Wirsching et al., 2003)  
1.5.1 Filamentous phage  
Bacteriophages are viruses which appear as thin and long filamentous particles containing 
circular single-stranded (ss) DNA (Figure 1.7). The actual length of the particle is determined 
by the length of the DNA it has encapsulated.  The filamentous phage belongs to a group of 
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related viruses which only infect gram-negative bacteria via specific adsorption to the tips of 
bacterial structures called F-pili. The F-pili are normally involved in the transmission of the F 
plasmid DNA, or chromosomal DNA containing the integrated plasmid DNA, from one 
bacterium to another.  Unlike other bacterial viruses, the filamentous phage does not kill its 
hosts, but rather induces a state in which the infected bacteria produce and secrete phage 
particles without undergoing lysis. Because of this non-lytic mode of release, it is possible to 
grow high-titre cultures of the virus and the growth curve of the filamentous phage will show 
a rapid increase of virus after a short latent period. The first progeny phage particles are 
released about 15 minutes after infection and the rate of production is exponential for the first 
60 minutes, after which it becomes linear as the bacteria enter stationary phase. The rate of 
production implies that roughly 1000 phage per bacterium are produced within the first hour 
after infection (Russel, 1991). 
 
 
 
1.5.1.1 Filamentous phage structure and life cycle  
Filamentous phage is virus that constitutes a large number of male-specific bacteriophage 
having similar size, shape, and lifecycle. The Ff filamentous phage particles (strains M13, f1 
and fd), are the most studied phage all of which infect E coli cells through their F pili. This 
Figure 1.7: Schematic diagram of a filamentous 
phage displaying single chain variable fragment 
(scFv) molecules. The phage consists of circular 
ssDNA surrounded by a coat protein. g8p (pVIII) is 
the major coat protein whereas g3p, at the tip of the 
phage, is one of the minor coat proteins. The genes 
encoding the variable domains of the scFv and a 
linker are fused to gene III (g3) in the genome of the 
filamentous phage. Consequently, the scFv is 
displayed as a fusion to g3p (pIII) protein at the tip of 
the phage. In reality, the scFv is not fused to all g3p 
protein molecules, and therefore the phage retains its 
ability to infect bacteria. Four g3p molecules are 
illustrated in the figure, three of which display scFv 
molecules. Obtained from (Azzazy and Highsmith, 
2002).  
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group of F-specific phage share 98% homology in their DNA sequence (Bradbury and Marks, 
2004). The phage particle has a filamentous shape of 930-nm in length, a diameter of 6.5-nm, 
and contains a circular single-stranded DNA genome (ssDNA) of about 6400 bp, packaged 
within five coat proteins named pVIII, pIII, pVI, pVII, and pIX (Figure 1.8). The filament 
tube is formed by the major coat protein, pVII1, which is a small protein of only 50 amino 
acids that wraps the phage DNA with 2800 of its copies arranged in a helical symmetry (Day 
et al., 1988, Rakonjac et al., 2011). 
The length of a virion is determined by the size of the DNA and its particular conformation as 
maintained by the capsid; inserting or deleting DNA is a simple way to control the length of 
the virion. When the phage DNA is extended as a result of DNA insertion, the number of 
pVIII copies increases to compensate for the increased length. While the wild-type Ff phage 
is normally ~900 nm long, the shortest virion that can be assembled is only 50 nm in length 
(Glucksman et al., 1992, Rakonjac et al., 2011).  
Additionally, there are five copies of pVII and of pIX that form a 30Å, plug structure at the 
proximal end of the virion which is the first part to cross the membrane when the phage 
leaves the host cell. These are two small hydrophobic peptides, 33 and 32 kDa, respectively, 
which play a part in the early stages of phage assembly, as they aid as a nucleus for the 
subsequent deposition of pVIII. In their absence, almost no phage particles are formed 
(Lopez and Webster, 1983, Russel, 1991). The distal end of the virion terminates with five 
copies of pIII and of pVI. These proteins are required for terminating the deposition of pVIII 
during phage assembly and for securing the phage to the bacterium pili (Russel, 1991). 
Negative staining of phage particles shows that pIII and pVI form a cylindrical shape with a 
pointed end, and pIII extends further as a thin protrusion (Specthrie et al., 1992). 
The filamentous phage is capable of infecting only male bacteria that carry the F sex pilus 
however, it does not produce a lytic infection in E. coli, but rather induces a state in which 
the infected bacteria produce and secrete phage particles without undergoing lysis. Infection 
is initiated by binding of the coat protein PIII to the sex pilus which results in retraction of the 
pilus and internalization of the phage (O'Neil and Hoess, 1995). The infected bacteria cannot 
produce sex pili which prevent infection of bacteria of more than one phage. A complex 
process takes place inside the cell where the phage is replicated. The replication is done in a 
controlled manner and infection with filamentous phage does not lead to death or lysis of the 
infected bacteria (Hong and Clayman, 2000). The infected bacteria continue to produce phage 
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on a continual basis. Assembly of the phage particles does not take place inside the cell. 
Instead, it occurs as the phage is extruded through the bacterial wall. The pIII and pVIII coat 
proteins are made with signal peptides that direct them to the periplasm of the Gram-negative 
E. coli. The other coat proteins contain hydrophobic sequences that lead to association with 
the inner membrane of the bacteria (Hammer et al., 1992). The phage ssDNA proceeds to the 
cytoplasmic face of the bacterial inner membrane by one of the phage control proteins (pV) 
and as it passes through the periplasm, it sheds pV and picks up the various coat proteins 
before it is released as complete virion into the medium (Azzazy and Highsmith, 2002). 
 
  
Figure 1.8: Schematic diagram of a filamentous phage. The phage particle has a filamentous shape of 
~930-nm in length, a diameter of ~6.5-nm, and contains a circular single-stranded DNA genome (ssDNA) 
of about 6400 bp, wrapped within five coat proteins named pVIII, pIII, pVI, pVI1, and pIX. Obtained 
from (http://www.asiyakm.yolasite.com/m13-vector.php.). 
 
1.5.1.2 Phagemid cloning vectors  
Phagemids, a more popular vector for display, are hybrids cloning vectors of phage and 
bacteria, as they contain the origins of replications for both the M13 phage and E. coli. 
Phagemids used for display also contain the gene for pIII, an antibiotic-resistance gene and 
appropriate multiple cloning sites (Mead and Kemper, 1988). However, they lack all other 
structural and nonstructural gene products required for creating a complete phage. Phagemids 
can be grown as plasmids and also can be packaged as recombinant M13 phage with the 
assistance of a helper phage that comprises a slightly defective origin of replication (such as 
VCSM13 or M13KO7) and supplies all the structural proteins required for creating a 
complete phage. This process is termed ―phage rescue‖ (Arap et al., 1998, Azzazy and 
Highsmith, 2002). 
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1.5.2 Antibody structure and fragments  
The basic structure of all antibodies consists of a pair of identical heavy chain polypeptides 
and a pair of identical light chain polypeptides joined together by disulphide bridges and 
noncovalent bonds. A full-size IgG antibody is a Y-shaped complex and each of the heavy 
chains in that complex is encoded for by: variable (VH), diversity (D), joining (JH), and three 
constant (CH) genetic fragments; while each of the light chains is encoded for by VL, JL, and 
one CL segments (Figure 1.9). The DNA and the amino acid sequences of the C region are 
relatively conserved within a given species while those of the V region are antigen-dependent 
(Natsume et al., 2009, Nelson and Reichert, 2009). 
Full-size antibodies can be fragmented by means of the genetic or chemical mechanisms. The 
chemical fragmentation involves use of reducing agents to break bonds within the hinge 
region. This is followed by digestion of the antibody with proteases including papain and 
pepsin. Genetic fragmentation, on the other hand, involve creation of a multitude of fragment 
containing molecules, each with unique binding and functional characteristics (Wirsching et 
al., 2003). 
Some of the most common fragments of an antibody include F (ab‘) 2, Fab‘ and Fv. All these 
fragments are antigen-binding fragments generated from the variable region of IgG and IgM 
and they vary in size (MW) and valency. Other than the binding antigen, there is an Fc 
content fragment which can be generated from heavy chain constant region of an 
immunoglobulin (Russel, 1991). 
Antibody fragments described in (Figure 1.10) include:  
(a) F(ab‘)2 Fragments: (110,000 Daltons) fragments comprise of two antigen-binding 
regions which are hinged through disulfides. 
(b) Fab‘ Fragments: (55,000 Daltons) fragments are obtained through chemical 
reduction of F (ab‘) fragments. Each fragment comprises a free sulfhydryl groups 
which are either be alkylated or utilized in conjugation with an enzyme, toxin or 
other proteins. Since it derived from F (ab‘) they sometimes contain a small 
portion of Fc. 
(c) Fab Fragments: (50000 Daltons) fragments are produced from IgM and IgG, 
consisting of the VL and CL of the light chain, and the VH and CH1 of the heavy 
chain linked by an intermolecular disulfide bond.   
22 
 
(d) scFv Fragments: (25,000 Daltons) are produced from IgM and IgG that contains a 
complete antigen-binding site. They are the smallest fragment produced from the 
IgM and IgG. They are similar to the Fab in regard to the binding properties and 
characteristics.  They have three-dimensional binding characteristics and binding 
properties like the Fab Fragment. The VL and the VH chains of these fragments 
are bound together by non-covalent interactions. Since the chain tends to break 
upon dilution, a method has been devised to cross-link the chain through peptide, 
Intermolecular and glutaraldehyde linkers. 
(e) "rIgG" Fragments: refers to reduced IgG (75,000 Daltons) or half-IgG. It is the 
product of selectively reducing just the hinge-region disulfide bonds. Although 
several disulfide bonds occur in IgG, those in the hinge-region are most accessible 
and easiest to reduce, especially with mild reducing agents like 2-
mercaptoethylamine (2-MEA). 
(f) Fc Fragments: (50000 Daltons) fragments comprises of CH3 and CH2 regions and 
part of the hinge region. The hinge regions are bound together by use of disulfides 
and non-covalent interactions. Like the other fragment of antibody, Fc fragments 
are produced from fragmentation of IgM and IgG. They are, however, produced 
from heavy chain constant region of an immunoglobulin. Unlike the other 
fragments, Fc fragments do not bind antigen. However, it is responsible for the 
effector functions of antibodies such as complement fixation (Greenwood et al., 
1991, Coulter and Harris, 1983, Nelson and Reichert, 2009). 
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Figure 1.9: Structure of human IgG1 antibody. The human IgG1 isotype consists of two immunoglobulin 
light chains and two immunoglobulin heavy chains. Heavy chains are covalently paired by disulfide bonds 
in hinge regions, and each heavy chain is connected to a light chain by a disulfide bond between CH1 and 
CL. A pair of VH and VL in Fab regions makes an antigen binding site. In the CH2 domains of Fc 
regions, an oligosaccharide is covalently attached to both domains at asparagine 297 (Asn-297). Obtained 
from (Natsume et al., 2009). 
 
Figure 1.10: Antibody fragments. Schematic representation of antibody fragments that can be generated 
by means of the genetic or chemical mechanisms. F(ab')2, Fab, Fab' and Fv are antigen-binding 
fragments that can be generated from the variable region of IgG and IgM. These antigen-binding 
fragments vary in size (MW), valency and Fc content. Fc fragments are generated entirely from the heavy 
chain constant region of an immunoglobulin. These and several additional unique fragment structures 
can be generated from pentameric IgM, including an "IgG"-type fragment, an inverted "IgG"-type 
fragment, and a pentameric Fc fragment. Modified from (Coulter and Harris, 1983). 
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1.5.3 Generation of monoclonal antibodies 
Monoclonal antibodies (mAb) are monospecific antibodies produced by in vivo or in vitro 
procedures or combinations thereof (Epstein and Epstein, 1986). Prior to production of 
antibodies, hybrid cells that will yield the antibodies are generated. The process starts with 
harvesting B-cells from the spleen of an animal (usually mouse) that has been challenged 
with the relevant antigen. These B-cells are then fused with myeloma tumour cells that can 
grow indefinitely in culture (Chronopoulou et al., 2014, 1986). The fused hybrid cells (called 
hybridomas) are immortal therefore; they will multiply rapidly and indefinitely and will 
produce large amounts of the desired antibodies (Hansel et al., 2010, Li et al., 1993, Asadi et 
al., 2008). The newly fused primary hybridoma cells can be grown indefinitely either in a 
suitable cell culture medium or by injecting into mice (in the peritoneal cavity, surrounding 
the gut) to produce tumours secreting an antibody-rich fluid called ascites fluid (Antibodies, 
1999, Hiatt, 1991, Horenstein et al., 1986). To isolate clones which are then characterised as 
monoclonal antibodies, these hybridomas have to be selected and subsequently cloned by 
limiting dilution using selective-media (Hiatt, 1991).  
These established methods in monoclonal antibody technology made it possible to generate 
murine antibodies, yet the use of these antibodies as human therapeutics was restricted by 
their immunogenicity in humans resulting in anti-idiotype antibodies (Richards et al., 1999, 
Kipriyanov and Little, 1999, Dekkers, 1985). In an effort to overcome this obstacle, 
approaches using recombinant DNA have been established since the late 1980s. One 
methodology is to merge mouse DNA encoding the binding portion of a monoclonal antibody 
with human antibody-producing DNA in living cells. The expression of this DNA through 
cell culture generated partially mouse, partially human monoclonal antibodies. To reflect the 
combination of mouse and human DNA bases used in the recombinant process, the 
descriptive term "chimeric" monoclonal antibody has been used (Chadd and Chamow, 2001). 
Considerable effort was devoted to genetically engineering monoclonal antibodies in order to 
make them less immunogenic. Technical advances have allowed the transition from mouse, 
via chimeric and humanized, to fully human mAbs (Figure 1.11). The reduction in 
immunogenic mouse sequences, led to mAbs having marked successes in the clinic
 
(Lonberg, 
2005, Reichert et al., 2005). 
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Figure 1.11: Schematic structure of the progressive development of monoclonal antibodies. From murine 
mAbs, to chimeric mAbs (with murine variable (V) regions grafted onto human constant (C) regions), to 
humanized (which consist of a human Ig scaffold with only the complementarity-determining regions 
(CDRs) being of murine origin), to the recently generated fully human mAbs. The CDRs within the Fab 
region of a mAb bind to specific targets and cause antagonism or signalling. The Fc region of a mAb is 
composed of the hinge and constant heavy-chain domains (CH2 and CH3) and has other functions, such 
as complement fixation or binding to Fc receptors. The nomenclature of mAbs reflects the type of mAb; 
for example, 'xi' in rituximab indicates that it is a chimeric mAb, 'o' is a mouse mAb, 'zu' is humanized 
mAb and 'u' is a human mAb. Obtained from (Hansel et al., 2010). 
 
1.5.4 Construction and screening of phage-displayed antibody libraries  
Recombinant phage antibody libraries can be constructed as either scFv or Fab antibody 
fragments from variable-region genes of lymphocyte cells of immunized or nonimmunized 
animals or humans (in vivo) or they can be synthesized (in vitro) (Figure 1.12). There are 
several types of phage display libraries such as protein libraries, peptide libraries and 
antibody libraries.  The type of the phage display library to be constructed depends on the 
application in which the library is intended (Longas et al., 2008, Gao et al., 1999). 
1.5.4.1 Construction of scFv phage display libraries  
The attempt to design and produce high throughput screening methods started in mid 1990s. 
A major advance was achieved when antibody libraries were made in phage display systems 
since the size and composition of the library was no longer restricted to the natural system 
(Burton, 1991). The effectiveness of the phage panning is that the essence of the natural 
antibody system can be replicated in phage by linking genotype and phenotype, which made it 
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possible to isolate highly specific antibodies to a range of structurally diverse antigens 
(Sheets et al., 1998, Winter et al., 1994).  
For phage display, the antigen-binding regions of VL and VH genes are cloned and used to 
construct scFv (or Fab) gene repertoires. A phage antibody library is created by cloning these 
repertoires as fusion proteins with a minor coat protein of bacteriophage (the gene 3 protein 
PIII). Each resulting phage has a functional antibody protein on its surface and encloses the 
gene encoding the antibody incorporated into the phage genome or phagemid vector (Figure 
1.13). Certain phage antibodies that specifically bind to proteins and small molecules can be 
separated from nonbinding phage antibodies with affinity chromatography techniques 
(Hoogenboom et al., 1991, Marks et al., 1991). The number and affinity of antibodies 
generated to a particular antigen will depend on the library size and diversity (Griffiths et al., 
1994, Vaughan et al., 1996). Libraries of larger than 10
8
 phage antibodies would increase the 
likelihood of recovering the original pairs of heavy and light chains expressed by the 
individual B-cells in vivo, thus yielding higher affinity antibodies (Vaughan et al., 1996). 
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Figure 1.12: Schematic representation of recombinant phage antibody libraries that can be generated in 
vivo and/or in vitro. Libraries can be constructed as either scFv or Fab antibody fragments from variable-
region genes of lymphocyte cells of immunized or nonimmunized animals or humans (in vivo) or they can 
be synthesized (in vitro). Obtained from (http://www.tradeget.com/listing/creative-biolabs/product-
services-detail/382790/300421/1/) 
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Figure 1.13: Construction of scFv phage display libraries. A synthetic scFv phage library is initially 
constructed from naive human B cells and contains up to a billion different specificities. Each specific, 
unique single-chain fragment of an antibody variable region is composed of a random combination of one 
variable region of immunoglobulin light chain (VL) mimicking the Fab of IgG. This schematic represents 
the phagemid vector containing the scFv-gIII fusion gene. This encodes a scFv-pIII chimeric protein, 
which is expressed on the surface of phage containing the modified vector. This chimeric protein interacts 
with antigens in a similar fashion as the Fab fragment of a normal antibody, allowing selection for 
binding specificities. Obtained from (Sharma et al., 2007). 
1.5.3.2 Types of antibody repertoires 
Antibody repertoires are collections of immunoglobulin (Ig) genes that encode heavy and 
light chains therefore; they provide a rich source for monoclonal antibodies (mAbs).  With 
regard to antigenic specificity, antibody repertoires can be obtained from in vivo sources and 
they are classified as immune and Naïve repertoires, or made artificially in vitro and they 
referred as transgenic and synthetic repertoires (Beerli and Rader, 2010). 
1.5.3.2.1 Naïve repertoires:  
Naïve repertoires are generated by tapping the natural primary unselected immune repertoire, 
from which antibody fragments with binding affinities to a wide range of antigens can be 
isolated (Ahrens, 2005). It involves harvesting the V genes from the IgM mRNA of B cells 
isolated from peripheral blood lymphocytes (PBLs), bone marrow, tonsils or spleen cells. 
Using specific primer sets and PCR, IgM and/or IgG variable regions are amplified and 
cloned into the vectors designed for selection and screening by affording a compartmental or 
physical linkage of phenotype (protein) and genotype (cDNA) (Beerli and Rader, 2010, 
Perelson and Oster, 1979). Monoclonal antibodies derived from naïve repertoires mostly have 
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lower affinities compared to mAbs from immune repertoires, but this limitation can be 
overcome by increasing the number of independent clones, thereby generating a larger 
antibody library of at least 10
8
 individual clones (Perelson and Oster, 1979, Beerli and Rader, 
2010, Vaughan et al., 1996, Sheets et al., 1998).  
1.5.3.2.2 Immune repertoires:  
Immune antibody libraries take benefit of the diversity created in vivo by the immune system: 
in this case the source of variable immunoglobulin genes are B-cells from an immune patient 
or an animal that been immunized with the antigen of interest therefore, immune libraries are 
obtained only against the set of antigens to which an immune response was induced (Yang et 
al., 1999, Vaughan et al., 1996). The antibody genes can be recovered from the B-cells by 
PCR and library selection or by fusion into a monoclonal cell line by hybridoma technology 
(Lewis and Crowe, 1993, Hoogenboom, 1997)  
The resulting libraries are enriched in antigen-specific immunoglobulin domains, some of 
which have already been matured by the immune system, and may therefore yield high-
affinity antibodies even when the library size is not as large as the naive ones; sufficient is 
10
6–7
 of different clones with unique and functional scFv´s (Galson et al., 2014, 
Hoogenboom, 1997).  
1.5.3.2.3 Synthetic repertoires 
In synthetic repertoires, variability is entirely created outside the natural host. Synthetic 
repertoires are generated by mutational modification of the CDR sequence of selected 
frameworks coding antibody variable domains. CDRs are modified by predetermined level of 
randomization. These repertoires are then cloned into an antibody domain framework and 
subcloned to phage display vectors to generate a library of about 10
7—
10
10
 clones (Villa et al., 
2008, Hoogenboom, 1997). 
There are also synthetic repertoires which are produced by selecting one or more antibody 
frameworks within the CDR loops. The CDR regions can be completely or partially designed 
from randomized oligonucleotides (Griffiths et al., 1994). 
The types of the synthetic repertoires can be constructed either with restricted V-gene usage 
or by all of the known V-gene segments of the species. High diversity in composition, 
structure and length is found particularly in the CDR3 VH, which significantly contributes to 
antigen-binding, making this particular CDR an attractive target for randomization.  Efficient 
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cloning system and a combination of the dual antibody cloning strategy allows construction 
of very large repertoires with about 10
9-11
 individual clones (Villa et al., 2008, Griffiths et al., 
1994). The main advantage of these repertoires over the naïve repertoires is that the local 
variability, contents and overall diversity can be controlled and defined. The main differences 
between the three repertoires are summarized in (Table 1.2) (Hoogenboom, 2002). 
 
Type of 
repertoire 
Advantages Disadvantages Main applications 
Immune 
 
 
 
High frequency of 
binders 
Library has to be rebuilt 
for each antigen 
Study of humoral response 
in disease (viral infections, 
cancer and autoimmunity) In vivo affinity 
maturation 
Bias against self-
antibodies 
 Antigen has to be 
immunogenic 
High-affinity diagnostic 
antibodies 
Na  ve 
Can be used against 
any antigen 
Has to be very large to 
obtain good affinities 
Selection of high-affinity 
human antibody for imaging 
or therapy 
Scaffold and 
somatic mutations 
selected by 
evolution 
Bias towards certain 
sequences and against 
self 
 
Synthetic 
Expand the 
structural scope of 
binding-site 
repertoires 
Has to be very large to 
obtain good affinities 
More suitable for use in 
automated selection and in 
microarray field (genomics 
or proteomics) 
Special ‗built-in‘ 
design possible for 
specific 
applications 
A high percentage of 
‗non-viable‘ sequences 
Immunogenicity? 
 
Table 1.2: Major differences between the three types of binding-site repertoires. Obtained from 
(Hoogenboom, 2002). 
 
 
 
 
31 
 
1.5.5 Selection of antibody libraries: Bio-panning 
The basic method for sequential affinity screening of the phage display libraries for specific 
binding phage from a large excess of non-binding clones is often referred to as ―biopanning‖ 
(Parmley and Smith, 1988). The phage antibody selection involves the immobilization of the 
ligand of interest on a solid support, followed by applying the phage display library (in the 
form of purified virions) in solution to it to allow binding of specific variants. To eliminate 
the adherent non-binders, multiple rounds of washing are performed, and what remains bound 
is eluted. Some unspecific binding of phage to the matrix surrounding the ligand occurs 
therefore; at least three rounds of panning are usually required in order to amplify the binding 
variants and to exclude the ―background‖ of non-specific binders (Figure 1.14) (Di Niro et 
al., 2010, Rakonjac et al., 2011, Lee et al., 2007). 
Several selection methods for the separation of the positive binders are available and that 
include selection using immobilized antigens, in vivo selection, selection using antigens and 
selection in cells.(Di Niro et al., 2010, Vaughan et al., 1996). 
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Figure 1.14: Schematic representation of phage panning. A phage library displaying potential binding 
sites on their surface is exposed to the target antigen, immobilized on a solid surface in this example (step 
1). After washing away unbound phages (step 2), binders are then eluted by infection and multiplication 
in E. coli (step 3). Clones are then amplified producing a phage mixture that is enriched with relevant 
(i.e., binding) phage (step 4). The repeated cycling of these steps is referred as ―panning‖. At the end of 3–
4 rounds of panning the enriched phage population is recovered by infection of a suitable bacterial host 
and sequenced to identify the interacting peptides or protein fragments. Obtained from (Tonelli et al., 
2012). 
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1.5.5.1 Selection using immobilized antigens 
Conventionally, biopanning has been achieved using an antigen absorbed on a plastic surface, 
such as immunotubes or enzyme immunoassay plates (Marks et al., 1991, Kang et al., 1991). 
Biopanning can also be performed using affinity chromatography by immobilizing the target 
antigen in a column (Griffiths et al., 1994, Garrard and Henner, 1993). The column will 
washed after that to eliminate the unspecific antibodies, and the bound specific phage 
antibodies are eluted from the column and amplified in E.coli cells. For affinity selection, 
BIAcore chip sensors can also be used as an antigen-binding medium (Malmborg et al., 
1996). One disadvantage of using this method for biopanning arises from the conformational 
stability of the antigen; since some selected phage antibodies against adsorbed antigens 
cannot bind the antigen in its native conformation (Sanna et al., 1995). 
1.5.5.2 Selection using antigens in solution.  
This method avoids the conformational changes of the antigen molecules often causes by 
immobilizing the antigen on a solid surface. The use of tagged soluble antigens to bind to 
antibodies in a solution allows accurate quantification of the antigen concentration (Hawkins 
et al., 1992), and minimizing the concentrations leads to selection of high affinity antibodies. 
After incubating the antibodies with an antigen conjugated with biotin, bound phage 
antibodies are separated using avidin magnetic beads or streptavidin-covered paramagnetic 
beads. The specifically bound phages can then be eluted from the antigen and characterized. 
A shortcoming of this method is the co-selection of anti-streptavidin antibodies. Incubation of 
the antibodies with streptavidin-covered beads so as to remove any streptavidin-specific 
antibodies can solve this problem (Ebersbach et al., 2012, Matz and Chames, 2012). 
1.5.5.3 Selection on cells 
Attempts have been made to target antigens in their native conformation at the surface of 
cells by means of directly selecting antibodies and peptides binding cell-surface receptors 
from phage libraries through incubation with entire cells  (Andersen et al., 1996, Barry et al., 
1996, Cai and Garen, 1995, de Kruif et al., 1995b).  
Direct panning on cell surface antigens can be achieved using either a cell monolayer or a cell 
suspension. Since antigens are normally in low concentration on the cell surfaces and in order 
to optimize the selection of antigen-specific antibodies and minimize the selection of 
nonspecific antibodies, a negative selection procedure can be completed before the positive 
selection (de Kruif et al., 1995a). Cells with the bound phage antibodies can be collected after 
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that using fluorescently labeled antibody specific to another antigen on the target cell surface. 
The cells are then collected by a FACS-sorter (Kupsch et al., 1999). 
1.5.5.4 In vivo selection 
In this selection, phage libraries are injected intravenously into an animal and then tissues are 
collected and examined for phage bound to tissue-specific endothelial cell markers 
(Pasqualini and Ruoslahti, 1996, Hong and Clayman, 2000). The technique, which was first 
established by Pasqualini, was initially used to isolate peptides that bind to cerebral vascular 
endothelium and renal in vivo. Later it was used for identification of receptors-ligand pairs in 
various body organs such as uterus, testiness, adrenal gland, lungs and kidney (Pasqualini and 
Ruoslahti, 1996, Tonelli et al., 2012). In vivo selection has a number of advantages. First, 
peptides displayed on the phage particles are isolated based on functionality, and will have 
overcome natural mechanisms of degradation. Second, peptides recognizing unspecific 
molecules are depleted from circulation. Third, this method proved to be able to identify 
receptors expressed selectively on tumour endothelium and these receptors may serve as 
molecular targets for the development of diagnostic techniques and targeted therapies.  
1.5.6 Reformatting of phage-displayed antibody fragments 
Phage display technology enables thousands of phage clones to be readily screened for 
antibodies with specificity to a target antigen (Hallborn and Carlsson, 2002). However, the 
functional evaluation of antibodies while still fused to the bacteriophage is limited and 
generally requires the re-engineering of phage clones to enable expression and purification of 
soluble recombinant antibody fragments (Chen et al., 2014). The antigen binding regions 
(variable heavy and light chain genes) of a positive phage binder can be conveniently 
reformatted into soluble antibody fragments or full monoclonal antibodies yet, when the final 
therapeutic format is whole immunoglobulin G (IgG), it is preferable that the antibodies are 
reformatted directly into IgG molecules and expressed in mammalian cells to enable 
comprehensive antibody characterization and to overcome lipopolysaccharide contamination 
from bacterial production which can interfere with in vitro cellular assays and in vivo 
functional screening (Chen et al., 2014).  
Antibody fragments isolated from phage display can be reformatted to whole 
immunoglobulins by using PCR to separately amplify the heavy and light chain variable 
regions from the phagemid vector, and cloning these into mammalian expression vectors 
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carrying the heavy and light chain constant regions, respectively, of the desired antibody 
isotype (Jones et al., 2010). 
1.5.7 Recent innovations in display technology  
The first report describing display of a foreign polypeptide on the surface of a bacteriophage 
particle dates from 1985 (Smith, 1985). Since then, phage display as a method for focused 
molecular evolution has tremendously influenced the work and discoveries done in the fields 
of immunology, cell biology, pharmacology and drug discovery. Numerous academic and 
industrial laboratories have adopted the technique and contributed to its advancement. 
Versatile library designs, display vectors and innovative screening strategies have been 
established to meet particular desires (Bass et al., 1990, McCafferty et al., 1990, Barbas et al., 
1991, Smith and Scott, 1993, Szardenings, 2003) 
Some essential applications that involve the use of phage technology include:  epitope 
mapping of antibodies (Rowley et al., 2004), in vitro development of antibodies (Conrad and 
Scheller, 2005, Hoogenboom, 2002) and antibody alternates in the form of randomized 
fragments on diverse scaffold proteins (Skerra, 2007, Gronwall and Stahl, 2009), screening 
for receptor agonists and antagonists (Schooltink and Rose-John, 2005, Lee et al., 2001, 
McConnell et al., 1998), discovery of inhibitors (Hawinkels et al., 2007, Kay and Hamilton, 
2001, Hyde-DeRuyscher et al., 2000) and enzyme substrates (Deperthes, 2002, Sedlacek and 
Chen, 2005), identifying functionally coupled proteins and analysis of protein–protein 
interactions (Sidhu and Koide, 2007, Hertveldt et al., 2009), improving proteolytic and 
folding stability of muteins (Jung et al., 1999), designing catalytic antibodies (abzymes) and 
enzymes with novel specificities (Fernandez-Gacio et al., 2003), construction of gene 
delivery vehicles (Sergeeva et al., 2006) and vaccine design (De Berardinis and Haigwood, 
2004, Manoutcharian et al., 2001). 
Taken together, the unlimited flexibility and applicability of this technique assert that an 
extensive range of life and material sciences will continue to benefit from phage display and 
all of the various associated technologies it has inspired in years to come. 
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1.6 Aims and Significance:   
The project described in this thesis endeavoured to characterise the biological function of the 
extracellular domain region of PTPRJ by isolating monoclonal antibodies that react 
specifically with the extracellular domains of mouse and human PTPRJ using phage display 
technology.  
We hypothesized that PTPRJ regulates motility in monocytes and proliferation and 
differentiation in epithelial and endothelial cells. We also hypothesised that extracellular 
cross-linking of PTPRJ modulates its intracellular phosphatase activity, resulting in altered 
cell function. Both hypotheses were impossible to be tested without the availability of 
specific antibodies against the ECD region of PTPTRJ. Therefore, the overall aims of this 
project were to isolate monoclonal antibodies specific to the ECDs of mouse and human 
PTPRJ using the phage display technology and to use these antibodies as tools to investigate 
the function of PTPRJ in diverse biological functions.    
The basic plan to fulfil these aims was to clone and express the ECDs of mouse and human 
PTPRJ and to use these recombinant ECDs as antigens for the biopanning procedure then, to 
reformate the positive selected clones from the phage panning as fully functional human or 
humanised antibodies and to use these reformatted antibodies as tools to characterize and 
investigate the potential function of the ECDs of mouse and human PTPRJ in different in 
vitro bioassays.  
 
 
 
 
 
 
 
37 
 
CHAPTER 2 
 
Cloning and expressing the extracellular 
domain of mouse and human PTPRJ 
 
2.1 Introduction 
PTPRJ is a Class III RPTP. This molecule contains an extracellular domain predicted to 
comprise eight to ten fibronectin type III repeats (FNIII), a transmembrane segment and an 
intracytoplasmic tail which contains a single PTP domain. The presence of the phosphatase 
domain on the cytoplasmic tail of the protein indicates its involvement in signal transduction 
pathways; whereas the presence of the fibronectin III motifs in the extracellular domain 
indicates a possible participation in cell adhesion processes (Gaya et al., 1999, Palou et al., 
1997).  
Cellular adhesion to the extracellular matrix is an essential feature in developmental 
processes, inflammation, tissue repair and immune surveillance. The structural diversity of 
the extracellular domain of receptor-like PTPs implicates that it may be a target for binding 
of regulatory ligands. A mutant form of the extracellular domain of PTPRJ failed to respond 
to Matrigel
TM 
(a preparation of extracellular matrix proteins) stimulation, suggesting a 
possible role of the ligand for modulating PTPRJ activity (Sorby et al., 2001). Soluble 
thrombospondin-1 (TSP1) was found to interact with the extracellular domain of PTPRJ with 
high affinity and specificity, and its binding enhanced PTPRJ catalytic activity. The study 
indicates that TSP1 is a receptor for PTPRJ (Takahashi et al., 2012). Syndecan-4 (SD-4) is 
another ligand that mediates the inhibitory function of the highly-glycosylated dendritic 
antigen-presenting cells (DC-HIL) through the association with PTPRJ (Chung et al., 2011). 
A recent study proposed Syndecan-2 as a key novel ligand for PTPRJ (Whiteford et al., 
2011).  
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To date, several proteins have been identified as potential PTPRJ substrates. These include 
PDGFR, HGFR (c-Met), p120ctn, c-Src (C-terminal inhibitory tyrosine), VEGF receptor 2, 
EGF receptor, hepatocyte growth factor receptor (HGFR), FGF receptor, Erk1/2, 
phospholipase Cγ1 and P13K (Lunardi et al., 2002, Holsinger et al., 2002).  Unfortunately, 
most of these putative substrates were identified using substrate trapping methodologies in 
vitro or overexpression approaches in cell lines and have not been validated in vivo (Lunardi 
et al., 2002, Du and Grandis, 2015, Takahashi et al., 2014). 
As yet, no human antibodies against the ectodomain of PTPRJ are available and the function 
of PTPRJ as a therapeutic target cannot be evaluated. In this thesis, I will describe a 
biopanning procedure for isolating antibodies that react specifically with the extracellular 
domain of mouse and human PTPRJ from naïve human Fab antibody libraries and from an 
immunised shark library. For this purpose, it was necessary to clone and express the extra 
cellular domains of both mouse and human PTPRJ to form the basis for the phage 
biopanning.  
Different vectors and expression systems were used to generate the recombinant ECD but 
only one method proved to give sufficient yield and quality of PTPRJ suitable for subsequent 
use as target antigens for phage library panning.  
2.2 Materials and Methods  
Several methods were used in an attempt to clone and express the extracellular domains of 
mouse and human PTPRJ. Nucleotide sequences of the ECDs were sub-cloned from full 
length PTPRJ templates into pGEM-T Easy vector to construct an intermediate vector and 
inserts were confirmed by PCR, sequencing and restriction enzyme digestion. After the 
validation of sequences, the correct clones were subsequently cloned into mammalian 
expression vectors pPyEBV and pcDNA3.1+, and into bacterial expression vector pMAL-
c2X. However, none of these strategies showed detectable levels of the ECD expression.  
The UQ Protein Expression Facility (PEF) was contracted to screen for the expression of the 
ECDs of mouse and human PTPRJ in three different bacterial expression systems. Full length 
templates were provided and pOPIN-MBP, pOPIN-NHis and pOPIN-Trx vectors were used 
for the cloning and the expression. Different expression conditions were tested and total and 
soluble fractions of different time points were analysed.  
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In addition, for mammalian expression, the ECD of mouse and human PTPRJ were cloned 
into pGene B vector designed for inducible expression.  
2.2.1 Identification of the ECD regions from the mouse and human PTPRJ full lengths. 
Mouse and human wild-type PTPRJ reference sequences were obtained from the NCBI 
database (http://www.ncbi.nlm.nih.gov/); accession numbers: NM_008982.4 and 
NP_002834.3 respectively. The extracellular, transmembrane and intracellular domains were 
identified using Simple Modular Architecture Tool (http://smart.embl-heidelberg.de/). 
(Figure 2.1)  and (Figure 2.2). 
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Mouse PTPRJ 
 
Name Start End  E-Value 
signal peptide 1 35 N/A 
FN3 40 112 0.00000285 
FN3 121 256 0.00000376 
FN3 268 345 0.0000456 
FN3 356 431 0.00000532 
FN3 442 520 2.19e-7 
FN3 529 605 0.05 
FN3 620 702 27.7 
transmembrane region 875 897 N/A 
PTPc 941 1201 3.37e-133 
 
 MKPAARETRTPPRSPGLRWALLPLLLLLRQGQVLCAGAAPNPIFDIEAVVSPTSVLLTWK 
HNDSGASECRIENKMESNLTFPVKNQTSCNITGLSPGTSYTFSIISVTTNETLNKTITTE 
PWPVSDLHVTSVGVTQARLTWSNANGTASYRMLIEELTTHSSVNISGLKPGTNNSFAFPE 
SNETQADFAVAEEVPDANGTKRIPVTNLSQLHKNSLVSVDPPSGQDPSLTEILLTDLKPD 
TQYNATIYSQAANGTEGQPRNKVFKTNSTQVSDVRAMNISASSMTLTWKSNYDGSRTSIV 
YKIHVAGGTHSVNQTVNKTEAIILGLSSSTLYNITVHPFLGQTEGTPGFLQVYTSPDQVS 
DFRVTNVSTRAIGLAWRSNDSKSFEIFIKQDGGEKHRNASTGNQSYMVEDLKPGTSYHFE 
IIPRGPDGTEGLSSTVNGSTDPSAVTDIRVVNISTTEMQLEWQNTDDASGYTYHLVLESK 
SGSIIRTNSSQKWITVGSLTPGTLYNVTIFPEVDQIQGISNSITQYTRPSSVSHIEVNTT 
TTTAAIRWKNEDAASASYAYSVLILKTGDGSNVTSNFTKDPSILIPELIPGVSYTVKILT 
QVGDGTTSLVPGWNLFCTEPEPVTSFHCEVVPKEPALVLKWACPFGMYTGFELGVRSDSW 
DNMTRLENCTSDDDTECRTEVAYLNFSTSYNISIATLSCGKMALPAQNICTTGITDPPTP 
DGSPNITSVSHNSVKVKFSGFEASHGPIKAYAVILTTGEAAQPSADVLKYTYEDFKRGAS 
DTYVTYLIRIEEKGQSQGLSEVLNYEIDVGNQSTTLGYYNGRLEPLGSYRACVAGFTNIT 
YNLQNDGLINGDESYVSFSPYSEAVFLPQDPGVICGAVFGCIFGALAITAVGGFIFWRKK 
RTDAKNNEVSFSQIKPKKSKLIRVENFEAYFKKQQADSNCGFAEEYEDLKLIGISLPKYT 
AEIAENRGKNRYNNVLPYDISRVKLSVQTHSTDDYINANYMPGYHSKKDFIATQGPLPNT 
LKDFWRMVWEKNVYAIVMLTKCVEQGRTKCEEYWPSKQAQDYGDITVAMTSEVVLPEWTI 
RDFVVKNMQNSESHPLRQFHFTSWPDHGVPDTTDLLINFRYLVRDYMKQIPPESPILVHC 
SAGVGRTGTFIAIDRLIYQIENENTVDVYGIVYDLRMHRPLMVQTEDQYVFLNQCVLDII 
RAQKDSKVDLIYQNTTAMTIYENLEPVSMFGKTNGYIA 
 
Figure 2.1: Identification of the ECD regions from mouse PTPRJ sequence. A) Domain architecture 
analysis by SMART (http://smart.embl-heidelberg.de/). B) Predicted domains, repeats, motifs and 
features of mouse PTPRJ. C) Full length Amino Acids Sequence of mouse PTPRJ. This sequence was 
obtained from NCBI (http://www.ncbi.nlm.nih.gov/). Domains identified in A and B are displayed on the 
sequence in C. Highlighted in yellow is the signal peptide, highlighted in grey is the extra cellular domain 
region. Fibronectin type three repeats are underlined and start of each repeat is indicated with red text. 
Highlighted in green is the transmembrane helix region and highlighted with pink is the Protein tyrosine 
phosphatase catalytic domain. 
A) 
B) 
C) 
41 
 
Human PTPRJ 
 
Name Start End  E-Value 
signal peptide 1 35 N/A 
FN3 119 196 0.00000248 
FN3 207 354 0.00718 
FN3 366 443 0.00272 
FN3 454 528 0.000241 
FN3 540 615 2.52e-7 
FN3 626 704 0.00000992 
FN3 719 801 55.3 
FN3 816 941 30 
transmembrane region 974 996 N/A 
PTPc 1040 1300 9.68e-134 
 
MKPAAREARLPPRSPGLRWALPLLLLLLRLGQILCAGGTPSPIPDPSVATVATGENGITQ
ISSTAESFHKQNGTGTPQVETNTSEDGESSGANDSLRTPEQGSNGTDGASQKTPSSTGPS
PVFDIKAVSISPTNVILTWKSNDTAASEYKYVVKHKMENEKTITVVHQPWCNITGLRPAT
SYVFSITPGIGNETWGDPRVIKVITEPIPVSDLRVALTGVRKAALSWSNGNGTASCRVLL
ESIGSHEELTQDSRLQVNISGLKPGVQYNINPYLLQSNKTKGDPLGTEGGLDASNTERSR
AGSPTAPVHDESLVGPVDPSSGQQSRDTEVLLVGLEPGTRYNATVYSQAANGTEGQPQAI
EFRTNAIQVFDVTAVNISATSLTLIWKVSDNESSSNYTYKIHVAGETDSSNLNVSEPRAV
IPGLRSSTFYNITVCPVLGDIEGTPGFLQVHTPPVPVSDFRVTVVSTTEIGLAWSSHDAE
SFQMHITQEGAGNSRVEITTNQSIIIGGLFPGTKYCFEIVPKGPNGTEGASRTVCNRTVP
SAVFDIHVVYVTTTEMWLDWKSPDGASEYVYHLVIESKHGSNHTSTYDKAITLQGLIPGT
LYNITISPEVDHVWGDPNSTAQYTRPSNVSNIDVSTNTTAATLSWQNFDDASPTYSYCLL
IEKAGNSSNATQVVTDIGITDATVTELIPGSSYTVEIFAQVGDGIKSLEPGRKSFCTDPA
SMASFDCEVVPKEPALVLKWTCPPGANAGFELEVSSGAWNNATHLESCSSENGTEYRTEV
TYLNFSTSYNISITTVSCGKMAAPTRNTCTTGITDPPPPDGSPNITSVSHNSVKVKFSGF
EASHGPIKAYAVILTTGEAGHPSADVLKYTYEDFKKGASDTYVTYLIRTEEKGRSQSLSE
VLKYEIDVGNESTTLGYYNGKLEPLGSYRACVAGFTNITFHPQNKGLIDGAESYVSFSRY
SDAVSLPQDPGVICGAVFGCIFGALVIVTVGGFIFWRKKRKDAKNNEVSFSQIKPKKSKL
IRVENFEAYFKKQQADSNCGFAEEYEDLKLVGISQPKYAAELAENRGKNRYNNVLPYDIS
RVKLSVQTHSTDDYINANYMPGYHSKKDFIATQGPLPNTLKDFWRMVWEKNVYAIIMLTK
CVEQGRTKCEEYWPSKQAQDYGDITVAMTSEIVLPEWTIRDFTVKNIQTSESHPLRQFHF
TSWPDHGVPDTTDLLINFRYLVRDYMKQSPPESPILVHCSAGVGRTGTFIAIDRLIYQIE
NENTVDVYGIVYDLRMHRPLMVQTEDQYVFLNQCVLDIVRSQKDSKVDLIYQNTTAMTIY
ENLAPVTTFGKTNGYIA 
Figure 2.2: Identification of the ECD regions from human PTPRJ sequence. A) Domain architecture 
analysis by SMART (http://smart.embl-heidelberg.de/). B) Predicted domains, repeats, motifs and 
features of mouse PTPRJ. C) Full length Amino Acids Sequence of human PTPRJ. This sequence was 
obtained from NCBI (http://www.ncbi.nlm.nih.gov/). Domains identified in A and B are displayed on the 
sequence in C. Highlighted in yellow is the signal peptide, highlighted in grey is the extra cellular domain 
region. Fibronectin type three repeats are underlined and start of each repeat is indicated with red text. 
Highlighted in green is the transmembrane helix region and highlighted with pink is the Protein tyrosine 
phosphatase catalytic domain. 
A) 
B) 
C) 
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2.2.2 Oligonucleotides and PCR amplification 
Primers were designed to amplify the coding region of the extracellular domains of human 
PTPRJ from the full length template in pGene B vector (kindly provided by Dr Dmitry A. 
Ovchinnikov, AIBN, UQ) and to include appropriate cloning restriction sites. Primer 
sequences to amplify the ECD of human PTPRJ and their expected product size are given in 
(Table 2.1). The ECD of mouse PTPRJ in pGene B was obtained from Dr Dmitry A. 
Ovchinnikov (AIBN, UQ) and used for expression without further modification.  
All oligonucleotides were synthesised by either Geneworks (Adelaide, Australia) or Sigma 
(Sydney, Australia). 
 
Target 
Sequence 
Primer 
direction 
 
 
Primer Sequence (5’ to 3’) Amplicon 
size (Rich 
et al.) 
ECD Human 
PTPRJ 
 
F 
 
GGTACCAAGCTTGCCGCCACCATGAAGCCGGCGGCGCGGGAGGC 
 
~2.8 kb 
R 
GCGGCCGCACCGGTCTAGTGATGGTGATGGTGATGCGATCCTCTT
CCACAGATGACACCTGGATCC 
 
Table 2.1: Oligonucleotides used to clone the ECD of human PTPRJ cDNA into pGene B. HindIII site 
and Kozak sequences were added to the forward primer. Flexible linker and His tag sequence were added 
to the reverse primer followed by a stop codon and AgeI and NotI sites. 
 
The PCR product of human ECD was amplified from full length template using Platinum® 
PCR SuperMix High Fidelity according to manufacturer‘s instructions. 50 μL reaction was 
prepared by combining 45 μL Platinum® PCR Super Mix High Fidelity (Life Technologies), 
forward and revers primers at 200 nM final concentration and 0.2 to 1 μg full length DNA 
template. Amplification reactions were performed in a DNA Engine (Applied Biosystems® 
Veriti® Thermal Cycler) using the following cycling: initial denaturation at 94°C for 2 min, 
then 30 cycles with denaturation at 94°C for 30s, annealing temperature at 55-60°C and 
extension at 68°C for 3 min. An additional extension cycle of 68°C for 7 minutes was also 
included. The PCR product was analysed by agarose gel electrophoresis. 
2.2.3 Agarose gel electrophoresis 
DNA was resolved and visualised using agarose gel electrophoresis. Agarose gels contained 
0.8 % agarose in 1x TAE buffer and 1:10,000 dilution of SYBR® Safe DNA Gel Stain (Life 
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Technologies). Samples were mixed with 1x loading buffer (New England Biolab) and run at 
90 to 100 volts for 30 min. DNA fragments were visualised in a UV transilluminator (Bio-
Rad, Hercules, CA, USA) and sizes estimated by comparison with 1 Kb HyperLadder 
(BioLine, Australia).  
To purify PCR products away from primers, nucleotides, polymerase and salt and to obtain 
concentrated DNA the QIAquick gel extraction kit (QIAGEN Pty Ltd, Doncaster, VIC, 
Australia) was used according to the manufacturer‘s instructions.  
2.2.4 Restriction digestion and ligation 
Restriction endonucleases HindIII and AgeI were supplied by New England BioLabs 
(Beverly, MA, USA) and used to digest the PCR product and the expression vector pGene B 
(kindly provided by Dr Matt Sweet, IMB, UQ) according to the manufacturer‘s instructions. 
DNA ligations were performed using Rapid DNA Ligation Kit (Roche, Indianapolis, USA) 
according to manufacturer‘s instructions. The ligation reaction contained 1:3 molar ratio of 
pGene B vector to the PCR insert and the ligation reaction incubated at room temperature for 
20 min then placed on ice for the E. coli transformation. 
2.2.5 E.coli transformation 
Transformation of E.coli was performed by the addition of 2-5 μL of a DNA ligation reaction 
to 50 μL aliquot of competent E. coli (One Shot® TOP10 Chemically Competent E. coli; 
Invitrogen) and incubated on ice for 30 minutes. Cells were heat shocked at 42°C for 45s and 
incubated on ice for 2 minutes to allow cell recovery. 250 μL of Luria Bertani (LB) medium 
(10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl) was added and cells were grown for 1 
hour at 37°C with shaking at 200 rpm. After incubation, cells were spread on LB-ampicillin 
agar plates (LB media with 15 % w/v Bacto-agar, containing 100 μg/mL of ampicillin) and 
incubated overnight at 37°C. 
2.2.6 PCR colony screening 
To determine the presence of the insert at the expected size, colony PCR was performed 
using GoTaq® Green Master Mix (Promega Corporation, U.S.A). 10 μL PCR reaction was 
prepared by mixing 5 μL Green Master Mix, 0.5 μL upstream primer (pGene forward primer 
at 10μM), 0.5 μL downstream primer ( pcDNA3.1/BGH reverse primer at 10 μM) and 4 μL 
Nuclease-Free Water. Single colonies from the plates were added to each reaction mix by 
picking the colonies with a sterile pipette tips and dipping them in the PCR mix. Tips were 
held in reserve in sterile 2 ml tubes to be used for miniprep cultures if insert was present by 
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PCR screening. PCR cycles were performed using the following conditions: initial 
denaturation at 95°C for 2 min, then 25 cycles with denaturation at 95°C for 15s, annealing 
temperature at 55-60°C and extension at 72°C for 3 min. An additional extension cycle of 
72°C for 7 minutes was also included. The PCR product was analysed by agarose gel 
electrophoresis as described in section 2.2.3 (Refer to P42)  and clones with the correct insert 
size at about 3kb were grown overnight in 5 mL LB media with Ampicillin. A PureLink® 
Quick Plasmid Miniprep Kit (Invitrogen) was used to purify high-copy plasmid DNA as per 
the manufacturer‘s specifications. 
2.2.7 Restriction enzyme analysis 
Restriction analysis of purified plasmid was conducted to confirm the presence of the insert. 
Restriction enzymes (HindIII and AgeI) from New England Biolabs, were used and the 
following reaction was prepared: 1 µl of 10X NEB CutSmart buffer, 200-500 ng of purified 
plasmid, 0.5 µL of HindIII enzyme, 0.5 µL of AgeI enzyme and sterile deionised water to 
10µl final volume. Reaction was incubated for 2h at 37C in a water bath and then loaded in 
1% agarose/ Syber Safe gel and run for 30 min at 90 V. 
2.2.8 DNA sequencing 
Positive constructs were sequenced using Sanger sequencing at the Australian Genome 
Research Facility (AGRF, The University of Queensland, Brisbane) to confirm that the ECD 
sequence was in frame with the C-terminal fusion His tag and that there were no PCR-
introduced mutation. The forward and reverse reactions were sent in 12 µl total volume (200 
ng of the purified plasmid and 0.5 µl of either 10 μM forward primer or 10 μM reverse 
prmer). Primers used for sequencing are detailed in (Table 2.2). Sequencing results were 
analysed using Sequencher 4.1 software.  
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Target 
Sequence 
 
Primer name 
 
Primer Sequence (5’ to 3’) 
E
C
D
 H
u
m
a
n
 P
T
P
R
J
 
 
PGene-F-primer CTGCTATTCTGCTCAACCT 
seqhDEP1-798    CAATACAACATCAACCCG 
seqhDEP1-1502   CATTGGTGGCTTGTTCCC 
seqhDEP1-2202   GCCCTGGTTCTCAAATGG 
seqhDEP1-F1b    ACAGGCTTACGTCCAGCG 
pcDNA3.1-R- primer TAGAAGGCACAGTCGAGG 
 
Table 2.2: Oligonucleotides used for sequencing. Internal sequencing primers were designed for Human 
PTPRJ at approximately 800 bp distance. 
 
2.2.9 Large scale plasmid DNA isolation 
Successfully sequenced clones from the human ECD of PTPRJ and the construct of the 
mouse ECD provided by Dr Dmitry A. Ovchinnikov (AIBN) in pGene B vector were then 
transformed into TOP10 chemically competent cells. 1 µl of each plasmid DNA were added 
to a thawed vial of 50 µl TOP10 cells and mixed gently. Cells were then incubated on ice for 
30 min and then heat-shocked for 45 seconds at 42°C without shaking. Immediately, tubes 
were transformed to ice to recover for 2 min and 250 µl of room temperature LB medium was 
added to each tube. Tubes were then incubated at 37°C for 1 hour with shaking (200 rpm). 
The entire transformation reactions were added to 500 ml of LB containing ampicillin 
antibiotic at 100 µg/ mL final concentration and grown overnight at 37°C with shaking. 
Plasmid DNA maxipreps were then performed using the PureLink® Quick Plasmid Miniprep 
Kit (Invitrogen) to purify high-copy plasmid DNA as per the manufacturer‘s specifications. 
2.2.10 Mammalian cell expression  
The pGene and pSwitch system was used to express the ECDs of mouse and human PTPRJ. 
Typically, cells making the pSwitch protein needs to be activated by the addition of 
mifepristone. The construct that been used for this transfection is a modified pSwitch that is 
constitutively active without the need to add mifepristone. Therefore, co-transfecting the 
pGene plasmid and modified pSwitch plasmid (GVP plasmid) gives constitutive strong 
expression. The product of the pSwitch plasmid will activate expression from the pGene 
plasmid. 
The ECD expression was accomplished by using suspension Chinese Hamster Ovary cells 
adapted for suspension culture (CHO-S) cells and maintained in CD-CHO (Invitrogen) 
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supplemented with 8 mM GlutaMAX™ (Life Technologies). pGene B with the ECD inserts 
and GVP plasmids were co-transfected using PEI-Max (prepared in water) (Polysciences 
Inc). The transfection complex is prepared at a ratio of PEI: DNA of 3.5: 1. For transient 
transfection a 0.75: 0.25 v/v ratio of cells: transfection complex is used, therefore each 
750 μL of cells (at 1.5 × 106 cells/mL) in CD-CHO is transfected with 1.6 μg DNA and 
5.6 μg PEI in 250 μL of OptiPro SFM medium (Invitrogen). The complex was incubated for 
15 min at room temperature without disruption before addition to the cell suspension. At 
4 hours post transfection the cells were diluted by doubling the total volume with CD-CHO, 
Gibco® CHO CD Efficient Feed™ A and Gibco® CHO CD Efficient Feed™ B (Invitrogen), 
were added at 7.5% in addition to 0.4% Anti-Clumping Agent (Invitrogen) before 
transferring the cultures to humidified incubators at 32 °C and 7.5% CO2 with shaking at 
160–250 rpm for up to 14 days or until cell viability dropped to 70% during which 
recombinant protein is secreted into the culture media. Expression was performed such that 
the final volume after feeding was 300 mL. 
2.2.11 Purification of the recombinant proteins 
Cells and cellular debris were removed by centrifugation and secreted proteins were purified 
from the culture media using affinity chromatography. A 5 mL, HisTrap™ column from GE 
Healthcare was used. Before the loading, adjustment of the feed pH to ~7.0 was required and   
pH meter was used to monitor the pH. To start the purification cycle, the HisTrap excel and 
Desalting columns were attached to chromatography system (AKTA Explorer, GE 
Healthcare Life Sciences) and flushed with DI water followed by NaOH sanitisation solution 
at 0.1 M for 1 hour. Subsequently the system was flushed with DI water until the pH was 
neutral. For chromatography run, inlet lines were placed in: equilibration buffer (20 mM 
sodium phosphate, 500 mM NaCl, pH 7.4), Wash buffer (20 mM sodium phosphate, 500 mM 
NaCl, 30 mM imidazole, pH 7.4) and desalting buffer (1 x DPBS).  After the adjustment of 
the supernatant‘s pH, it was loaded onto the column and a new manual run was started with 
Record On and the following settings:   
 
 
Pressure limits 0.3  MPa 
Wavelengths  280, 260, 410 nm 
UV Averaging Time 5.12 sec 
AirSensor1 Enabled 
AirSensorP960 Enabled 
Equilibration flow rate: 5 ml/min       
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The peak was eluted using basic buffer that had been supplemented with a gradient of 
imidazole concentrations (50 mM, 300 mM and 500 mM). After that, the UV trace returned 
to baseline, columns were washed and once the pH has returned to neutral, recording was 
stopped. 
To desalt the purified proteins using the size exclusion chromatography, the product was 
loaded onto the column and a new manual run with Record On was started using 1 x DPBS as 
a final storage buffer and the following settings: 
Pressure limits  0.3 MPa 
Wavelengths  280, 260, 214 nm 
UV Averaging Time 5.12 sec 
AirSensor1 Sensitivity Low 
AirSensor1 Enabled 
AirSensorP960 Enabled 
Equilibration flow rate: 5 ml/min     
Final buffer exchanged product was collected into a 50 mL tube and the concentration was 
measured via A280 (Nanodrop-1000) using 1 x DPBS buffer as a blank. 
The Nanodrop reading of the desalted mouse ECD was low; therefore Spin Column (Ultracell 
30 kDa, Amicon Ultra 4) was used to concentrate the product as per the manufacturer‘s 
specifications. 
2.2.12 Western blotting 
To validate the expression and purification of the recombinant ECDs, SDS-PAGE and 
western blotting was used. Purified proteins were mixed with NuPAGE® LDS Sample 
Buffer (Life Technologies) and heated at 70°C for 10 min then loaded into Novex® 
NuPAGE® Pre-Cast Gels with MES running buffer. SeeBlue® Plus2 Pre-stained Protein 
Standard (NuPAGE system, Life Technologies) was used as a molecular weight marker. 
Proteins were separated by SDS-PAGE for 40 min at 200 V and following separation, gels 
were either stained using Coomassie Brilliant Blue (BioRad) according to manufacturer‘s 
instructions or transferred to a membrane for western blot analysis using the trans-blot turbo 
transfer System (Bio-Rad) for 10 min at high molecular weight setting. Membranes were then 
blocked in blocking solution (2% skim milk in PBST) for one hour with shaking followed by 
another one hour incubation with blocking solution containing the primary Anti His antibody 
(Invitrogen, Life Technologies). Membranes were then washed 3 x 5 min each in PBST and 
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developed with Bio-Rad Chemiluminescence detection system and visualised by the 
ChemiDoc™ MP imaging system. His tagged proteins (mainly 2G7) were used as positive 
controls to detect the expression using the anti His antibody.      
2.3 Results 
2.3.1 Amplifying the extracellular domains of human PTPRJ:  
Full length cDNA of human PTPRJ (Kindly provided by Dr Dmitry A. Ovchinnikov, AIBN) 
was used as a cloning template for the ECD. PCR product of the ECD of approximately 2.8 
kb was amplified (Figure 2.3) and purified by QIAquick gel extraction kit (QIAGEN Pty Ltd, 
Doncaster, VIC, Australia). The ECD containing N-terminal polyhistidine (6xHis) tag, which 
facilitates the purification on a nickel column, was successfully inserted into the mammalian 
expression vector pGene B. The resultant plasmid was confirmed by performing colony PCR, 
enzyme digestion and sequencing (Figure 2.4) and (Figure 2.5). Colony PCR, using the 
vector forward and reverse primers, identified the positive clones that contain the correct size 
of insert. Enzyme digest confirmed the presence of target sequence by showing a digest band 
at the size of the cloned insert. Sequencing of positive clones confirms the insertion of the 
target sequence in frame with the vector promoter and indications any major mutations that 
sometimes occur during cloning and alter the protein folding afterward.  
  
 
 
 
 
 
 
                 
 
 
 
 
 
PCR product  
~2.8kb 
Figure 2.3: Agarose gel electrophoresis representing PCR 
products of the ECD amplified from the full length 
templates of human PTPRJ.  Lane 1: Bioline Hyperladder 
I, lane 2: ECD of human PTPRJ at ~ 2.8kb 
  
1
1
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2.3.2 Expression of the ECD of mouse and human PTPRJ:  
pPyEBV vector was the first expression option to generate the recombinant ECD proteins of 
mouse and human PTPRJ. In order to optimize the expression in CHO cells using the 
pPyEBV vector, it was decided to design the forward primer to include the immunoglobulin 
kappa chain leader sequence to replace the native leader sequence of the PTPRJ which 
contains the first 35 amino acids of the sequence (Figure 2.6). This alternative leader 
sequence has previously been successful for the secretion of many recombinant proteins in 
CHO cells (Lo et al., 1998, Peroutka et al., 2008, Cowen et al., 2002). The reverse primer was 
designed to add the six His tag to the C-termini of the constructs for detection and 
purification purposes.  
1 2 3 12 4 5 6 7 8 9 10 11 13 14 15 
PCR product  
~2.8kb 
Figure 2.4: Agarose gel electrophoresis representing colony PCR screening for the insert of human 
ECD into pGene vector. Lane 1: Bioline Hyperladder I, lane 2- 15: PCR product from 14 randomly 
selected colonies.  All 14 colonies contained a product at the expected molecular weight for the ECD of 
human PTPRJ at ~ 2.8kb. 
1 2 3 4 
~10 kb 
  
~6 kb 
  
~2.8 kb 
  
Figure 2.5: Agarose gel electrophoresis 
representing miniprep digested with HindIII 
and Agel to confirm the insertion of human 
ECD into pGENE vector. Lane 1: Bioline 
Hyperladder I, lane 2: undigested miniprep. 
Lane 3: single digest with HindIII, lane 4: 
double digest with HindIII and Agel.  
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Figure 2.6: Constructs designed to express the ECDs of mouse and human PTPRJ. A) Represents the full 
length template and (B) represents the amplified construct that was inserted into the mammalian 
expression vector, pcDNA3.1+ and pPyEBV. 
 
Two separate attempts to express PTPRJ ECDs in CHO cells using pPyEBV as an expression 
vector failed to show any level of PTPRJ expression as detected by SDS-PAGE and western 
blotting (Figure 2.7). To determine whether there was a problem with the pPyEBV vector, 
mammalian expression in HEK and CHO cells using pcDNA3.1+ and the same coding 
sequences, which were used during previous attempts, was carried out. However, again, there 
was no evidence of PTPRJ expression as detected by SDS-PAGE and western blotting 
(Figure 2.8). Although there were no bands at the expected molecular weight of the full 
ECDs, the SDS page showed strong bands at the molecular weight of approximately 17 kDa 
enclosed within the cell pellets. These bands were possibly representing a truncated or 
deformed PTPRJ that was expressed but never secreted or they were possibly representing 
variant isoform of the full PTPRJ. The reason for the lack of the full ECDs expression was 
unknown; however one possibility is a lack of compatibility of the replaced ―optimal‖ leader 
sequence. As such, the ECDs were re-amplified to retain their native leader sequence from 
the full length templates. 
The new constructs of the ECD of mouse and human PTPRJ with the native leader sequence 
were inserted into the expression vector pcDNA3.1+ and CHO cells were used for this 
expression. However, two transfection attempts showed no sign of expression at the expected 
molecular size as detected by SDS-PAGE and western blotting using anti His antibody as an 
expression detector (data not shown).   
(A) 
(B) 
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Since expression in mammalian cells failed, two alternative strategies were chosen: (a) 
Expression in bacteria and (b) Expressing single FNIII domains from the ECD.  
 
  
 
Figure 2.7: Western blot analysis of mammalian expression to express the ECDs of mouse and human 
PTPRJ using pPyEBV vector. Lanes 1, 6, 7 and 8 represent positive controls (sample in lane 8 was very 
diluted), lane 2 and 3 expected to represent human ECD at ~100 kDa in cell pellet and supernatant 
respectively, lanes 4 and 5 expected to represent mouse ECD at ~100 kDa in cell pellet and supernatant 
respectively, lanes 9 and 10 represent mock -transfection negative controls and lane 11 represents 
SeeBlue Plus Prestained protein standard (Invitrogen). Anti His antibody (Invitrogen, Life Technologies) 
was used for detection purpose and His tagged proteins were used as positive controls. 
 
  
 
 
 
    
   
Figure 2.8: Western blot analysis of mammalian expression using CHO cells and pcDNA3.1+ vector to 
express the ECDs of mouse and human PTPRJ. Lane 1: represents SeeBlue Plus Prestained protein 
standard (Invitrogen), Lanes 2 and 3 expected to represent human ECD at ~100 kDa in cell pellet and 
supernatant respectively, lanes 5 and 6 expected to represent mouse ECD at ~100 kDa in cell pellet and 
supernatant respectively, lanes 4 and 7 represent mock -transfection negative controls and lane 8 
represents the positive control. Anti His antibody (Invitrogen, Life Technologies) was used for detection 
purpose and His tagged protein (2G7) was used as a positive control. 
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- Bacterial expression 
Although bacterially expressed protein may not be the ideal target for phage panning, due to 
the absence of post-translational glycosylation, it was attempted due to the lack of success of 
mammalian cell expression. Bacterial expression of the ECD of mouse and human PTPRJ 
was carried out using pMAL-c2X vector. The background of this expression was high and we 
could not capture strong evidence of the ECDs expression (Figure 2.9). Therefore, we did not 
proceed further with that expression. 
In order to minimize time delays, the UQ Protein Expression Facility (PEF) was engaged to 
screen for the expression of the ECDs of mouse and human PTPRJ in three different bacterial 
expression systems. Full length templates were provided and pOPIN-MBP, pOPIN-NHis and 
pOPIN-Trx vectors were developed for the cloning and the expression. Different expression 
conditions were tested and total and soluble fractions of different time points were analysed 
using SDS-PAGE followed by Coomassie Blue staining. For human PTPRJ, expression of a 
soluble product was obtained using a number of conditions tested. However mouse PTPRJ 
was insoluble under all conditions tested. Larger scale expression of human PTPRJ ECD was 
completed, but purified materials were highly susceptible to degradation, showing a number 
of smaller bands (Figure 2.10). Whilst this could still be used for panning, it cannot be used 
for functional studies without further purification. 
- Expressing FNIII repeats from the ECD of human PTPRJ 
To exclude the possibility that the large size of the ECD domain of the protein was hindering 
the expression, we planned to express individual FNIII repeats from the ECD complex. FNIII 
number one and eight from human ECD of PTPRJ were chosen for this purpose. Both regions 
were synthesised by GeneArt, Life Technologies, Germany, and inserted into the mammalian 
expression vector pcDNA3.1+ and the insertion was confirmed by colony PCR (Figure 2.11), 
enzyme digest (Figure 2.12) and sequencing. However, FN8 showed no evidence of 
expression as detected by SDS page and western blotting while FN1 expressed at high level 
but the molecular size of the expressed protein was almost double of the expected size under 
reduced condition (Figure 2.13). 
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Figure 2.9: Analysis of the bacterial expression of mouse and human ECDs using pMAL-c2X vector. First 
lane represents SeeBlue Plus Prestained protein standard (Invitrogen). The contaminating bands detected 
in the filtered, soluble and total samples appear to be histidine-related as confirmed by anti-His western 
blot. This suggests possible truncated or degraded versions of the full length of PTPRJ. Red arrow 
indicates band at the size of interest. 
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Figure 2.10: Analysis of protein purification process of human ECD by PEF. MBP affinity purification 
process analysed by A. SDS-PAGE and B. Western blot. The contaminating bands detected in the SDS-
PAGE appear to be histidine-related as confirmed by anti-His western blot. This suggests possible 
truncated or degraded versions of the full length NHis-MBP-h ECD of PTPRJ. Red arrow indicates band 
of interest. Lane allocations shown in (Table 2.3) below. 
 
Lane                                                                    Sample 
1  Novex® Sharp Pre-stained MW ladder 6  2012-673 elution fraction A3 
2  2012-673 total 7  2012-673 elution fraction A4 
3  2012-673 soluble fraction 8  2012-673 elution fraction A6 
4  2012-673 filtered soluble fraction (MBP load) 9  2012-673 elution fraction A8 
5  2012-673 MBP column flow through 10  2012-673 elution fraction A10 
 
Table 2.3:  Lane allocations for analysis of protein purification process of human ECD by PEF. For 
(Figure 2.9) above. 
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Figure 2.11: Agarose gel electrophoresis representing colony PCR screening for the insert of FNIII 
number 1 and 8 into pcDNA 3.1+ vector. Lane 1: Bioline Hyperladder I, lane 2- 11: PCR product from 10 
randomly selected colonies. All 10 colonies contained a product at the expected molecular weight for the 
FNIII #1 at ~ 276 bp. Lane 12- 21: PCR product from 10 randomly selected colonies. All 10 colonies 
contained a product at the expected molecular weight for the FNIII #8 at ~ 396 bp. Arrow indicates PCR 
products at the expected size.  
 
 
Figure 2.12: Agarose gel electrophoresis representing miniprep digested with HindIII and NotI to 
confirm the insertion of FNIII #1 and #8 into pcDNA 3.1+ vector. Lane 1: Bioline Hyperladder I, lane 2- 4 
double digest of FNIII #1 in pcDNA 3.1+ minipreps with HindIII and NotI, lane 5- 7 double digest of 
FNIII #8 in pcDNA 3.1+ minipreps with HindIII and NotI. All digested minipreps showed bands at the 
expected size confirming the present of the insertion into the expression vector.   
 
 
 
FNIII #1 FNIII #8
FNIII #8
FNIII #1 FNIII #8
1         2         3        4        5        6         7         8        9        10      11     12        13       14     15       16       17       18      19       20       21      
1           2          3             4                         5            6            7         
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Figure 2.13: Western blot analysis of the expression of fibronectin type three repeats (FNIII) number 1 
and 8 from human ECD. Lane 1: represents SeeBlue Plus Prestained protein standard (Invitrogen), lane 
2 mock transfection negative control, lane 3 positive control his tagged protein (2G7), lane 4 expected to 
represent FNIII number 1 at ~ 12 kDa, lane 5 expected to represent FNIII number 8 at ~ 15 kDa. 
 
2.3.3 Expressing the ECD of mouse and human PTPRJ using a modified inducible 
expression system: 
Since previous attempts to express the ECD of mouse and human PTPRJ had been 
unsuccessful, expression using an inducible system was considered as a last alternative 
strategy, as it has been successfully used before for the expression of full length PTPRJ 
(Kellie et al., 2004). The GeneSwitch system is a mifepristone-inducible mammalian 
expression system initially developed by Wang et al (Wang et al., 1994) which uses a 
combination of regulatory mechanisms derived from various human and yeast 
transcription factors. Regulation of this system by mifepristone is based on an auto -
regulatory feedback loop that involves the binding of a GAL4 directing protein to 
GAL4 upstream activating sequences (UAS) in both the promoter driving the 
expression of the GAL4 regulatory protein and the promoter driving transgene 
expression (Figure 2.14). The pSwitch construct encodes a regulatory protein (GAL4-
DBD/hPR-LBD/p65-AD) that comprises a truncated human progesterone receptor 
ligand binding domain (Kastner et al., 1990, Vegeto et al., 1992, Wang et al., 1997), 
the human p65 activation domain from NF-κB (Deloukas and van Loon, 1993, Ruben 
 1              2             3             4             5        
 1         2          3          4         5 
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et al., 1991, Schmitz and Baeuerle, 1991) and the yeast GAL4 DNA binding domain 
(Giniger et al., 1985, Marmorstein et al., 1992). The construct that been used to drive this 
expression is a modified pSwitch that is constitutively active without the need to add 
mifepristone. The modified promoter of the Csf1r (c-fms) gene, containing a deletion of 
the trophoblast-specific promoter (Ovchinnikov et al., 2008), was co-transfected with the 
pGene vector containing the ECDs of mouse and human PTPRJ, to induce a strong 
expression. 
 
 
Figure 2.14: The GeneSwitch mammalian expression system. The GeneSwitch transcription 
factor is inactive until it comes in contact with the GeneSwitch regulatory protein which 
expressed from pSwitch upon binding of the mifepristone. Once activated, the complex of 
the GeneSwitch protein-mifepristone then binds GAL4USA to activate transcription, and 
drive high-level expression of the desired protein. Obtained from 
(http://jvbios.tripod.com/mifepristoneinducibleoncolyticadenovirusforcancertherapy/index) 
   
Mifepristone 
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The ECD of mouse PTPRJ in pGene B was generated by Dr Dmitry A. Ovchinnikov (AIBN, 
QU). However, the human PTPRJ was available in pGene as a full length construct only, 
therefore re-cloning of the ECD region of human PTPRJ (including the native leader 
sequence) from the full length was required. The pGene vector was originally constructed to 
include both His and V5 tags downstream of the desired sequence and in order to contain 
these two tags to be expressed with the target protein, a stop codon should not be included in 
the designing of the reverse primer. However, to avoid complications that may incorporate 
with frame shifting following the ECD sequence insertion, a new reverse primer was 
designed to include the His tag protein sequence, a stop codon and a restriction site for 
cloning.  
After the insertion of the human ECD into the pGene expression vector was confirmed by 
colony PCR screening, restriction enzyme digest and plasmid sequencing, large scale plasmid 
DNA was prepared for use in mammalian cell transfection to express the ECDs of mouse and 
human PTPRJ.  
CHO cells were co-transfected with pGene vector that contains the ECD sequence of either 
mouse PTPRJ or human PTPRJ and the adapted vector GVP. Cells were allowed to express 
the recombinant proteins and secrete them in the supernatant for 10-14 days. The viability of 
the cells was monitored during the protein expression and supernatants containing the 
recombinant proteins were harvested when the cells viability started to drop down to around 
80%.  Harvested supernatants were tested for the present of the recombinant proteins by SDS 
page before any further purification steps. As shown by the SDS-PAGE page analysis (Figure 
2.15), the pSwitch expression system proved to be the only method to successfully express 
and yield a relatively good level of both PTPRJ ECDs from all the approaches that had been 
tested during the expression attempts. Harvested supernatants were then used for purification 
using a HisTrap™ column.  
To further confirm the presence of the recombinant ECDs at the correct molecular weight and 
to observe the purity of the generated proteins, purified ECDs were separated by SDS-PAGE 
and detected by western blotting with Anti His antibody. Detection of His tagged ECDs by 
western blotting revealed that ECDs were present at the expected molecular weight thus, the 
expression using the pGene system was successful (Figure 2.16). 
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~100 kDa 
  
1 2 3 
Figure 2.15: SDS page of the 
recombinant ECDs of mouse and 
human PTPRJ. Lane 1: SeeBlue Plus 
Prestained protein standard 
(Invitrogen), lane 2: recombinant 
mouse ECD. Lane 3: recombinant 
human ECD.  
  
1 2 1 2 
~100 kDa 
  
~100 kDa 
  
Figure 2.16: Western blotting of the recombinant ECDs of mouse and human PTPRJ with 
Anti His antibody. Lane 1: SeeBlue Plus Prestained protein standard (Invitrogen), lane 2 
(A): recombinant human ECD and lane 2 (B): recombinant mouse ECD. 
  
(A) 
  
(B) 
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2.4 Discussion: 
Cellular adhesion to the extracellular matrix is an essential feature in developmental 
processes, immune surveillance, inflammation and tissue repair. The structural diversity of 
the extracellular domain of PTPRJ implicates that it may be a target for binding of regulatory 
ligands. It was reported that a mutant form of the extracellular domain of PTPRJ failed to 
respond to Matrigel
TM 
stimulation, suggesting a possible role of the ligand for modulating 
PTPRJ activity (Sorby et al., 2001). Furthermore, a monoclonal antibody against the 
ectodomain sequence of PTPRJ inhibits endothelial-cell growth and blocks angiogenesis in 
mouse cornea in vivo (Takahashi et al., 2006). It also found to inhibit monocyte chemotaxis 
in vitro which implicates PTPRJ and its putative ligands in inflammation (Dave et al., 2009).  
The extracellular region of PTPRJ appears to have a critical function in many biological 
aspects. Therefore, cloning and expressing the ECD section will aid for better understanding 
of the actual function of this molecular both in vivo and in vitro.  
Although smaller parts of the ECD of PTPRJ have been cloned and expressed (Paduano et 
al., 2012, Sorby et al., 2001, Takahashi et al., 2006, Iuliano et al., 2009), an attempt to 
express the complete ECD region of PTPRJ has not been reported.  
This project aimed to isolate antibodies against the ectodomain sequence of PTPRJ using 
phage display technology, therefore recombinant purified ECDs were desired as the target 
antigens for the panning. Mammalian expression system was the first choice to generate the 
recombinant ECDs for the following reasons: 
To generate antibodies that are able to bind to the native form of PTPRJ by phage display, 
panning should be performed on antigens that represent the native protein structure, including 
disulphide bonds and glycosylation. Prokaryotic expression system has advantages of high 
expression level, short time of expression, easy operation, low cost and easy cultivation. 
However, prokaryotic cells lacks endoplasmic reticulum and Golgi apparatus which are 
essential for glycosylation. Therefore, proteins expressed in bacteria often are non-functional 
because these cells are not equipped to accomplish the required post-translational 
modifications and molecular folding. Additionally, many proteins become insoluble as 
inclusion bodies which are very problematic to recover without harsh denaturants and 
subsequent cumbersome protein-refolding procedures (Demain and Vaishnav, 2009, Zerbs et 
al., 2009, Chen, 2012). On the other hand, protein generated by mammalian cell expression is 
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almost equivalent to the native proteins in terms of structure, glycosylation style and the way 
of glycosylation (Khan, 2013, Nettleship et al., 2010, Hartley, 2012). Another advantage of 
mammalian expression system is that the expressed protein can be cultured in suspension or 
in adherent cells and most importantly, the resultant protein can be secreted and easily 
harvested from the cell supernatant (Nettleship et al., 2010). 
The ECD sequence of PTPRJ is highly glycosylated and is predicted to contain 
approximately 37 potential protein N-glycosylation sites (Honda et al., 1994, Kuramochi et 
al., 1996, Ostman et al., 1994). Therefore, using a mammalian cell expression system is the 
logical method to express the ECDs as properly folded antigens for phage panning. 
The yield of protein expression from heterologous genes introduced into mammalian cells 
depends upon multiple aspects including; DNA copy number, efficiency of transcription, 
mRNA stability, mRNA processing, mRNA transport and translational efficiency then 
protein processing, transport and stability (Kaufman, 2000). In most cases, the first challenge 
to transiently express recombinant proteins is selecting the host cells and the expression 
vector that contains a strong promoter for a specific expression target. When the RNA cannot 
be detected, then it always advisable to try a different expression system or vector since it is 
possible that for some unanticipated reason improper transcription or mRNA processing 
occurs (Nettleship et al., 2010, Savitsky et al., 2010). Although several attempts with 
different expression vectors were performed to express the ECDs of mouse and human 
PTPRJ, only one strategy proved to yield a satisfactory level of the recombinant proteins.   
The manipulation of gene expression by the Gene-Switch inducible expression system has 
been reported to allow temporal and tissue-specific control of gene expression that allows 
researchers to manipulate a gene‘s temporal and spatial expression pattern (del Valle 
Rodriguez et al., 2012, Poirier et al., 2008, Bhat et al., 2004). The Gene-Switch system that 
been used in this project is a modified system where the translation can be activated even in 
the absence of mifepristone and the protein can be expressed without the need of further 
expression triggers (Ovchinnikov et al., 2008). In addition, this system has been successfully 
used before to express full length PTPRJ in fibroblast (Kellie et al., 2004). By using the 
modified Gene-Switch system, a high yield of the recombinant proteins were detected and 
harvested from the supernatants just a few days after transfection of CHO cells with the 
pGene vectors that contains the ECD sequences of mouse and human PTPRJ. There are 
several possibilities to explain why among all other expression attempts, only this modified 
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inducible expression system was able to drive the expression of the recombinant ECDs. It is 
possible that expressing the ECD part of the PTPRJ is toxic to the host cell‘s biological 
functions therefore, the cells might lose their ability to express and secrete the recombinant 
proteins. The other possibility is the vector promoter. pGene vector was the only expression 
vector that been used in this project with GAL4 promoter while the other mammalian 
expression vectors used to express the ECDs contain the CMV promoter which might be 
appropriate for most proteins but not for PTPRJ  ECDs. Further investigation of the 
expression of PTPRJ ECDs using another expression vectors with GAL4 promoter would 
determine whether it was the promoter that effects expression or another cause. The main aim 
of expressing the ECDs was to use them as antigens for the phage panning therefore; 
obtaining the required yield of the recombinant ECDs was the most important task of this 
chapter aside from how and which mammalian expression system would consistently ensure 
this.  
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CHAPTER 3 
 
Phage panning and generation of 
recombinant monoclonal antibodies 
against the ECDs of  mouse and human 
PTPRJ 
 
3.1 Introduction 
Phage display technology represents one of the most powerful tools for selection and 
production of recombinant antibody fragments with specific binding properties from a vast 
number of variants against a wide range of target molecules, such as proteins, 
oligosacharides, glycoproteins, nucleic acids, toxins or low molecular weight compounds 
(Willats, 2002, Yau et al., 2003). 
Since its introduction almost 20 years ago by George P. Smith (Smith, 1985) , phage display 
technology has revolutionized approaches to the analysis of biomedical problems, rapidly 
impacting the fields of immunology, pharmacology, cell biology, biotechnology, and drug 
discovery (Griffiths et al., 1994).  
The basic method for sequential affinity screening of the phage display libraries for specific 
binding phage from a large excess of non-binding clones is often referred to as ―biopanning‖ 
(Parmley and Smith, 1988). The phage antibody selection involves the immobilization of the 
ligand of interest on a solid support, followed by applying the phage display library (in the 
form of purified virions) in solution to it to allow binding of specific variants. To eliminate 
the adherent non-binders, multiple rounds of washing are performed, and what remains bound 
is eluted. Some non-specific binding of phage to the matrix surrounding the ligand occurs 
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therefore; at least three rounds of panning are usually required in order to amplify the binding 
variants and to exclude the ―background‖ of non-specific binders (Di Niro et al., 2010, 
Rakonjac et al., 2011, Lee et al., 2007). 
The unlimited flexibility and applicability of this technique assert that an extensive range of 
life and material sciences will continue to benefit from phage display and all of the various 
associated technologies it has inspired in years to come. 
The aim of this chapter is to isolate monoclonal antibodies specific to the ECDs of mouse and 
human PTPRJ using the phage display technology. Firstly, phage panning was performed 
using BSA conjugated peptides as antigens but unfortunately, the generated antibodies were 
nonspecific to the desired antigens.  After we successfully expressed and purified the ECDs 
of mouse and human PTPRJ, another phage panning was completed using these recombinant 
ECDs as target antigens. Two different types of phage libraries were used and two specific 
antibodies were isolated, reformatted and characterized as detailed in this chapter.  
3.2 Materials and Methods  
There were two major attempts to generate recombinant monoclonal antibodies against the 
ECDs of mouse and human PTPRJ during this project. In order to minimize time delays due 
to the unavailability of the recombinant ECDs at the beginning (see chapter 2), first phage 
panning was performed using peptide sequences that might act as antigenic epitopes for 
panning using the Sheets library.  
Sheets scFv library, in pHEN1 phagemid vector, is a naïve human library with a reported 
diversity of 6.7 x 10
9
 and it was obtained from Prof James Marks (UCSF) (Sheets et al., 
1998). The production of phage particles that express and display antibody fragments on the 
tips of the gene III protein was achieved by transformation of suppressor XL1-Blue bacteria 
(Strategene) with the phagemid vector followed by rescue of the phage with M13KO7 helper 
phage.  
After the recombinant ECDs of mouse and human were successfully expressed, another 
phage panning was performed. In this attempt, three phage libraries were used; the Sheets 
library, the mAbLAb library and the immunised shark library.  
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mAbLAb library is a human naive scFv library, prepared from the peripheral blood 
leukocytes of 50 human blood donors and containing 5x10
9
 clones, was obtained from the 
National Biologics Facility (AIBN, Brisbane, Australia).  
Immunized shark library was kindly provided by Prof Ross Barnard (SCMB, The 
University of Queensland) and it was created by immunizing two sharks (shark #7 and shark 
#8) with KM-H2 and L-428 cells (human Hodgkin's Lymphoma cell lines) over a period of 
four months.  
Shark # 7 Orectolobus ornatus was immunised with 1000 µg KM-H2 (1000 µg of KM-H2 
membrane preparation and 20 µg CD83-Fc (R&D Systems) to be used as an antigen marker 
to enable ELISA monitoring of immune response. The RNA was extracted from peripheral 
blood lymphocytes (obtained by caudal venepuncture under anaesthesia, (Stoskopf et al., 
1984))  and from the spleen after the course of immunizations, using (Qiagen RNeasy Mini 
kit). The RNA from PBL and spleen was pooled together prior to RT-PCR using the RT-PCR 
kit (Qiagen OneStep). Products were then extracted from agarose gel, purified and cloned 
into a storage vector, pCR®2.1-TOPO® (Life Technologies). After conformation of the 
sequences, they were re-cloned into pCANTAB-5E (Amersham Pharmacia) and transformed 
into E.coli XL1-Blue (Agilent - Stratagene) then stored at -80°C to be used for phage 
panning. 
Shark #8 Orectolobus ornatus was immunized with 1 X10
6
 L428 cells and 250 µg Oatp14 
protein (Proteintech) that can act as an antigen marker to enable ELISA monitoring of 
immune response. Under anaesthesia, PBLs were collected by caudal venepuncture for RNA 
isolation (Qiagen RNeasy Mini kit). RNA was amplified by RT-PCR (Qiagen OneStep RT-
PCR kit), then re-amplified using BIOTAQ Red DNA Polymerase (BioLine). PCR products 
were extracted from the agarose gel, then cloned into pCANTAB-5E and transformed into 
E.coli XL1- Blue to be stored at –80ºC for phage display. 
Prior to panning, shark libraries were amplified and pooled together to create one single 
library with approximately 1x10
7 
diverse clones. The reason to use this library for panning on 
the ECD of human PTPRJ will be discussed in the results part of this chapter.  
During the second phage panning attempt, three antibodies were generated and reformatted as 
shown in (Table 3.1). 
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Panning antigen Against Control antigen Library used Generated Ab 
BSA conjugated Peptide 1 m- ECD 
Un-conjugated 
BSA 
The Sheets library 
(naïve human 
library) 
PEP 1 Ab 
BSA conjugated Peptide 2 m/h- ECD PEP 2 Ab 
BSA conjugated Peptide 3 
h- ECD 
PEP 3 Ab 
BSA conjugated Peptide 4 PEP 4 Ab 
Recombinant m-ECD  m- ECD 
Non-related His 
tagged protein  
The Sheets 
library+ mAbLAb 
library ( naïve 
human libraries) 
B12 Ab 
Recombinant h-ECD h- ECD 
The Sheets 
library+ mAbLAb 
library ( naïve 
human libraries) 
No antibody 
generated 
Immunized shark 
library 
Sh4V Ab 
shdAb Ab 
 
Table 3.1: Antigens, libraries and generated antibodies. The table summarizes the panning attempts to 
generate the recombinant monoclonal antibodies that are specific to the ECDs of mouse and human 
ECDs using the naïve human libraries and the immunized shark library.    
 
3.2.1 Design and conjugation of PTPRJ peptides to Bovine Serum Albumin (BSA): 
Six putative peptide antigens were identified from the ECDs of mouse and human PTPRJ 
using CLC Main Workbench 6 surface probability program (Table 3.2). Peptides were 
synthesized by PEPTIDE 2.0 (Chantilly, VA, USA) to 98- 86% purity. All peptides contained 
an acetylated N-terminal cysteine residue to facilitate immobilization. Four out of these six 
peptide (one mouse specific, two human specific and one mutual sequence between mouse 
and human) were conjugated to BSA and purified following the manufacturer‘s protocol 
(Imject Maleimide Activated Carrier Protein Spin Kit, Thermo Scientific). 
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Target protein Peptides 
ECD of  h PTPRJ 066-CESFHKQNGTGTPQVETNTS-084  (peptide 3) 
ECD of  h PTPRJ 268-CYNINPYLLQSNKTKGDPLG-286  (peptide 4) 
ECD of  h PTPRJ and 
ECD of  m PTPRJ 
805-CTRNTCTTGITDPPPPDGSP-823 
706-CTRNTCTTGITDPPPPDGSP-724      
ECD of  h PTPRJ and 
ECD of  m PTPRJ 
863-CSADVLKYTYEDFKKGASDT-881  (peptide 2) 
764-CSADVLKYTYEDFKKGASDT-782 
ECD of  m PTPRJ 389-CKQDGGEKHRNASTGNQSYM-407  (peptide 1)   
ECD of  m PTPRJ 171-CGTNNSFAFPESNETQADFA-189 
 
Table 3.2: Peptide antigens derived from the ECDs of mouse and human PTPRJ. Surface probability for 
these peptides was obtained using CLC Main Workbench 6 program. Highlighted in yellow is the 
sequence number of the amino acids at the start and the end of the peptides. Selected peptides were 
synthesized by PEPTIDE 2.0 (Chantilly, VA, USA). Peptides highlighted in gray were used for the phage 
panning. 
 
3.2.2 Phage panning on the conjugated peptides and the recombinant ECDs:  
To enrich the pool of the positive phage binders to a desired antigen, at least three rounds of 
panning should be performed. Each round of panning is about five days protocol divided as 
follow:  
- Day one: Coating 
Antigens (conjugated peptides or recombinant ECDs) were diluted to 10 µg/ mL in 1 mL 
PBS and added to 5 mL Nunc Immunotubes. For each antigen, two other tubes were coated 
with un-conjugated BSA (for panning with BSA conjugated peptides) or un-related His 
tagged recombinant protein (for panning with the recombinant ECDs) to be used for the 
negative selection to minimise the non-specific binders by prior exposure of the library to the 
negative control antigen. The tubes were then securely capped and placed on a rotating wheel 
overnight either at room temperature (conjugated peptides are stable at room temperature) or 
at 4°C  (the stability of the recombinant ECDs at room temperature is unknown therefore the 
coated tubes were kept rotating overnight at 4°C  to avoid protein degradation).  
5 ml 2YT broth (10 g yeast extract, 16 g tryptone and 5 g NaCl/ L. Autoclaved at 121°C for 
20 mins) with tetracycline (3 µg/mL) was inoculated with a single colony of XL1-Blue 
(Agilent - Stratagene) from a streak 2YT tetracycline plate (15g agar/ L of 2YT media added 
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prior to autoclaving and 3µg/mL tetracycline was included after media cooling) and 
incubated overnight at 37 ˚C with shaking at 220 rpm. 
- Day two: Binding 
The contents of the immunotubes were discarded and the tubes were washed three times with 
PBS. To block any remaining binding sites on the immunotubes, 4 mL of 2% M-PBS (2 g 
skim milk powder + 100 mL PBS) were added to each tube. Tubes then kept rotating with the 
blocking reagent for 1 hour at room temperature. Meanwhile, phage library (either the naïve 
human library or the immunized shark library) was prepared with 1 mL M-PBS to obtain 
(10
13 
phage for first round of panning, 10
12 
phage for second round and 10
11 
phage for third 
round). After one hour, the blocking solution from one negative tube was discarded and the 
blocked phage library in M-PBS was added to the tube and incubated on the rotating wheel 
for 1 hour. The blocking solution then removed from the second negative tub and the 
unbound phage particles from the first negative tube were transferred to the second one and 
kept rotating for 1 hour. After the exclusion of the non-specific binders, blocked phage 
library was finally transferred to the tube that was coated with the target antigen to perform 
the actual panning and kept rotating at room temperature for another hour. 
In the final step, unbound non-specific phage particles were discarded. The tubes were 
washed three times with PBS and then three times with PBS-T (PBS+ 0.1% Tween-20). The 
number of washes with each buffer was increased for the following rounds of panning (five 
times for round two and ten times for round three). To elute the specific bound phages to the 
target antigens, 1 mL of Elution Solution (200 mM glycine, pH2.5, autoclaved at 121°C for 
20 mins) was added to the tube after washing and incubated for 8 minutes on a rotating 
wheel.  After that, the phage eluate was added to 1 mL of Neutralisation Buffer (1 M Trizma, 
pH7.4, autoclaved at 121°C for 20 mins). Sterile glycerol to a final concentration of 20% was 
added to half of the neutralized elution and stored at -80 ˚C. The other half was used to infect 
XL1-Blue cells for amplification of the isolated positive binders. 
150 μL of the overnight culture from day one was added to a fresh 15 mL volume of 2YT 
broth with tetracycline. The culture was incubated at 37 ˚C with shaking at 220 rpm until 
OD600 between 0.6 and 0.8 as measured by the BioPhotometer (Eppendorf). To determine the 
output titre of the eluted phage, serial 10-fold dilutions of the eluate phage were prepared and 
1 μL of each dilution was added to 100 μL of log-phase XL1-Blue cells at 0.6- 0.8 OD and 
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incubated at 37 ˚C for 30 minute. Then 20 μL of each of the four dilutions was plated on a 90 
mm 2YT Ampicillin 2% Glucose and 100 µg/mL Ampicillin. 
For the infection, 10 mL of the log phase culture was infected with the remaining 1 mL 
neutralized eluate and incubated at 37 ˚C for 30 min. After incubation, the infected cells were 
pelleted by centrifugation at 2000 x g for 15 minutes and resuspended in 0.5 mL 2YT broth 
and spread evenly over two 150 mm 2YT Ampicillin Glucose agar plates. The plates were 
incubated overnight at 30 ˚C to ensure propagation of most clones. 
- Day three: Phage rescue 
Glycerol stocks of infected cells were made by scraping the bacterial cells from both 
overnight plates using 10 mL of 2YT-AmpGlu broth. Glycerol was added to the recovered 
bacterial slurry at a final concentration of 20%. While some of the glycerol stock was used 
for phage rescue, the rest was aliquoted and stored at -80 ˚C. 
The output titre of the round of panning was calculated from dilutions of infected cells with 
countable colonies. With each round of biopanning, an enrichment in the output (the number 
of cells infected with the eluted phage) comparative to the input (the number of phage 
particles used for biopanning) should occur. 
Output titre = number of colonies x dilution factor x 100/20 x 1000μL/ mL x 2mL (volume 
adjustment) 
For the phage rescue, phage particles were prepared by sub-culturing a volume of the 
glycerol stock in 50 mL 2YT-AmpGlu broth to achieve a starting OD600 between 0.05 and 
0.1. The culture was incubated at 37 ˚C with shaking at 220 rpm until it reached OD600 
between 0.4 and 0.6 followed by the addition of 1 x 10
11
 M13KO7 helper phage particles to 
the culture. The flask was incubated for 30 minute at 37 ˚C to complete the infection with the 
helper phage, then incubated for a further 30 minutes at 37 ˚C whilst shaking at 220 rpm. Co-
infected cells were recovered by centrifugation at 2000 x g for 20 minutes. The cells were 
resuspended in 100 mL 2YT supplied with Ampicillin and Kanamycin (30 µg/mL) and 
incubated overnight at 30 ˚C with shaking at 220 rpm. 
5 ml 2YT broth with tetracycline was inoculated with a single colony of XL1- from a streak 
2YT tetracycline and incubated overnight at 37 ˚C with shaking at 220 rpm. 
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- Day four: Precipitation 
Phage particles that been secreted overnight into the culture media were harvested by 
centrifugation of the overnight culture at 2000 x g for 30 minutes. Phage particles were 
precipitated from the culture supernatant by addition of 1/5 volume of PEG-NaCl (20% 
polyethylene glycol-6000 + 2.5M NaCl. Autoclaved at 121°C for 20 mins) then incubated on 
ice for 1 hour. The precipitate was pelleted by centrifugation at 10000 x g for 20 minutes at 4 
˚C. The supernatant was discarded and the pellet resuspended in 10 mL cold PBS. The 
suspension was exposed to a second round of precipitation on ice using 1/5 volume of PEG-
NaCl again and centrifugation at 10000 x g for 20 minutes at 4 ˚C. The final pellet was 
resuspended in 3 mL cold PBS-glycerol and the purified phage particles were titred and 
stored in aliquots at -80 ˚C. 
To determine the phage titre, 50 μL of the overnight culture was sub-cultured into a fresh 5 
mL volume of 2YT with tetracycline. The culture was incubated at 37 ˚C with shaking at 220 
rpm until OD600 between 0.6 and 0.8. Ten, ten-fold dilutions of purified phage in PBS were 
made in 1.5 mL tubes. 1 μL was removed from each dilution and transferred to a new 
corresponding 1.5 mL tube. 100 μL of the log-phase culture was added to each tube. Bacterial 
infection with phage occurred during a 30 minute incubation at 37 ˚C. 20 μL of each dilution 
was spotted on a 2YT-AmpGlu agar plate which was incubated overnight at 37 ˚C 
- Day five: Phage titre 
The number of countable colonies that corresponded to the relevant phage dilution was used 
to calculate the phage titre. Calculating the final titre is necessary to determine the volume 
that needed to be used as a phage library for the subsequent rounds.  
Cfu/mL = number of colonies x dilution factor x 100/20 x 1000 (volume adjustment).   
3.2.3 Polyclonal phage ELISA: 
To determine the enrichment of the positive binders to the target antigen, the pool of phage 
particles obtained after each round of panning was diluted to 10µg/ mL in 10ml PBS and 200 
µl was transferred to each well of the 96 well plates (one plate per antigen) and incubated 
overnight at room temperature or at 4°C. Following day, plates were washed three times with 
PBS-T then blocked with 2% M-PBS. Meanwhile, 90 µl of phage stock from each round of 
panning was blocked in 1800 µl MPBS. After one hour incubation, the blocking solution was 
discarded from the plate and 200 µl of blocked phages were added to each well as a 10-fold 
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serial dilution then incubated for one hour. Plates were washed with PBS-T and 200 µl of 
HRP-conjugated Anti-M13 (GE Healthcare) diluted to 0.1 µg/mL in 10% M-PBS was added 
to each well followed by an additional 1 hour incubation. Negative controls were also 
included as 'No Phage' controls and 'No antigen' controls. After washing final wash, 100 µl of 
TMB substrate (Sigma Aldrich) was added and allowed to develop the chromogenic signal 
for about 10 min. The reaction was stopped with 100 µl 1M sulphuric acid and measurement 
of the absorbance at 450 nm was carried out on a microplate reader. 
3.2.4 Monoclonal phage ELISA: 
To isolate individual clones and to determine the binding reactivity of these clones, 
monoclonal phage ELISA was performed as follow: 
- Day one: The monoclonal ELISA should be performed from the last panning round 
completed (at least round three) therefore; single colonies from the last cell glycerol stock 
were grown by streaking 40µl onto multiple 2YT-AmpGlu agar plates. The plates were then 
incubated overnight at 37 ˚C. 
- Day two: 90 walls of a 96 well microtitre plate with 150 μL of 2YT-AmpGlu in each 
well was inoculated with single colonies from the overnight plates. Walls H7 to H12 were 
kept as sterile technique controls. The plate was incubated overnight at 37 ˚C with shaking at 
180 rpm.  
- Day three: On the following day, new plate with 150 μL of 2YT-AmpGlu in each well 
was inoculated with 5 µl of the corresponding walls from the overnight plates. Plates were 
then incubated shaking for three hours at 37°C. Glycerol was added at 20% final 
concentration to the overnight culture plate and stored at -80 ˚C. To rescue the phage, a 50 μL 
2YT broth volume containing 4 x 10
8
 pfu of M13KO7 helper phage was added to each well.  
The plate was incubated at 37 ˚C for 30 minutes and then a further 30 minutes at 37 ˚C whilst 
shaking at 180 rpm. The plate was then spun at 3200 x g for 20 minutes and the supernatant 
of each well was discarded. The bacterial pellets were resuspended in 200 μL 2YT-AmpKana 
and incubated shaking overnight at 30°C.  
200 µL of target antigen was diluted to 3µg/ mL in PBS and used to coat the walls of a 96 
walls MaxiSorp plate (NUNC). The plate was incubated overnight at 4 ˚C. 
- Day four: The content of the overnight coated plate was discarded followed by three 
consecutive washes with PBS-T. The plate then blocked for 1 hour using 2% M-PBS. 
The plate with the soluble phage particles were harvested by centrifugation of the overnight 
culture plate at 3200 x g for 10 minutes. 150 µL of the supernatants from each well were 
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transferred into a new microtitre plate into the corresponding walls and blocked with equal 
volume of MPBS. After one hour incubation, the blocking buffer was discarded and 100 µL 
of the phage supernatants, diluted 1:1 in the blocking buffer, was added to relevant walls of 
the coated plate and incubated for one hour to allow binding. Following incubation, three 
washes with PBS-T were performed. Probing for phage binding was performed with 200 µL 
of HRP-conjugated anti-M13 (GE Healthcare) diluted to 0.1 µg/ mL in 2% M-PBS. Three 
final washes with PBS-T were performed, then 100 µL TMB substrate (Sigma Aldrich) was 
added to develop the chromogenic signal. The reaction was stopped with 2M sulphuric acid 
and the absorbance at 450 nm was measured.  
3.2.5 Sequencing of positive clones: 
Where more than 48 clones were positive, high-throughput sequencing of positive clones was 
performed in 96-well plate format. scFv DNA was amplified in a 96-well plate by colony 
PCR from the monoclonal glycerol stock using pHEN-forward  and M13- forward primers ( 
M13- forward act as a reverse primer in this case). PCR clean-up and sequencing was 
performed by the Australian Genome Research Facility (AGRF, The University of 
Queensland, Brisbane). For less than 48 clones, individual positive clones were sequenced by 
growing each clone in 5 mL 2YT-AmpGlu overnight at 37ºC. Phagemid DNA was extracted 
using the PureLink® Quick Plasmid Miniprep Kit (Invitrogen) to purify high-copy plasmid 
DNA as per the manufacturer‘s specifications (Refer to P44). Sequencing reactions were 
prepared using 200 ng DNA with 1 μL of either 10 μM forward or reverse primers in separate 
tubes (Table 3.2). Sequences were analysed and dominant and unique sequences were 
identified by using ExPASy translate tool, EMBL-EBI Clustal multiple alignment tool and 
CLC Main Workbench 6 program. Contig sequences were first translated into six frames and 
the correct reading frame determined by conserved sequences. After identification of heavy 
and light chains, sequences were then aligned to define the unique clones. 
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library Forward primer (5' to 3') Reverse primer (5' to 3') 
Sheets library CAGGAAACAGCTATGAC GAATTTTCTGTATGAGG 
mAbLAb library TGATTACGCCAAGCGCGCC TTTCAACGGTCTATGCGGCACC 
Immunised shark library AACAGCTATGACCATG Was not required  
 
Table 3.3: Primers used for sequencing of the positive clones. The table lists forward and reverse primers 
used to sequence the positive clones that been generated from panning on each library. The shark 
sequence is short (about 400bp) therefore; one direction primer was enough to cover the whole sequence. 
 
3.2.9 Preparation of purified phage particles: 
Positive clones were expressed as purified phage particles to further examine the binding of 
the positive clones to the desired antigens and to pick the best binder for the final 
reformatting as fully functional antibody. 
- Day one: 5 mL of 2YT-AmpGlu media was inoculated with the positive clone from 
the monoclonal glycerol plate and incubated overnight at 37° C with 220 rpm 
shaking. 
- Day two: 50 µL of the overnight culture was subcultured into fresh 5 mL 2YT-
AmpGlu and incubated shaking at 37° C until it reached the OD600 of 0.4 then, 10
11 
of 
M13K07 (helper phage ) was added and culture was incubated at 37° C for 30 mins 
non-shaking followed by 30 min shaking at 220 rpm. 
After incubation, the culture was centrifuged at 2000g for 10 min then resuspended in 
10 mL 2YT-AmpKana media and incubated overnight at 30° C with shaking. 
- Day three: overnight culture was centrifuged at 2000g for 10 min and supernatant was 
transferred to a new tube. For the precipitation, 2 mL PEG-NaCl was added to the 
supernatant then incubated on ice for 1 hour. 
After one hour, the suspension was centrifuged at 10,000g for 15 min and the 
resulting pellet was resuspended in 5 mL cold PBS followed by addition of 1 mL 
PEG-NaCl and incubation on ice for another hour. 
A final centrifugation at 10,000g for 15 min was performed and resulting pellet was 
resuspended in 1 mL cold PBS-20% glycerol and stored at -20° C. 
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3.2.8 Reformatting of positive clones into human IgG1 framework using mAbXpress 
vector system: 
To PCR amplify the variable regions from the phagemid vectors; variable gene-specific (VH 
and VL) primers (Geneworks) with 15 bp extensions complementary to the expression vector 
ends were used (Table 3.4). 
mAbXpress vectors (Jones et al., 2010) that code for human constant regions of Lambda λ 
light chains (NBF326) or the IgG1 heavy chain (NBF305) were used with the In-Fusion® 
HD Cloning Kit (Clontech) to enable ligation-free insertion of variable regions of the isolated 
antibody fragments (Figures 3.1 and 3.2). 
To amplify the variable regions of the heavy and light chains from the phagemid, PCR 
reactions prepared to contain the following: 
~10 ng DNA Template 
0.5 µL of the 10 µM forward primer 
0.5 µL of the 10 µM reverse primer 
20 µL Platinum PCR SuperMix High Fidelity (Life Technologies). 
Amplification reactions were performed in a DNA Engine (Applied Biosystems® Veriti® 
Thermal Cycler) using the following cycling:  
Initial denaturation at 94°C for 2 min then 30 cycles with denaturation at 94°C for 15s, 
annealing temperature at 55-60°C for 15s and extension at 68°C for 30s. An additional 
extension cycle of 68°C for 7 minutes was also included. 
5 µL of the PCR product was analysed by agarose gel electrophoresis (Refer to P42). After 
the conformation of the heavy and light chains amplification by gel imaging, another 5 µL of 
the PCR reaction was treated with 2 µL of Cloning Enhancer (Clontech). The mixture was 
incubated at 37 ˚C for 15 minutes and then 80 ˚C for 15 minutes in a thermal cycler. 
Lambda λ light chain (NBF326) and IgG1 heavy chain vectors (NBF305) were linearized 
using a single endonuclease restriction enzyme (SacI, New England Biolabs). Restriction 
endonuclease digest reactions were prepared as follow: 
1 µg vector DNA  
2.75 µL of the 10X NEB CutSmart buffer 
0.5 µL SacI (NEB)  
Nuclease-Free water to 20 µL final volume  
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Reactions were incubated at 37 °C for 2 hours to enable the digest of the vectors. After that, 
the linearized vectors were electrophoresed on a 1% agarose gel and the appropriate bands 
were excised and purified using the QIAEX II Gel Extraction Kit (Qiagen) according to 
manufacturer‘s instructions (Refer to P43). 
Cloning enhancer-treated PCR products from previous step were cloned into the appropriate 
linearized vectors using In-Fusion® HD Enzyme (Clontech) that prepared as follow: 
50-200 ng Linearized vector 
4 µL Cloning enhancer-treated PCR product 
2 µL 5 x In-Fusion® HD Enzyme Premix 
Nuclease-Free water to 10 µL final volume 
All components were incubated at 50 ˚C for 15 minutes and then used for transformation of 
One Shot® TOP10 Chemically Competent E.coli (Invitrogen) according to manufacturer‘s 
instructions (Refer to P39). 
100 µL of the transformation reaction was spread on LB-Kanamycin agar plates and 
incubated overnight at 37 ˚C. 
Colonies that grew overnight were screened for the insertion of the heavy and light chains by 
colony PCR (Refer to P39). Forward and reverse primers used for colony PCR were also 
utilized for sequencing (Table 3.5). 
Following correct sequence confirmation, PureLink™ HiPure Plasmid Filter Maxiprep Kits 
(Life Technologies) were used for DNA purification from a 500 mL LB broth and kanamycin 
culture (Refer to P45). The DNA was used for mammalian cell expression of IgG1 
antibodies. 
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Table 3.4: Primers used for reformatting of the positive clones. Forward and reverse primers 
used to reformat the heavy and light chains from each positive clone to be expressed as fully 
functional human antibodies. Primers were designed to include 15 bp extensions 
complementary to the expression vector ends (only the specific regions listed in this table and 
not the 15bp homologous extensions) and 'AG' dinucleotide to keep inserted sequence in frame 
with the expression vectors. Positive clone from panning on the shark library reformatted as 
fully functional human antibody and as a dAb antibody.  
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Figure 3.1: Plasmid map of λ light chain vector (NBF326). SacI linearization site used for In-Fusion® 
cloning is shown at 4568 bp (Jones et al., 2010). 
 
Figure 3.2: Plasmid map of IgG1 heavy chain vector (NBF305). SacI linearization site used for In-
Fusion® cloning is shown at 4569 bp (Jones et al., 2010). 
 
 
NBF326 JW8-Exp-hLambda
4893 bp
MT2A CDS
Neomycin
ATG
Bacterial Transcript start Kan
End of Lonza mCMV
Start of Lonza mCMV
SV40pro F primer
SV40 enhancer
pBABE 3 primer
EBV rev  primer
hLambda region
InFusion Cloning Site
SV40 Poly A
TK minimal promoter
mCMV-short LONZA
AmpR promoter
SV40 promoter
pBR322 origin
f1 origin
SV40 origin
TATA
TK PA terminator
MT2A human mRNA
BamHI (3599)
ClaI (1216)
EcoRI (3443)
HindIII (4489)
PstI (4628)
NotI (38)
SacI (4568)
ApaLI (2980)
ApaLI (4555)
XbaI (1)
XbaI (48)
AvaI (4266)
AvaI (4466)
AvaI (4795)
NcoI (1105)
NcoI (1808)
NcoI (3595)
NcoI (4505)
NBF305 JW8 ExpHC1
5581 bp
MT2A CDS
Neomycin
IgG1 HC
ATG
Bacterial Transcript start Kan
End of Lonza mCMV
Start of Lonza mCMV
SV40pro F primer
SV40 enhancer
pBABE 3 primer
EBV rev  primer
IgG1 HC Constant region
Variable region
Lonza Kozak
Infusion Cloning Site
SV40 Poly A
TK minimal promoter
mCMV-short LONZA
AmpR promoter
SV40 promoter
pBR322 origin
f1 origin
SV40 origin
TATA
TK PA terminator
MT2A human mRNA
Signal Peptide
EcoRI (3443)
HindIII (4489)
XmaI (5292)
SacI (4569)
BamHI (3599)
BamHI (5038)
NcoI (1105)
NcoI (1808)
NcoI (3595)
NcoI (4506)
78 
 
Sequence region  Forward primer (5' to 3') Reverse primer (5' to 3') 
Heavy chain TAACACCGCCCCGGTTTTCC TCACCAGGCAGCCCAGAGCG 
Light chain TAACACCGCCCCGGTTTTCC CAGGCAGACCAGGGTGGCC 
Table 3.5: Primers used for colony PCR screening and sequencing with mAbXpress vectors. Forward and 
reverse primers used to confirm the insertion of the heavy and light chain sequences into the mAbXpress 
vectors. 
 
3.2.10 Reformatting of antibody fragments from the shark library into human dAb FC: 
There was an attempt to reformat the positive clone that been generated from panning on the 
ECD of human PTPRJ using the immunized shark library into human IgG1 using the method 
explained above by cloning the same variable region for both heavy and light chains. The 
other attempt was to reformat the same positive clone into a human dAb FC by sub-cloning 
the variable region into the dAb Fc mammalian expression vector NBF218 (Figure 3.3) using 
endonuclease restriction sites BamHI and NheI.   
This vector contains an immunoglobulin kappa leader sequence, followed by BamHI and 
NheI sites for insertion of a gene of interest, followed by a human Fc coding region.  The 
vector carries the β–lactamase gene that confers ampicillin resistance for propagation in E. 
coli. 
 
Figure 3.3: Open reading frame of NBF218 vector. This is a proprietary mammalian expression vector 
containing a Vh domain sequence in frame with a human Fc domain.  The existing Vh domain was 
excised using BamHI and NheI and replaced with the shark domain sequence generated from panning on 
human ECD of PTPRJ using the immunized shark library. 
 
 
 
 
 
 
pDOM  dAb-Fc Open Reading Frame
1123 bp
Leader Sequence dAb Insert Human Fc
BamHI (65)EcoRI (2)
HindIII (1119)
Nco I (15)
NheI (434)
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Sequence region Forward primer (5' to 3') Reverse primer (5' to 3') 
dAb-FC variable 
region 
GGCTACTAGAATTCGCCGCCACCATGG
AGACC 
TTAAGTAAGCGGCCGCTATCACTTGCC
AGGGGACAGGCTCAG 
 
Table 3.6: Primers used for colony PCR screening and sequencing with NBF218 vector. Forward and 
reverse primers used to confirm the insertion of the variable region into the NBF218 vector. 
 
PCR amplification of the variable region from phagemid DNA was performed using forward 
and reverse primers that introduced the BamHI and NheI restriction endonuclease sites (Table 
3.4). PCR reaction was prepared by mixing: 
~10 ng DNA Template 
0.5 µL of the 10 µM forward primer 
0.5 µL of the 10 µM reverse primer 
20 µL Platinum PCR SuperMix High Fidelity (Life Technologies). 
Amplification reaction was performed using the following cycling:  
Initial denaturation at 94°C for 2 min then 25 cycles with denaturation at 94°C for 15s, 
annealing temperature at 55-60°C for 15s and extension at 68°C for 30s. An additional 
extension cycle of 68°C for 7 minutes was also included.  
After the PCR cycles were completed, both PCR products and the NBF218 vector were 
subjected to restriction endonuclease digestion with BamHI and NheI (Refer to P43).  
For the restriction reactions, 3 µg NBF218 vector and 0.5 μg of the PCR product (each in 
separate tube) were mixed with:   
5 μL of the10 x CutSmart™ buffer (NEB) 
1 μL BamHI (NEB)  
1 μL NheI (NEB)  
Nuclease-Free Water up to 50 µL Volume  
Both digestion reactions were kept at 37°C for 2 hours then run on a 1% agarose gel at 90 V 
for 30 minutes. The appropriate bands at the expected sizes were excised and purified using 
the QIAEX II Gel Extraction Kit (Qiagen) according to manufacturer‘s instructions. 
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Ligation of the NBF218 vector and shdAb insert was performed using Rapid DNA Ligation 
Kit (Lunardi et al.) using the following conditions: 
150 ng digested insert shdAb  
50 ng digested and gel purified NBF218 vector 
1 µL of the 5x DNA Dilution Buffer 
5 µL of the 2X DNA Ligation Buffer 
0.5 µL DNA Ligase  
10 µL total volume reaction was incubated at room temperature for 15 minutes and then 2 µL  
used for transformation of TOP 10  chemically competent cells according to manufacturer‘s 
instructions (Refer to P43). 
100 µL of the transformation reaction was spread on LB-Ampicillin agar plates and incubated 
overnight at 37 ˚C. 
Colonies that grew overnight were screened by colony PCR (Refer to P43) using the PCR 
primers from (Table 3.6) followed by sequencing with the same primers to ascertain that the 
correct dAb sequence was integrated into the NBF218 vector. 
Following correct sequence confirmation, PureLink™ HiPure Plasmid Filter Maxiprep Kits 
(Life Technologies) were used for DNA purification from a 500 mL LB broth and ampicillin 
culture (Refer to P45). The DNA was used for mammalian cell expression of shdAb 
antibody.  
3.2.11 Expression of the antibodies using mammalian cell expression system: 
All the antibodies were expressed using Chinese hamster ovary cells either by transfecting 
the cells with a single vector that coding the human FC region with the shark variable region 
(218 NBF vector with shdAb variable region) or by co-transfecting the cells with the heavy 
and light chain vectors (NBF305 and NBF326) to express fully assembled IgG1 antibodies 
following the same protocol for mammalian cell expression clarified in chapter 2 (Refer to 
P45) 
3.2.12 Purification of the recombinant monoclonal antibodies: 
All generated antibodies were purified from the culture media using protein-A 
chromatography method. The system (AKTA Explorer chromatography system, GE 
Healthcare) and column (5 mL Protein-A HiTrap™ column from GE Healthcare) were 
cleaned by flushing with 0.5 M NaOH followed by neutralization with 1 M Tris HCl pH 8.3. 
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Cellular debris was removed by centrifugation and supernatants containing the secreted 
antibody were filtered with Sartobran P300, 0.45/0.2 µm capsule filters (Sartorium Stedim) 
then pH adjusted to 7.1 and was loaded onto the column at a flow rate of 1 mL/ min. Elution 
was performed using 0.1 M glycine pH 2.7 followed by neutralization with 1/10 total elution 
volume of 1 M Tris pH 8.3. The neutralized product was desalted (buffer-exchanged) and the 
antibodies with low concentration were concentrated using Macrosep Advance Centrifugal 
Devices (Herminghaus et al.).  
3.3 Results: 
3.3.1 Panning using the conjugated peptides 
Due to the difficulties in expressing recombinant ECDs as described in Chapter 2, it was 
decided to perform the phage panning using peptides conjugated to BSA. The amino acid 
sequence of peptide number one (PEP 1) was designed to be unique to the mouse ECD of 
PTPRJ, while PEP 3 and PEP 4 were designed to be unique to the human ECD of PTPRJ. 
PEP 2 was intended to be specific to the ECD sequence of both mouse and human PTPRJ. 
(Refer to P 67) 
After obtaining the peptides from PEPTIDE 2.0 (Chantilly, VA, USA), they were conjugated 
to BSA through an acetylated N-terminal cysteine residue that facilitates immobilization in 
all peptides. Conjugated peptides then used as antigens for the phage panning and non-
conjugated BSA was used to perform negative selection to eliminate the BSA phage binders. 
3.3.1.1 Polyclonal phage ELISA from panning on the conjugated peptides 
Three rounds of panning on each peptide were completed using the Sheets (Sheets et al., 
1998) naïve human library. Polyclonal phage ELISA was then performed on the pool of 
phage isolated after each round of panning to determine if there was an enrichment of binders 
to the antigens of interest.  
The results showed that there was an enrichment of binders after the third round of panning 
for each of the peptides, with A450 readings at about 2.5 after round 3 for all four peptides at 
a titre of 0.01, compared with A450 readings of <1 after one round of panning  (Figure 3.4). 
This is expected to indicate that the pool of phage particles following the third round of 
panning contained a number of scFv candidates that have specificity to the peptides. Further 
analysis was then carried out by testing individual clones from the third round of panning for 
each peptide for binding by monoclonal phage ELISA. 
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3.3.1.2 Monoclonal phage ELISA from panning on the conjugated peptides 
The glycerol stocks containing phage particles that were rescued from the final rounds of 
panning on each peptide were streaked out on agar plates and up to 90 individual clones were 
randomly picked and screened for their ability to recognize the conjugated peptides in a 
monoclonal phage ELISA. Results showed high numbers of positive clones were binding to 
the conjugated peptides with absorbance signals above 2 (Figure 3.5) while none of these 
positive clones gave an absorbance above 1 when they were tested against the unconjugated 
BSA (Figure 3.6). 
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Figure 3.4: Polyclonal phage ELISA from panning on the conjugated peptides. Binders to the peptides 
were enhanced following second and third round of panning. 
Dilutions Dilutions 
Dilutions Dilutions 
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Figure 3.5: Monoclonal phage ELISA from the third round of panning on the conjugated peptides. 
Figure represents the positive clones that bind to peptide 1, 2, 3 and 4 respectively. PEP 1 represents 
peptide 1, PEP 2 represents peptide 2, PEP 3 represents peptide 3 and PEP 4 represents peptide 4. Labels 
1-12 and A-H represent the columns and the rows of a 96-well plate. Colours indicate individual clones 
from the 96-well plate.  
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Figure 3.6: Monoclonal phage ELISA from panning on the conjugated peptides to test the binding of the 
positive clones to the unconjugated BSA negative control. Figures show that no clones produced 
significant absorbance above 1.0, therefore selected clones were expected to be specific to the desired 
peptides. PEP 1 represents peptide 1, PEP 2 represents peptide 2, PEP 3 represents peptide 3 and PEP 4 
represents peptide 4. Labels 1-12 and A-H represent the columns and the rows of a 96-well plate. Colours 
indicate individual clones from the 96-well plate.  
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3.3.1.3 Sequencing of positive clones from panning on the conjugated peptides and 
reformatting 
Due to the large number of positive clones obtained from the monoclonal ELISA of the 
conjugated peptides, a 96-well plate format was used to enable sequencing of a greater 
number of clones. Sequences were analysed by comparing the CDR regions of both variable 
heavy (Figure 3. 7) and light (Figure 3. 8) chains to identify the dominant and unique clones 
from panning on each peptide. Sequence analysis showed a number of unique and dominant 
clones and it was difficult to decide which clones should proceed to reformatting into IgG1 
framework. A total number of 18 clones (1-A1, 2-C1, 2-F1, 2-B2, 2-G2, 2-H2, 2-F3, 2-H3, 2-
E4, 2-G4, 3-F1, 3-A2, 3-H2, 3-A3, 3-B3, 3-A4, 4-F2 and 4-C3) were expressed as purified 
phage particles to further characterise the binding of these positive clones to the conjugated 
peptides as well as the native mouse and human PTPRJ. The binding of these purified phage 
particles were tested by flow cytometry, western blotting, ELISA and immunofluorescence 
(data not shown). The binding properties of these particles to the conjugated peptides and to 
the native PTPRJ was inconsistent from one test to another, making the results inconclusive 
and it was not possible to select the best phage for reformatting based on these semi 
quantitative binding assays. In addition, purified phage often display low affinity binding, 
until reformatted into an IgG backbone, which can account for apparent lack of binding on 
some assays. Since there was specific binding of phage to peptides (Figures 3.5 and 3.6), the 
most dominantly represented sequences from each peptide panning were selected for 
reformatting (1-A1, 2-F1, 2-H3, 3-A4 and 4-F2). Out of the 25 clones that were screened 
from each panning, 1-A1 was represented by 16 clones, 2-F1 was represented by 6 clones, 2-
H3 was represented by 3 clones, 3-A4 was represented by 16 clones and 4-F2 was 
represented by 17 clones.  
The variable regions from the phagemid vectors of the selected clones were PCR amplified 
(Figure 3.9) and mAbXpress vectors (Jones et al., 2010) that code for human constant regions 
of Lambda λ light chains (NBF326) or the IgG1 heavy chain (NBF305) were used with the 
In-Fusion® HD Cloning Kit (Clontech) to enable ligation-free insertion of variable regions of 
the isolated antibody fragments. Insertion of the variable heavy and light chains was 
confirmed by colony PCR screening (Figures 3.10) and sequencing. Clone 2-H3 was 
excluded from further processing due to a mutation in the variable light chain, while all the 
remaining clones were in-frame with the expression vectors. Recombinant antibodies were 
then expressed using Chinese hamster ovary cells by co-transfecting the cells with the heavy 
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and light chain vectors containing the variable regions from the positive phagemid to express 
fully assembled IgG1 antibodies. Ten days post transfection, supernatants were collected and 
purified using protein-A chromatography (Figure 3.11).  
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Figure 3.7: sequence analysis of the CDR regions of the variable heavy chains from panning on the 
conjugated peptides. CLC Main Workbench 6 program, ExPASy translate tool and EMBL-EBI Clustal 
multiple alignment tool were used to identify the unique and dominant sequences. PEP 1 represents 
peptide 1, PEP 2 represents peptide 2, PEP 3 represents peptide 3 and PEP 4 represents peptide 4. 
Heavy hain 
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Figure 3.8: sequence analysis of the CDR regions of the variable light chains from panning on the 
conjugated peptides. CLC Main Workbench 6 program, ExPasy translate tool and EMBL-EBI Clustal 
multiple alignment tool were used to identify the unique and dominant sequences. PEP 1 represents 
peptide 1, PEP 2 represents peptide 2, PEP 3 represents peptide 3 and PEP 4 represents peptide 4. 
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Figure 3.9: Agarose gel electrophoresis showing PCR products of the heavy and light chains amplified 
from the phage clones selected from panning on the conjugated peptides. Lane 1: Bioline Hyperladder I, 
lane 2- 6: amplified heavy chain products at about 400 bp, lane 7- 11: amplified light chain products at 
about 400 bp. Arrow indicates PCR products of the heavy and light chains at the expected size.  
 
 
 
Figure 3.10: Agarose gel electrophoresis representing colony PCR screening for the insert of variable 
heavy and light chains from panning on the conjugated peptides into the mAbXpress vectors. First lane 
contains HyperLadder™ I molecular weight marker. For each clone, five colonies from heavy and light 
chain were screened for the present of the insert. PCR products pointed by the arrows at ~ 600 bp 
indicates positive colonies with successful insert and PCR products at ~ 300 bp indicate negative colonies 
with no insert. 
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Figure 3.11: SE-HPLC analysis of the purified monoclonal antibodies generated from panning on the 
conjugated peptides. P1-A1 is an antibody generated from panning on peptide #1 and it was predicted to 
be specific to the mouse ECD of PTPRJ. P2-F1 is an antibody generated from panning on peptide #2 and 
it was predicted to cross react with both mouse and human ECDs of PTPRJ. P3-A4 is an antibody 
generated from panning on peptide #3 and it was predicted to be specific to the human ECD of PTPRJ. 
P4-F2 is an antibody generated from panning on peptide #4 and it was predicted to be specific to the 
human ECD of PTPRJ (Refer to P 67). 
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3.3.1.4 Characterisation of the binding of reformatted antibodies derived from panning 
on the conjugated peptides 
The recombinant antibodies were characterised by western blot, flow cytometry, ELISA and 
immunofluorescence to confirm the specificity of these reformatted antibodies towards the 
peptides and towards the native mouse and human PTPRJ, but results were conflicting (data 
not shown due to the large number of figures and images obtained). The peptides used for 
panning were designed carefully to ensure that the generated antibodies would expect to have 
high specificity to PTPRJ ECDs. Conversely, frequent non-specific binding of the antibodies 
and unexpected cross-reactivity towards mouse and human PTPRJ were observed.  
To understand whether it was a fortuitous cross-reactivity of the antibodies binding or 
another possible problem accrued during panning or reformatting of these antibodies, a test 
ELISA was performed. Phage clones from panning on peptide number 4 were grown from 
glycerol plate and were tested for binding against all the conjugated peptides used for 
panning (Figure 3.12). While these phage clones were expected to bind only to the 
conjugated peptides against which they were panned, the ELISA results revealed that the 
phage clones were binding to all the conjugated peptides. Since the phage clones were 
binding to each conjugated peptide in the same way, it was clear that they were binding to a 
shared epitope of the four conjugated peptides. The four peptides all contain an acetylated N-
terminal cysteine which is used to conjugate to BSA via a maleimide linkage.  Although free 
BSA was used for negative subtraction during the panning, and no binding was observed for 
free BSA, it is possible that the clones are binding to a shared epitope at the linkage between 
the peptide and the BSA. To test this theory, another test ELISA was performed but this time 
the same phage clones were tested against the non-conjugated peptide number 4. 
Unfortunately, the results confirmed that the generated monoclonals were not specific to the 
targeted antigens (Figure 3.13). This shows that negative selection using free BSA was not 
optimal, since the phage binders isolated seem to be binding to the junction between the BSA 
protein and the acetylated N-terminal cysteine. Thus for future work using conjugated 
peptides, BSA conjugated to a non-related peptide should be used for negative selection 
rather than free BSA. At this point, recombinant ECDs of mouse and human PTPRJ became 
available, and efforts were switched to generate antibodies against the recombinant 
extracellular domains. Therefore, the causes for this spurious cross-reactivity were not 
investigated further. 
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Figure 3.12: Binding of phage clones from panning on the conjugated peptide number 4 to conjugated 
peptide number 1, 2, 3, and 4. PEP 1, PEP2, PEP3 and PEP4 represent the binding of the PEP4 phage 
clones to conjugated peptides 1, 2, 3 and 4 respectively. The ELISA result indicated non-specific binding 
of all conjugated peptides to the clones from single conjugated peptide panning. 
 
 
Figure 3.13: Binding of phage clones from panning on the conjugated peptide number 4 to (A) conjugated 
and (B) non-conjugated peptide number 4. ELISA result shows that although many clones bind to the 
conjugated peptide, none are binding to the non-conjugated peptide.  
94 
 
3.3.2 Panning on the recombinant ECDs of mouse and human PTPRJ 
The antibodies generated from panning on the conjugated peptides were characterised as non-
specific binders therefore, they were not appropriate for the purpose of studying the 
biological effect of the ECD of PTPRJ. While it was possible to perform another panning on 
the conjugated peptides using BSA carrier protein with unrelated peptide for the negative 
selection steps, the ECDs of mouse and human PTPRJ were successfully expressed and 
purified by this time (Chapter 2). In this attempt, recombinant ECDs were used as antigens 
for the phage panning and unrelated His tagged protein (His-tagged EGFR-specific scFv) was 
used for the negative selection to eliminate the non-specific phage binders to the His tag. 
3.3.2.1 Panning on the recombinant ECD of mouse PTPRJ   
Three iterative rounds of biopanning on the recombinant mouse ECD were completed using 
the human naive scFv library (mAbLAb). Normally, three rounds of phage panning on the 
target antigen are sufficient to enhance the positive binders. However, in some cases, up to 
five rounds of phage panning are required to reasonably enrich the pool of positive binders.  
Following the third round of panning on the mouse ECD, poly-clonal ELISA was performed 
and the results showed a satisfactory enrichment of the target specific phage through the 
iterative rounds of biopanning (Figure 3.14).  
The glycerol stock containing phage particles that were rescued from the third round of 
biopanning was streaked out on agar plates and up to 90 individual clones were randomly 
picked and screened for their ability to recognize the recombinant ECD of mouse PTPRJ. 
However, the monoclonal ELISA did not show any positive clones with an absorbance higher 
than 2 (Figure 3.15) which is generally required before further processing of the panning. 
Therefore, and in order to improve the enrichment of the positive binders, a fourth round of 
panning was performed on the ECD of mouse PTPRJ followed by another polyclonal ELISA. 
The pool of positive binders after fourth round of panning reached the absorbance of 3 
(Figure 3.16) thus, the possibility of selecting a relatively strong positive clone was greater. 
The polyclonal ELISA was followed by a monoclonal ELISA to identify individual positive 
clones. Among the 90 clones that were tested for binding to the recombinant ECD, one clone 
(B12) gave a maximum absorbance reading of 4 (Figure 3.17). 
To confirm the binding of B12 clone that generated the highest absorbance reading during the 
monoclonal ELISA, to the recombinant mouse ECD, and to negate the possibility of the high 
absorbance reading being due to nonspecific binding to the plate, this clone was expressed as 
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a purified phage particle and another ELISA was performed against the recombinant mouse 
and human ECDs (Figure 3.18). ELISA result confirmed that clone B12 is binding selectively 
to both PTPRJ ECDs with maximum absorbance, and this absorbance can be titrated down. 
There was minimal binding to the His tagged control protein (His-tagged EGFR-specific 
scFv), hence, the possibility of selecting a nonspecific clone against the tag was eliminated. 
Variable gene-specific (VH and VL) primers were used to PCR amplify the variable regions 
from the B12 phagemid clone (Figure 3.19), and mAbXpress vectors that code for human 
constant regions of the λ light chains and the IgG1 heavy chain were employed to reformat 
and express this clone as fully functional human antibody. Successful insertion of the variable 
heavy and light chains into the expression vectors was confirmed by colony PCR screening 
(Figure 3.20) and sequencing. CHO cells were co-transfected with heavy and light chain 
vectors and secreted antibody was purified using protein-A chromatography method that 
generated purified desalted antibody at a concentration of 1.34 mg/ mL. Characterisation of 
the purified antibody by SDS-PAGE (Figure 3.21) shows a non-reduced major polypeptide 
with a molecular weight of approximately 150 kDa (Lane 3), consistent with that of complete 
IgG1 and (Lane 2) shows a reduced polypeptides running at about 50 kDa and 25 kDa, 
consistent with heavy and light chains respectively. The purity of the antibody was 
investigated by SE-HPLC and a single major peak was obtained, showing no evidence of 
degradation (Figure 3.22).  
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Figure 3.14: Polyclonal phage ELISA after three rounds of panning on recombinant ECD of mouse 
PTPRJ. Binders to the recombinant mouse ECD were enhanced following first, second and third rounds 
of panning to reach an absorbance of 2.5 compared to the negative control His tagged protein with a 
maximum absorbance of 1.5. No phage and no antigen negative controls were also included.  
 
Figure 3.15: Monoclonal phage ELISA after third round of panning on the recombinant ECD of mouse 
PTPRJ. Whilst most clones showed absorbance higher than control values, only one of the selected clones 
had an absorbance at 2. In addition to the recombinant mouse ECD, clones were tested against unrelated 
His tagged protein (His-tagged EGFR-specific scFv) to eliminate the possibility of generating antibodies 
against the His tag. The binding of the clones was determined by the absorbance value measured after 
probing with HRP-conjugated α–M13. Labels 1-12 and A-H represent the columns and the rows of a 96-
well plate. 
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Figure 3.16: Polyclonal phage ELISA after fourth round of panning on the recombinant ECD of mouse 
PTPRJ. Binders to the recombinant mouse ECD were enhanced following first, second, third and fourth 
rounds of panning to reach an absorbance of 3 compared to the negative control His tagged protein with 
a maximum absorbance of just above 0.5. No phage and no antigen negative controls were also included.  
 
Figure 3.17: Monoclonal phage ELISA after fourth round of panning on the recombinant ECD of mouse 
PTPRJ. One selected clone showed a maximum absorbance with the recombinant ECD at about 4. In 
addition to the recombinant mouse ECD, clones were tested against unrelated His tagged protein (His-
tagged EGFR-specific scFv) to eliminate the possibility of generating antibodies against the His tag. The 
binding of the clones was determined by the absorbance value measured after probing with HRP-
conjugated α–M13. Labels 1-12 and A-H represent the columns and the rows of a 96-well plate. 
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Figure 3.18: Binding of B12 purified phage clone to the recombinant mouse and human PTPRJ. ELISA 
result confirms the binding of B12 to the recombinant mouse and human ECDs at a maximum 
absorbance of about 4. No cross-reactivity of the B12 clone with the unrelated His tagged protein (His-
tagged EGFR-specific scFv) was detected. The binding of the clone was determined by the absorbance 
value measured after probing with HRP-conjugated α–M13. 
 
 
 
 
 
 
 
 
 
 
 
3 2 1 
Figure 3.19: Agarose gel electrophoresis after PCR 
amplification of the variable heavy and light chains from 
the phage monoclonal B12. Lane 1: HyperLadder I 
molecular weight marker, lane 2: amplified variable 
heavy chain, lane 3: amplified variable light chain. Arrow 
indicates PCR products at the expected molecular weight 
of ~400 bp. 
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Figure 3.20: Agarose gel electrophoresis of B12 colony PCR screening for the insertion of the 
variable heavy and light chains into the expression vectors. A) Colonies screened for the 
insertion of the variable heavy chain, B) Colonies screened for the insertion of the variable light 
chain. Lane 1: HyperLadder™  molecular weight marker, lane 2- 15: colonies screened with 
successful insertion showed a product at ~ 600 bp, while colonies with PCR products at ~ 200 bp  
indicate colonies with no variable region inserted.  
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Figure 3.22: SE-HPLC analysis of the purified monoclonal antibody B12 generated from panning on the 
recombinant mouse ECD. 
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Figure 3.21: SDS gel page of the 
recombinant monoclonal antibody B12 
generated from panning on the recombinant 
mouse ECD. Lane 1: SeeBlue Plus 
Prestained protein standard (Invitrogen), 
lane 2: reduced recombinant antibody B12 
with heavy chain running at 50 kDa and 
light chain running at 25 kDa. Lane 3: non-
reduced recombinant antibody B12 with 
intact antibody running at 150 kDa.  
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3.3.2.2 Panning on the recombinant ECD of human PTPRJ   
The initial panning attempt to generate antibodies against the ECD of human PTPRJ was 
performed using the human naïve scFv library (mAbLAb). Two separate pannings up to four 
rounds were performed however, in both attempts there was no satisfactory enrichment of 
any positive binders and the absorbance did not exceed the 1.5 absorbance units (Figure 3. 
23). An absorbance reading below 2, especially after fourth round of panning, indicates that 
there are no positive binders to the antigen in the library.  
 
 
 
Figure 3.23: Polyclonal phage ELISA after fourth round of panning on the recombinant ECD of human 
PTPRJ using the naïve human library (mAbLAb). Binders to the recombinant mouse ECD were slightly 
enhanced following first, second, third and fourth rounds of panning. However, with an absorbance 
below 1.5, the chance of picking positive clones from monoclonal ELISA was very low.  Negative control 
His tagged protein (His-tagged EGFR-specific scFv), no phage and no antigen negative controls were also 
included. 
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For the second attempt to generate monoclonal antibodies against the ECD of human PTPRJ, 
an immunized shark library was used. The shark library was kindly provided by Prof Ross 
Barnard (SCMB, The University of Queensland) and it was created by immunizing two 
wobbegong sharks with KM-H2 and L-428 cells (human Hodgkin's Lymphoma cell lines). 
The original aim of the Barnard lab was to generate a human dendritic cell-biased 
recombinant antibody library. These two human Hodgkin's Lymphoma cell lines have 
phenotypic similarities to dendritic cells (Uehira et al., 2001) and recently published data 
from the FANTOM 5 consortium showed that dendritic cells have a high level of PTPRJ 
expression http://fantom.gsc.riken.jp/5/sstar/EntrezGene:5795. Therefore, the probability of 
generating positive binders from panning using the immunised shark library might be greater 
than with the naïve human library.  
Three rounds of panning using the shark library were completed and followed by a polyclonal 
phage ELISA. The results indicated an enrichment of the phage binders of up to 2.7 
absorbance units after the third round of panning (Figure 3.24). Once the enrichment of the 
positive binders was confirmed, monoclonal phage ELISA was performed and from the 90 
clones that were screened, two clones (G6 and H9) showed a maximum absorbance reading 
of ≥ 4 (Figure 3.25). Sequence analysis of these two positive clones revealed that they came 
from the same phage clone and were therefore duplicates.   
3.3.2.3 Reformatting of the positive clone from panning on the recombinant ECD of 
human PTPRJ using the immunized shark library.  
There were two attempts to reformat the positive clone that was generated from the 
immunized shark library. Due to the unusual structure of the shark antibodies as a single-
domain antibody comprising one variable domain (VH) (Figure 3.26), it was challenging to 
use the mAbXpress system to express a common immunoglobulin G (IgG) antibody. 
However, the risk was taken to clone the VH region from the shark clone (Figure 3.27) into 
both the heavy and light chain mAbXpress vectors, to reformat and express this clone as a 
'quadrant' antibody containing four VH domains (Sh4V). Successful insertion of the variable 
chain into the expression vectors was confirmed by colony PCR screening (Figure 3.28) and 
sequencing.  
 
103 
 
 
Figure 3.24: Polyclonal phage ELISA after third round of panning on the recombinant ECD of 
human PTPRJ using the immunized shark library. Binders to the recombinant human ECD 
were enhanced following first, second and third rounds of panning to reach an absorbance of 
2.7 compared to the negative control His tagged protein (His-tagged EGFR-specific scFv) with 
a maximum absorbance below 0.5. No phage and no antigen negative controls were also 
included. 
Figure 3.25: Monoclonal phage ELISA after third round of panning on the recombinant ECD of human 
PTPRJ using the shark library. Two selected clones (G6 and H9) showed a maximum absorbance with 
the recombinant ECD at about 4 absorbance units. In addition to the recombinant human ECD, clones 
were tested against unrelated His tagged protein (His-tagged EGFR-specific scFv) to eliminate the 
identify binders to the His tag. The binding of the clones was determined by the absorbance value 
measured after probing with HRP-conjugated α–M13. Labels 1-12 and A-H represent the columns and 
the rows of a 96-well plate. 
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Figure 3.27: Agarose gel electrophoresis 
representing PCR amplification of the variable 
chain from the shark positive clone to be 
reformatted as a quadrant antibody (Sh4V). 
Lane 1: HyperLadder™ I molecular weight 
marker, lane 2: PCR product at about 400 bp 
that was amplified for the insertion into the 
heavy chain expression vector, lane 3: PCR 
product at about 400 bp that was amplified for 
the insertion into the light chain expression 
vector. 
Figure 3.26: Schematic representation of shark 
antibody structure. The new antigen receptor 
(IgNAR) from sharks is a disulphide bonded 
dimer of two protein chains, each containing one 
single variable region and five constant 
domains. Obtained from (http://www.chemie.tu-
darmstadt.de/media/arbeitsgruppe_kolmar/bild
er_fuer_science/IgG-VNAR-VHH-Allgemein_-
Alex-Diss_richtig.jpg). 
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Figure 3.28: Agarose gel electrophoresis representing Sh4V colony PCR screening for the insertion of the 
variable heavy and light chains into the expression vectors. A) Colonies screened for the insertion of the 
variable region into the heavy chain vector, B) Colonies screened for the insertion of the variable region 
into the light chain vector. Lane 1: HyperLadder™ I molecular weight marker, lane 2- 15: colonies 
screened with successful insertion showed a product at ~ 600 bp, while colonies with PCR products at ~ 
200 indicate colonies with no variable region inserted.  
CHO cells were co-transfected with heavy and light chain vectors, each containing the shark 
VH region, and secreted antibody was purified using protein-A chromatography that 
generated purified desalted antibody at a concentration of 0.2 mg/ mL. It was suspected that 
the intact whole mAb structure for Sh4V may be unstable due to electrostatic repulsion from 
the identical sequences of the variable heavy and light chains (pI = 8.44, positively charged in 
cell culture supernatant, pH = 7.3). SE-HPLC and SDS-PAGE page were performed in order 
to determine the apparent MW and size of the purified antibody.  The sample was analysed 
using a Tosoh Biosciences TSKgel SW3000 column. Although the sample concentration was 
very low to achieve a suitable signal/noise ratio, it was evident that the sample contained 
different species of multiple sizes (Figure 3.29, A). It appears that the sample contains very 
~600bp 
  
~200bp 
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high molecular weight aggregates (HMWA) along with some species at sizes less than 
expected for an intact antibody (150 kDa). The sample was concentrated using an Amicon-4 
ultracentrifugal concentrator to a concentration of 0.6 mg/mL and re-run on the column. The 
chromatogram (Figure 3.29, B) shows an uneven baseline due to carryover contamination 
from a previously run sample that was partially retained on the column however the principal 
features of the Sh4V was still discernible (although the relative peak areas appear slightly 
different to the sample run at 0.2 mg/mL).  The retention times for both the 0.2 mg/mL and 
0.6 mg/mL runs appear identical however. 
The presence of multiple molecular weight species as shown in (Table 3.7) indicated that the 
intact mAb structure was not stable. It appears that this mAb has a propensity to aggregate 
into higher order structures and also appears to have fragmented or more likely has not folded 
and assembled correctly during expression and secretion.  The 2
nd
 peak (Figure 3.29) may 
represent some intact mAb that appears at a lower MW but was partially retained on the 
column due to non-specific adsorption or perhaps has a tighter conformation than the 
globular protein standards.  Alternatively it may be a lower MW species such as 2 x heavy 
chains or heavy-light chain (less likely due to the same instability prediction from 
electrostatic repulsion). There was clear evidence for independent light chain or single dAb 
(variable heavy or light chain) species as shown by peaks 3 and 4 however. This theory was 
confirmed by SDS-PAGE analysis of the purified antibody (Figure 3.30). A reduced sample 
of mAb is predicted to contain heavy and light chains at the molecular weights of 50 kDa and 
25 kDa respectively and the non-reduced sample expected to represent a fully intact antibody 
at the molecular weight of 150 kDa however, no major bands of the correct molecular 
weights were present in the SDS-PAGE possibly because the instability of the whole 
antibody structure.  
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Figure 3.29: SE-HPLC analysis of the purified monoclonal antibody Sh4V generated from panning on the 
recombinant human ECD using the immunized shark library. A sample of Sh4V in D-PBS (pH 7.3) was 
analysed using a Tosoh Biosciences TSKgel SW3000 column at  flow rate of 0.5 mL/min in a running 
buffer of 100 mM Sodium phosphate pH 6.8 + 200 mM NaCl , at two different concentrations: A) 0.2 
mg/mL and B) 0.6 mg/mL.  
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Sample Peak 
Ve 
(Sheets et 
al.) 
Ve 
(mL) 
Calculated 
  MW (kDa) 
Possible Ab Species 
1 11.777 5.8885 >500 HMWA 
2 19.557 9.7785 74 
2H (96 kDa) or HL (71 kDa) or 
intact mAb retained on the 
column 
3 22.057 11.0285 25 Light chain (23 kDa) 
4 24.015 12.0075 11 
VH or VL (12 kDa) 
 
Table 3.7: Apparent molecular weights and possible antibody species from (SE-HPLC) analysis of Sh4V 
antibody. Molecular weights were calculated using a standard curve generated of the retention times of 
known molecular weight standards. 
 
 
The second approach to reformat the positive shark clone from panning on the recombinant 
human ECD using the shark immunized library was to express the shark Vh domain as a 
fusion to a human Fc domain antibody as a single domain antibody (sdAb), also termed a 
heavy chain antibody (hcAb) (Figure 3.31). The variable region from the positive clone was 
PCR amplified (Figure 3.32), incorporating BamHI and NheI sites for cloning, and then 
cloned into an in-house expression vector (NBF218), which contains a dAb-Fc with a BamHI 
site in the leader sequence and a NheI site between the dAb and the Fc region. Correct 
1 2 3 
~70 kDa 
  
~55 kDa 
  ~40 kDa 
  
Figure 3.30: SDS page of the recombinant 
monoclonal antibody Sh4V generated from 
panning on the human ECD using the immunized 
shark library. Lane 1: SeeBlue Plus Prestained 
protein standard (Invitrogen), lane 2: reduced 
recombinant antibody Sh4V with heavy chain 
running at ~55 kDa and light chain running at ~40 
kDa. Lane 3: non-reduced recombinant antibody 
Sh4V with intact heavy and light chains running 
at ~70 kDa  
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insertion of the variable region into the expression vector was confirmed by colony PCR 
screening (Figure 3.33) and sequencing. The antigen binding site of a sdAb is composed of 
only one domain, called VH, in contrast to regular antibodies in which that region is 
composed of VH and VL. The sdAb also lacks the CH1 domain of a heavy chain, and the 
hinge region is elongated in comparison to regular IgG (Figure 3.26). CHO cells were 
transfected with the single expression vector, encoding the shark variable sequence and human Fc 
region. Secreted antibody was purified using protein-A chromatography and desalted into 
PBS. An Amicon-4 ultracentrifugal concentrator was used to concentrate the antibody to a 
final concentration of 6.5 mg/mL. Purified antibody was tested for any possible degradation 
by SDS-PAGE (Figure 3.34) and SE-HPLC analysis (Figure 3.35). Analysis of purified 
shdAb antibody indicated that reformatting the shark variable region into a single domain 
antibody resulted in an antibody that has better stability. 
 
 
 
Figure 3.31: Reformatting of the shark positive clone into a common IgG1 structure and into a single 
domain antibody structure. A) Variable region from the shark positive clone was cloned into both the 
heavy and light chain vectors to express a full antibody. B) The shark variable region was cloned into a 
dAb-FC vector to express a single domain antibody. Figure obtained from 
(http://www.chromotek.com/about-us/the-alpaca-antibody-advantage/).  
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Figure 3.33: Agarose gel electrophoresis representing colony PCR screening for the insert of the variable 
region of the shark positive clone to be reformatted as a single domain antibody (shdAb). Lane 1: 
HyperLadder™ I molecular weight marker, lane 2- 15: PCR products from the screened colonies. PCR 
product at ~ 1000 bp indicates positive insertion into the expression vector. 
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Figure 3.32: Agarose gel electrophoresis 
representing PCR amplification of the variable 
region from the shark positive clone to be 
reformatted as a single domain antibody (shdAb). 
Lane 1: HyperLadder™ I molecular weight marker, 
lane 2:  PCR product at about 400 bp 
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Figure 3.35: SE-HPLC analysis of the purified monoclonal antibody shdAb generated from 
panning on the human ECD using the shark library. 
 
 
 
 
Figure 3.34: SDS-PAGE of the recombinant 
monoclonal antibody shdAb generated from 
panning on the human ECD using the 
immunized shark library. Lane 1: SeeBlue 
Plus Prestained protein standard 
(Invitrogen), lane 2: reduced recombinant 
antibody shdAb running at ~30 kDa. Lane 3: 
non-reduced recombinant shdAb antibody 
running at ~75 kDa. 
3 2 1 
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3.4 Discussion: 
The major aim of this project is to characterize the expression of PTPRJ and investigate its 
biological function using antibodies against the extracellular domain. Several antibodies 
against the PTP domain are available, however there is a paucity of antibodies against the 
extracellular domain and in particular human monoclonal antibodies against the ECD regions 
of mouse and human PTPRJ are unavailable. The few commercially available antibodies 
have limited function and in our hands appear to bind with low affinity and with high 
backgrounds in e.g. western blotting and flow cytometry. Thus it was deemed important to 
generate our own antibodies. Phage biopanning technology was the preferred technique for 
this purpose mainly because the technique generates human-derived antibodies, if the library 
is made from human variable regions, and these antibodies can have therapeutic applications.  
Despite the difficulties that were initially encountered in generating recombinant antigens for 
biopanning, and panning on peptide mimics, eventually two monoclonal antibodies were 
successfully isolated and reformatted with specific binding of these antibodies to the ECD 
region of mouse and human PTPRJ. In addition, the few phage panning attempts that were 
unsuccessful provided some practical facts that must be considered in the planning of 
panning strategies, in regards to the type of the phage library, the panning antigens, negative 
subtraction, and the reformatting strategy.  
BSA conjugated peptides were used as alternative panning antigens in the first phage panning 
strategy, due to the difficulties that were encountered during the expression of the 
recombinant ECDs of mouse and human PTPRJ. This panning methodology enables selection 
of phage antibodies targeting specific epitopes on the surface of protein and eliminates the 
requirement of epitope mapping of the antibody binding. However, one disadvantage of using 
this method for biopanning arises from the conformational stability of the antigen; since some 
selected phage antibodies against adsorbed antigens cannot bind the antigen in its native 
conformation (Sanna et al., 1995) and similarly, antibodies that developed against a linear 
sequence may not recognize, or bind poorly to, native antigens in a correctly folded 
polypeptide. 
Peptides are often conjugated to another molecule, such as bovine serum albumin (BSA) or 
biotin, to allow immobilisation of the antigen for phage panning. Therefore, subtractive 
panning, or the incubation of phage antibody mixture with the carrier protein prior to its 
transfer to the peptide-carrier conjugate, should performed to select for peptide-specific 
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binding and remove carrier binding antibodies (Strachan et al., 2002, Barbas et al., 1993, 
Moghaddam et al., 2001, Sheedy et al., 2007). 
During panning on the BSA-conjugated peptides, subtractive panning was performed using 
unconjugated BSA to eliminate the nonspecific binders. Nevertheless, the isolated antibodies 
from panning on the conjugated peptides proved to be nonspecific to the target antigens. 
There have been several reports of antibodies that were generated from panning on 
conjugated peptides could bind to the peptides when they are conjugated to the carrier 
molecule but not to the peptides or the carrier molecule alone This phenomenon has been 
observed before; Moghaddam et al reported that they frequently isolate antibodies from phage 
libraries that can bind to low molecular weight molecules such as amphetamine and steroids, but 
only when conjugated to a carrier molecule, and do not bind to the carrier alone  (Moghaddam et 
al., 2001). In fact, subtractive panning should remove any antibody binding to the carrier 
protein, but not those antibodies binding to the bridging group linking the carrier protein and 
the peptide. As a consequence, the linkage itself is involved in the epitope, thereby panning 
antibody libraries with BSA-peptides conjugates may favour the enrichment of antibodies 
that preferentially bind the conjugated peptides rather than the peptides alone (Chames et al., 
1998, Moghaddam et al., 2001).  
For future consideration, subtractive panning, when carrier-peptides used for phage panning, 
should performed on the carrier molecular that was conjugated to unrelated control peptide to 
eliminate the carrier and the linkage binders rather than eliminating the carrier binders only. 
This strategy will reduce the number of non-specific phage antibodies isolated and increase 
the possibility of isolating antibodies with high specificity to the desired antigens.  
Once the recombinant mouse and human ECDs were successfully expressed, an alternative 
panning strategy was initiated using the fill length ECD polypeptides and exploiting a novel, in-
house generated, naïve human library mAbLAb. The recombinant ECDs contain N-terminal 
polyhistidine (6xHis) tag that was incorporated for detection and purification purposes. 
Therefore, subtractive panning using an unrelated His tagged protein was essential to exclude 
His tag binders from the panning library. One antibody from panning on the recombinant 
mouse ECD was isolated and reformatted as a complete fully human antibody. In contrast, 
panning on the recombinant ECD of human PTPRJ using the naïve human library failed to 
isolate any strong binders. The enrichment of the phage binders was very poor and no 
positive clones were identified from the monoclonal ELISA following fourth and fifth rounds 
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of panning. In humans, PTPRJ is widely expressed in many cell types, including epithelial 
and endothelial cells, fibroblasts, and most haematopoietic cells (Heddy, 2007, Lin et al., 
2004, Acton, 2012). It is possible that, since PTPRJ is a ubiquitously expressed molecule, 
many auto-reactive cell clones would be eliminated during development of the immune 
system, thus establishing tolerance to PTPRJ (Medzhitov et al., 2012, Fenner, 1983). This 
might result in few, if any PTPRJ-reactive clones in the cells used to generate the library 
from a naïve donor. Since the library used for panning is a naïve adult human library, 
tolerance may explain the lack of any positive binders.  
To increase the chance of isolating positive clones against the recombinant ECD of human 
PTPRJ from phage panning, another panning strategy was performed using an immunized 
shark library. This library was generated by immunizing the sharks with KM-H2 and L-428 
cells which were demonstrated to originate from the cells that had differentiated through the 
possible common DC-B-cell progenitors along a new proposed pathway (Uehira et al., 2001) 
. In addition, these cells were shown to be able to potently stimulate peripheral blood T cells 
and to have the strong endocytotic activity of fluorescein isothiocyanate-dextran, which 
further suggests the phenotypic similarity of these cells with dendritic cells (Uehira et al., 
2001). According to FANTOM 5 analysis of the PTPRJ expression, it was revealed that 
dendritic cells have a high level of PTPRJ expression therefore, we postulated that exploiting 
such a library generated from sharks immunized with the dendritic related cells, might 
enhance the chances of successfully isolating specific binders to the recombinant human 
ECD. After three rounds of panning using the shark immunized library, an enrichment of the 
positive binders was observed and one positive clone at the maximum binding absorbance 
was isolated.  
Shark antibodies are composed of a heavy-chain homodimer that does not associate with light 
chains. The variable region of these heavy-chain antibodies (termed VHH) is structurally 
different from those of conventional antibodies, particularly in the region that would usually 
form the interface with VL (Muyldermans et al., 1994, Greenberg et al., 1995, Dooley et al., 
2003a). Therefore, selection from the shark phage library results in the isolation of the VHH 
region only, thus the normal procedure of cloning individual heavy chain and light chain 
sequences into their respective vectors to express a fully conventional antibody cannot be 
used. Two models have been proposed concerning the reconstruction of the isolated positive 
clone into antibody-like structures.  First was to amplify the single variable region from the 
shark phage clone and ligate it into both the heavy and light chain vectors to express a typical 
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chimeric antibody (Sh4V). Since each single shark variable region constitutes an antigen 
binding site, this reformatting strategy would result in a homodimer molecule consisting of 
two heavy chains and two light chains each with an antigen-binding site eventuating in a 
quadrivalent antibody with two antigen binding sites per single Fab fragment. The second 
plan was to amplify the shark variable region and reformat it as a single domain antibody 
which would be very similar to the native bivalent shark antibody structure but with a human 
Fc region (shdAb). Both proposed structures were constructed by PCR, cloned into the 
expression vectors and were expressed using CHO cells. 
 It was suspected that the whole mAb structure for Sh4V might be unstable due to 
electrostatic repulsion from the identical sequences of the variable heavy and light chains (pI 
= 8.44, positively charged in cell culture supernatant, pH = 7.3). Analysis of the purified 
Sh4V antibody revealed that the sample of the antibody contained different species of 
multiple sizes. It was clear that the sample contains very high molecular weight aggregates 
(HMWA) along with some species at sizes less than expected for an intact antibody (150 
kDa). In order to determine the exact species presented, it would be necessary to perform MS 
analysis or SE-HPLC with light scattering detection. Analysis by SE-HPLC with LS 
detection was attempted however; the sample concentration was too low to determine the 
molecular weights.  In any case, this was considered unnecessary as the molecule was clearly 
unstable and would require re-engineering to produce a suitable therapeutic candidate. It is 
interesting to note that the observed instability was predicted according to the calculated 
instability index using the ProtParam tools on the ExPasy website. The instability index 
calculated for the whole mAb = 47.12 which is classed as unstable (> 40).  
On the other hand, analysis of purified shdAb antibody indicated that reformatting the shark 
variable region into a single domain antibody resulted in an antibody that has better stability 
than common antibody structure using the same variable region for both heavy and light 
chains.  
Essentially, reducing the size of the minimum antibody fragment, whilst retaining binding 
affinity and specificity, is one of the goals of antibody engineering. The initial efforts in this 
direction indicated that; it is possible to isolate clones capable of binding antigen with 
nanomolar affinity from a bacterial expression library of VH domains derived from 
immunized mice. However, analysis was limited by the low expression and poor solubility of 
the resultant clones due to exposure of the hydrophobic VL-interface region (Ward et al., 
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1989). Years after that, isolation of single domain antigen-binding clones with high affinity 
for antigen (nM range) and superior stability following prolonged incubation at 37 °C, 
became possible by using a library from an immunized camel  (Vu et al., 1997, Ghahroudi et 
al., 1997). Research has focused upon single-domain antibody fragments derived from or 
modelled upon the VHH domain of camelid species, which until the discovery of shark 
antibodies were thought to be the only species capable of produceing antibodies naturally 
lacking light chains (Flajnik and Rumfelt, 2000, Nuttall et al., 2001). Furthermore, the 
divergent nature of the V region suggested that sharks, via the unique immunoglobulin 
isotype, might be an alternative source for the provision of single-domain binding proteins.  
By using the immunized shark library for panning on the recombinant human ECD, there was 
an advantage of increasing the probability of isolating a specific positive clone against the 
target antigen, but it was also a chance to develop protocols to reformat shark clones as 
multivalent antibodies.   
To sum up, one monoclonal antibody was successfully isolated and reformatted from panning 
on the recombinant mouse ECD using the naïve human library and another recombinant 
monoclonal antibody was successfully isolated from panning on the recombinant human 
ECD using the immunized shark library and successfully reformatted as a signal domain 
antibody. Characterisation of the binding and the interaction of these isolated antibodies with 
the recombinant and native PTPRJ and the biological function of these antibodies in some in 
vitro bioassays is the topic for the following chapter. 
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CHAPTER 4 
 
Characterization of generated antibodies 
and biological effects.  
 
4.1 Introduction 
PTPRJ is widely expressed in many cell types, including epithelial and endothelial cells, 
fibroblasts, and most haematopoietic cells. Macrophages have high levels of PTPRJ 
expression and it is further up-regulated by pro-inflammatory stimuli (Osborne et al., 1998). 
Usually PTPRJ is restricted to the plasma membrane of macrophages and it regulates many 
signalling pathways leading to growth, activation, differentiation, phagocytosis and adhesion 
cell function in these cells (Nakamura et al., 2003, Dave et al., 2009). When stimulated by 
CSF-1/LPS, there is accumulation and re-arrangement of PTPRJ in region of membrane 
ruffling. In addition, PTPRJ transcription is down-regulated in response to CSF-1, whereas 
stimulating with LPS leads to an increase in its expression. Together, this suggested a role for 
PTPRJ in regulation of monocyte cell proliferation and/ or activation. Pre-treatment of bone 
marrow-derived macrophages (BMMs) with anti-PTPRJ monoclonal antibody repressed 
CSF-1-stimulated spreading, chemotaxis and reorganization of the cytoskeleton of 
macrophages without disturbing the total protein phosphotyrosine profile, the phospho-fms 
and phospho-Akt profile of PTPRJ-antibody treated cells.  These data suggested that PTPRJ 
is an important regulator of macrophage adhesion and spreading, which are the two key 
attributes important for inflammation.  
PTPRJ is known to regulate contact inhibition of cell growth that depends on homophilic 
interaction with VE-cadherin monomer of a neighbouring cell (Saito et al., 2007). The 
expression of PTPRJ in migrating and in proliferating endothelial cells is down-regulated 
following vascular injury and overexpression of PTPRJ in 3T3 cells resulted in distinct 
morphological changes with a significant reduction in the ability of the cells to adhere and 
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spread. These findings further support the inhibitory role of PTPRJ in cell growth, signalling 
and propagation in non-hematopoietic cells (Kellie et al., 2004, Borges et al., 1996). Thus, 
promoting growth in macrophages and inhibiting growth in non-hematopoietic cells indicate 
different roles of PTPRJ in different cell types. 
Loss of PTPRJ expression was reported in human pancreatic tumours, human and rat thyroid 
tumours, colorectal cancer, lung cancer, breast cancer, hepatoblastoma, hepatocellular 
carcinoma and transitional cell carcinoma of the bladder (Borges et al., 1996, Keane et al., 
1996, Lu et al., 1998, Luo et al., 2006, Trapasso et al., 2004, van der Bij et al., 2005, Zhang et 
al., 1997). Sequence alignments, homology modelling and secondary structure prediction of 
PTPRJ indicate that the majority of amino acid substitutions are localized to the extracellular 
part of PTPRJ, which is potentially available for interactions with other proteins and ligands. 
Therefore, any amino acid polymorphisms may lead to alterations in the signalling events and 
hence predisposition to cancer (Ruivenkamp et al., 2002). Most recent study demonstrated 
that higher levels of PTPRJ were detected in invasive breast cancer cells, and importantly 
promoted the ability of these cells to invade and form metastases in collaboration with EGFR 
to activate the Src kinase and the downstream pathways that are closely associated with 
breast cancer progression (Spring et al., 2015). Although these evidences revealed that 
PTPRJ could suppress tumours, the tumour-suppressive function of PTPRJ remains 
incompletely understood and answering how the PTPRJ enzyme normally functions may 
support the development of new anticancer drugs. 
To explore the role for PTPRJ as a potential therapeutic target, we have generated two 
monoclonal antibodies, B12 and shdAb, which both bind to the ectodomain sequences of 
mouse and human PTPRJ.  This chapter will show that isolated antibodies bind to 
recombinant and native PTPRJ with high affinity and specificity and will examine the 
biological effects of the isolated monoclonal antibodies demonstrated. Antibody B12 
significantly enhanced wound healing of HeLa and HaCaT cells and increased cell spreading. 
This antibody also inhibited dome formation in HC-11 cells (an in vitro assay for mammary 
cell differentiation). These findings and previous studies suggest that PTPRJ activity is 
potentially regulated by ectodomain-mediated oligomerization and that PTPRJ is a molecular 
target for anti-angiogenesis, anti-cancer and anti-inflammatory therapy. 
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4.2 Materials and Methods   
Two antibodies were generated from panning on the recombinant ECDs of mouse and human 
PTPRJ. Purified antibodies were characterized for their binding to the recombinant and native 
PTPRJ by ELISA, western blotting, flow cytometry and immunofluorescence. The affinity of 
the isolated antibodies to the recombinant mouse and human ECDs was also measured and 
the biological effect was tested in in vitro bioassays.   
4.2.1 Mammalian cell culture 
4.2.1.1 Cell lines: 
- HeLa is a cell line derived from human cervical cancer section. The cDNA encoding 
PTPRJ was originally isolated from a HeLa cell library (Ostman et al., 1994) and they 
found to express detectable levels of native PTPRJ (Ostman et al., 1994).  
- A549 cells are adenocarcinomic human alveolar basal epithelial cells derived after the 
culturing of explanted cancerous lung tissue (Giard et al., 1973). PTPRJ is widely 
expressed in endothelial and epithelial cells (Autschbach et al., 1999) and it found at 
detectable levels in A549 cells (Muscat, Al-Mansour and Kellie. Unpublished). 
Therefore they were used as a representative of epithelial cells. 
- HaCaT cells are immortal human keratinocytes frequently used as a paradigm for skin 
keratinocytes in vitro (Schoop et al., 1999). It was demonstrated that human skin cells 
are expressing PTPRJ during screening its expression in different human tissues 
(Autschbach et al., 1999) and the levels of PTPRJ expression in HaCaT cells were 
also detectable (Muscat, Al-Mansour and Kellie unpublished). 
- HC-11 cells are an immortalized line of normal murine mammary epithelial cells 
derived from the COMMA-1 D cell population, which differentiate in the presence of 
lactogenic hormones and produce -casein (Danielson et al., 1984). These mouse 
mammary epithelial cells have been widely used as a suitable model to study 
mammary epithelial cell proliferation, differentiation and signal transduction in vitro. 
They represent one of the few normal mouse mammary epithelial lines that are 
capable of differentiation in culture (Chammas et al., 1994). These cells were 
previously used to demonstrate the role of PTPRJ in regulating differentiation of 
normal mammary epithelia and its association with tumorigenesis (Smart et al., 2012). 
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4.2.1.2 Culture conditions  
HeLa, A549 and HaCaT cell lines were maintained in D-MEM (Dulbecco/Vogt Modified 
Eagle's Minimal Essential Medium, GIBCO) supplemented with 2 mM L-glutamine 
(Glutamax-1, Invitrogen), 10% heat-inactivated fetal bovine serum (JRH Biosciences, 
Lenexa, KS, USA), 20 U/ mL penicillin and 20 μg/ mL streptomycin (Invitrogen, Carlsbad, 
CA, USA). The cells were cultured in T75 filter cap flasks (Nunc). For routine culture, the 
medium was discarded and the cell monolayer was briefly rinsed with PBS before addition of 
0.25% (w/v) Trypsin- 0.53 mM EDTA (Invitrogen). The cells were incubated at 37°C for 5 to 
10 minutes and observed under an inverted microscope to confirm detachment of the cell 
layer. The washed cells were then re-plated in fresh culture medium and placed at 37°C in a 
humidified tissue culture incubator with 5% CO2. Cells were routinely split once they 
reached approximately 80% confluency. 
HC-11 cell line was maintained in in complete media consisting of RPMI 1640 (Invitrogen) 
supplemented with 10% heat-inactivated fetal bovine serum (JRH Biosciences, Lenexa, KS, 
USA), 20 U/mL penicillin and 20 μg/mL streptomycin, 2mM L-glutamine, 5 µg/mL insulin 
(Sigma), and 10 ng/mL Epidermal Growth Factor (EGF) (Sigma E9644). Routine cell culture 
passaging was performed as indicated above. 
4.2.2 ELISA assays using anti-PTPRJ antibodies 
To determine the binding of B12 and shdAb antibodies to the recombinant PTPRJ, the ECDs 
of mouse and human and also a control His tagged protein (EGFR-specific scfv), were 
diluted to 10μg/ mL in PBS and 200 μL was transferred to each well of Nunc Immunosorb 96 
well plate and incubated overnight at 4°C. The following day, plates were washed three times 
with PBS-T then blocked with 2% M-PBS. After one hour incubation, the blocking solution 
was discarded from the plate and 200 μL 10-fold serially diluted antibodies starting at 10μg/ 
mL in PBS were added then incubated for one hour. Plates were washed with PBS-T and 200 
μL of HRP-conjugated Goat Anti-human IgG (H+L) (Zymed) diluted to 0.1 μg/ mL in 2% 
M-PBS was added to each well followed by an additional 1 hour incubation. After final wash, 
100 μL of TMB substrate (Sigma Aldrich) was added and the chromogenic signal allowed to 
develop for about 10 min. The reaction was stopped with 100 μL 1M sulphuric acid and 
measurement of the absorbance at 450 nm was carried out on a microplate reader.  
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4.2.3 Western blot and dot blot of Anti-PTPRJ antibodies.  
Recombinant mouse and human ECDs were mixed with NuPAGE® LDS Sample Buffer 
(Life Technologies) and heated at 70°C for 10 min then loaded into Novex® NuPAGE® Pre-
Cast Gels with MES running buffer. SeeBlue® Plus2 Pre-stained Protein Standard (NuPAGE 
system, Life Technologies) was used as a molecular weight marker. Proteins were separated 
by SDS-PAGE for 40 min at 200 V and following separation, gels were transferred to a 
membrane for western blot analysis using the TransBlot Turbo transfer system (Bio-Rad) for 
10 min at high molecular weight setting. Membranes were then blocked in blocking solution 
(2% skim milk in PBST) for one hour with shaking followed by a further one hour incubation 
with blocking solution containing the B12 or shdAb antibodies. Membranes were then 
washed 3 x 5 min each in PBS-T and incubated with the secondary HRP-conjugated Goat 
Anti-human IgG (H+L) (Zymed) for 30 min. After final washes with PBS-T, membranes 
were developed with Bio-Rad Chemiluminescence detection system and visualised using the 
ChemiDoc™ MP imaging system (BioRad).  
To validate the binding of the generated antibodies to the native PTPRJ, western blotting was 
performed using HC-11 and A549 cells as non-recombinant sources for mouse and human 
PTPRJ respectively. T75 tissue culture flasks of HC-11 and A549 cells at 50-70% confluence 
were washed twice with PBS and cells were detached using 1.5 mL of Cell Dissociation 
Buffer, enzyme-free (Life Technologies). Cells were centrifuged on low speed (500 g for 5 
min), and media was aspirated then cells were gently washed with PBS twice to remove 
remaining media components. After washing and aspiration, cells were resuspended with 
NuPAGE® LDS Sample Buffer (Life Technologies) and heated at 70°C for 10 min then 
loaded into Novex® NuPAGE® Pre-Cast Gels with MES running buffer. Western blotting 
transfer and incubation were performed as described above.  
Dot blot was performed using dry nitrocellulose transfer membrane (BioTrac NT, 0.2 µm) by 
immobilizing 2 μL of suspended cells or the recombinant proteins, at 10 μg/mL, directly onto 
the membrane and leaving it to dry. Another 2 μL was added from each reaction and left to 
dry again before blocking the membrane with 2% milk in PBST for an hour. After blocking, 
primary antibodies including B12 Ab, shdAb and HRP anti His antibody (Invitrogen, Life 
Technologies), were diluted into the blocking solution and added to the membranes and 
incubated for another an hour before washing and adding the secondary anti human IgG to 
the membranes with shdAb and B12 antibodies as indicated above.   
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4.2.4 Characterisation of the binding of the recombinant monoclonal antibodies by flow 
cytometry  
HC-11, A549 and/or HeLa cells at 60-70% confluence were detached from T75 tissue culture 
flasks using 1.5 mL of Cell Dissociation Buffer, enzyme-free (Life Technologies). Cells were 
centrifuged on low speed (500 g for 5 min), and media was aspirated then cells were gently 
washed with PBS twice to remove remaining media components. After washing and 
aspiration, cells were resuspended in PBS to perform a cell count. Cells were centrifuged and 
resuspended in an appropriate volume of Flow Cytometry blocking Buffer (PBS containing 
2% fetal bovine serum (JRH Biosciences, Lenexa, KS, USA) so that the final cell 
concentration is 1x10
6 
cell/mL. 200 µl of suspended cells were transferred to each test tube 
and primary antibodies (B12 and shdAb) were added at a final concentration of 10 μg/mL and 
incubated for one hour on ice. A non-immune, isotype matched, human IgG1 (human IgG1, 
Whole Molecule. Jackson ImmunoResearch) was used as a negative control antibody and 
was incorporated in all the following characterisation and in vitro bioassays. Cells were then 
washed twice by centrifugation and resuspension in PBS followed by resuspending the cells 
in goat anti-human IgG Alexa Fluor 488 antibody (Jackson ImmunoResearch), diluted in 
serum-PBS at the recommended dilution. After one hour incubation with the secondary 
antibody, cells were washed 3 times to remove excess secondary antibody and the cell pellets 
were resuspended in 1 mL PBS and analysed using a Partec Cube8 flow cytometer. 
4.2.5 Characterisation of the binding of the recombinant monoclonal antibodies by 
Immunofluorescence 
Cells were plated onto Millicell EZ slides (Millipore) and cultured overnight. The following 
day, cells were washed three times with PBS and fixed with 4 % w/v paraformaldehyde in 
PBS for 30 minutes at 37°C. Cells were then permeabilised with 0.1 % Triton-X-100 for 5 
minutes at room temperature and washed twice with blocking solution (0.5 % BSA in PBS). 
Slide channels were incubated with primary antibodies diluted to 10 µg/mL in blocking 
solution for 1 hour at room temperature. Cells were washed three times with PBS and 
exposed to the goat anti-human IgG Alexa Fluor 488 antibody (Jackson ImmunoResearch), 
mixed with Phalloidin-Atto 565 (Sigma Alderich, St. Louis, MO, USA) for 1 hour in the dark 
then washed three times with PBS. Slides were mounted using DAKO Cytomation 
fluorescent mounting media (Dako Corporation, Carpinteria, CA, USA). Fluorescence 
microscopy was conducted on either epifluorescent/light microscope or laser confocal 
microscope (Carl Zeiss). 
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4.2.6 Binding affinity and kinetic analysis of the anti-PTPRJ antibodies measured by 
Biacore 
4.2.6.1 B12 antibody 
Kinetics and affinity of the antigen–antibody interaction were determined by Surface 
Plasmon Resonance (Spring et al.) using the Biacore T200 (GE Healthcare). A CM5 sensor 
chip was immobilized with ~ 9000 resonance units (RU) of anti-human Fc antibody (GE 
Healthcare, Human Antibody Capture Kit) and was used to capture the B12 antibody. Flow 
cell 1 (Fc1) was the reference surface for the assay and had no antibody captured on its 
surface. Flow cell 2 acted as the active surface for the assay where the captured B12 antibody 
was used to assess interaction with the recombinant mouse and human ECDs analytes. Two-
fold, serial dilutions of mouse and human ECDs from 2 μM to 2.47 nM were prepared using 
the instrument running buffer (1 X HBS-EP+, GE Healthcare) and high performance single-
cycle kinetics assays were performed. The flow rate used for injection of the capture antibody 
and the analytes was 30 μL/ minute. Variable B12 antibody capture times were used to allow 
approximately 90 RU of capture, and then association with different concentrations of 
analytes proceeded for 3 minutes. Dissociation of the antigen from the antibody was 
measured over 10 minutes. Regeneration of the anti-human Fc surface with 3M MgCl2 was 
performed at the completion of the single-cycle run. The flow rate used for regeneration was 
10 μL/ minute for 30 seconds. The BiaEvaluation software generated sensorgrams of the 
antigen-antibody interactions yielding association and dissociation rates, from which the 
stability dissociation constant was calculated assuming a 1:1 model of interaction. 
4.2.6.2 shdAb antibody 
A CM4 sensor chip was immobilized with ~5700 resonance units (RU) of the shdAb to be 
used as the ligand, for capture of the recombinant human ECD of ptprj analyte.  Fc1 was the 
reference surface for the assay and had no antibody immobilised on its surface. shdAb was 
immobilized via amine coupling in pH 5.5 acetate buffer on Fc2 for 420s at 10 μL/min using 
the shdAb antibody at the concentration of 65 μg/mL. Two-fold, serial dilutions of human 
ECD from 0.5 μM to 0.2 nM were prepared using the instrument running buffer (1 X HBS 
EP+) and high performance single-cycle kinetics assays were performed. The flow rate used 
for injection of the analytes was 30 μL/min. and proceeded for 3 minutes for each 
concentration. Dissociation of the antigen from the antibody was measured over 10 minutes. 
Regeneration of the antibody surface with 10 mM Glycine pH 1.7 was performed at the 
completion of the single-cycle analysis. The flow rate used for regeneration was 10 μL/min 
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for 30 seconds. BiaEvaluation software generated sensorgrams of the antigen-antibody 
interactions yielding association and dissociation rates, from which the stability dissociation 
constant was calculated assuming a 1:1 model of interaction. 
 4.2.7 Proliferation assay 
- Day one: HeLa and HC-11 cells were trypsinized from T-25 flasks and 5 ml of 
complete media was added to each flask. Then, cells were collected and centrifuged in 
a sterile 15 ml falcon tube at 500 g for 5 min. Cells were resuspended with 1 ml of the 
complete media to perform a cell counts. Cells were diluted to 75,000 cells per ml 
using complete media and 100 μL of cells (7500 total cells) were added into each 
well. Four plates were prepared for each cell line to perform four MTT time points 
and the plates were incubate overnight at 37°C in a humidified tissue culture 
incubator with 5% CO2. 
- Day two: media from three plates of each cell line was removed and replaced with 
100 μL complete media containing the treatment antibodies (B12, shdAb and control 
antibody). The negative control antibody used in this assay and the following assays is 
the non-immune, isotype matched, human IgG1 (Whole Molecule, human IgG. 
Jackson ImmunoResearch). Antibodies were used in two different dilutions (10 μg/ 
mL and 100 μg/ mL) with three repeats of each condition. Negative controls 
containing either no cells or cells with no antibody treatmen were also included. 
Plates were then placed back in the incubator. The fourth plate from each cell line was 
treated with MTT to perform the analysis of day 0 proliferation. MTT solution was 
prepared in PBS at 4 mg/mL and filtered using a 0.2 μM syringe filter (MDI02ADAP 
| Milli-DI®). 10 μL of the 4 mg/ml MTT reagent (Life Technologies) was added to 
each well (400 μg/mL final concentration), and then the plates placed back in the 
incubator at 37°C for 2-4 hours. After incubation with MTT, media was carefully 
removed without disturbing the cells and without rinsing with PBS. 100 μL MTT 
solvent (absolute DMSO) was added to each well then plates were placed on a shaker, 
protected from light, for 5 min to allow resuspension of the colour precipitate. 
Absorbance was measured at 570 nm in microtiter plate reader. 
- Day three, four and five: for each day, one plate from each cell line was treated with 
MTT as indicated above and the proliferation progress of the cells under each 
treatment condition and time point was recorded. 
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4.2.8 Differentiation assay with HC-11 Cells 
- Day one: HC11 cells were plated in a 24-well plate at the a confluency of 6.33x 105 
cells/ mL using complete growth medium as described above.  The cells were 
incubated at 37°C for three days to allow the cells to reach the confluency of 100%. 
- Day three: cells were checked for the correct confluency then washed twice with PBS. 
500 µL of the complete media, but excluding EGF, was added to each well then 
incubated at 37°C for 24 hours. 
- Day four: after EGF starvation, differentiation was induced in medium containing 
10% FCS, 20 U/ mL penicillin and 20 μg/ mL streptomycin, 5 µg/ mL insulin, 1μM 
dexamethasone (Sigma D8893) and 5 μg/ ml prolactin (Sigma L6520). Antibodies 
(B12, shdAb and the non-immune isotype matched human IgG) were added to the 
wells at 10 µg/ mL and 100 µg/ mL in triplicate. Non-proliferating EGF starved cells 
and proliferating cells with no antibody added were included as control conditions. 
Cells were incubated at 37°C for 48 hours to allow cell differentiation. 
- Day six: differentiation was monitored by detecting the formation of blister-like 
structures, called domes. The number of formed domes in each condition was counted 
then media was replaced with freshly prepared media as specified for day four. 
- Day eight: domes were counted again and checked for any formation effect resulting 
from the addition of the antibodies to the feeding media. Cells were then fixed with 4 
% w/v paraformaldehyde in PBS and stored at 4°C for any further analysis or 
staining.  
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4.2.9 Adhesion assay 
8-well Millicell EZ slides (Millipore) were coated with 10 µg/ mL and 100 µg/ mL of B12, 
shdAb and isotype negative control antibodies and kept overnight at 4°C. The following day, 
slides were washed three times with PBS then blocked with 0.5 % BSA in PBS for one hour 
at 37°C. HeLa and HC-11 cells were detached using enzyme-free cell dissociation buffer 
(Life Technologies) and diluted using serum-free medium to 1x 10
6 
cell/ mL. 200 µL of cell 
suspension was added to each well then incubated at 37°C for 3- 4 hours. After incubation, 
cells were fixed with 4 % w/v paraformaldehyde in PBS for 30 minutes at room temperature 
or overnight at 4°C. Then cells were washed twice with PBS and permeabilised with 0.1 % 
TritonX-100 for 10 minutes followed by another washing. The cells were stained with 
Phalloidin-Atto 565 in blocking solution for one hour then washed and mounted for 
fluorescence microscopy. 
4.2.10 Wound healing assay  
HeLa and HaCaT cells were trypsinized and seeded into 8-well Millicell EZ slides 
(Millipore) and allowed to grow at 37°C to reach 90-95% confluency. The cell monolayers 
were then wounded by scratching with a 20 μL pipette tip. Wells were then gently washed 
three times with serum-free media to remove the detached cells and 200 µL complete media 
containing B12, shdAb and negative control antibodies at 10 µg/ mL and 100 µg/ mL 
concentration were added. Cells were incubated for maximum of 24 hours then washed and 
fixed in 4% PFA and permeabilised in 0.1% Triton X-100. The cells were stained with 
Phalloidin-Atto 565 diluted in blocking solution (0.5 % BSA in PBS) then washed and 
mounted for fluorescence microscopy. ImageJ was used to analyse the images and closure of 
the gap was measured using Plot Profile analysis tool. Error bars show mean ±SEM. 
Statistical significance was determined using Student‘s T-test. 
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4.3 Results  
4.3.1 Assays to measure binding of the generated anti-PTPRJ antibodies to recombinant 
and native mouse and human PTPRJ 
4.3.1.1 ELISA 
To evaluate the binding performance of the isolated monoclonal antibodies, in addition to the 
specificity and possible cross reactivity, ELISA assays using the recombinant mouse and 
human ECDs with the generated antibodies B12 and shdAb were used. Recombinant mouse 
and human PTPRJ were coated on ELISA plates and serial dilutions of the generated 
antibodies were added. Un-related His tagged recombinant protein (Anti-EGFR) was used as 
a negative control for this experiment to assess the specificity of the generated antibodies to 
the ECD of PTPRJ and to test the possibility of the antibodies binding to the His tag or to the 
link between the recombinant ECD and the His tag. The ELISA results from the B12 
antibody (Figure 4.1) showed binding and cross-reactivity of the monoclonal antibody to both 
recombinant mouse and human PTPRJ at the maximum absorbance with negligible binding 
to the control His tagged protein.  
ELISA results from shdAb antibody, on the other hand, showed the binding of the antibody 
to recombinant human ECD only with no cross-reactivity to the recombinant mouse ECD or 
to the control His tagged protein (Figure 4.2). 
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Figure 4.1:  ELISA assays of B12 antibody to recombinant mouse and human PTPRJ ECDs. 
Recombinant mouse and human PTPRJ were coated on ELISA plates and 10 fold serial dilutions of B12 
antibody were added. Unrelated His tagged recombinant protein (EGFR-specific scFv) was used as a 
negative control.  
 
Figure 4.2: ELISA assays of ShdAb antibody to recombinant mouse and human PTPRJ ECDs. 
Recombinant mouse and human PTPRJ were coated on ELISA plates and 10 fold serial dilutions of 
shdAb antibody were added. Un-related His tagged recombinant protein (EGFR-specific scFv) was used 
as a negative control. 
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4.3.1.2 Western blot and dot blot 
To evaluate the binding of the generated antibodies to contiguous or conformational epitopes, 
a Western blot and a dot blot were performed. A549 and HC-11 cell pellets were also 
included to test the ability of the antibodies to recognise the native epitopes. Denatured 
recombinant and native PTPRJ were loaded into SDS-PAGE then transferred to a membrane 
and incubated with the B12 and shdAb antibodies.  
Western blot with B12 antibody (Figure 4.3) revealed a strong binding to recombinant mouse 
ECD showing a broad band centred around an apparent molecular weight of ~100 kDa with 
no evidence of positive binding to the recombinant human ECD. B12 also bound to PTPRJ 
derived from the cell pellet of A549 and HC-11. Bands around the molecular weight of 200 
kDa, reflect the binding of the B12 antibody to the full length of PTPRJ, were detected. At 
least three other bands from the cell pellets were also identified, which may be due to 
proteolytic degradation of the full length protein or other variant isoforms of the native 
PTPRJ. This will require confirmation by mass spectrometry analysis of excised bands. 
Repeated western blotting using shdAb with the recombinants and native PTPRJ, failed to 
show specific bands of PTPRJ at the expected sizes which may be due to that shdAb antibody 
only recognises undenatured PTPRJ. Boiling the sample in SDS may altered the structural 
integrity of the conformational epitopes therefore, a dot blot was deemed the best alternative 
to western blot as it will indicate the binding of the antibody to an undenatured  epitope.  In 
this assay, B12 and shdAb antibodies were tested against recombinant mouse and human 
PTPRJ as well as the native PTPRJ represented by HeLa, HC-11, and A549 cells. Anti His 
antibody was also included as a positive control for binding to the recombinant mouse and 
human ECDs (Figure 4.4). The figure shows a strong binding of the anti His antibody to the 
recombinant mouse and human ECDs as expected. B12, on the other hand, bound to both 
native and recombinant mouse and human PTPRJ. The shdAb antibody bound strongly to the 
recombinant mouse and human PTPRJ but there was a reduced binding to the native human 
PTPRJ, as represented by HeLa cell lysate (Figure 4.4).   
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Figure 4.3: Western blotting of B12 antibody to denatured PTPRJ. Reduced cell lysates were loaded onto 
a Mini Protean® TGX Stain-Free™ Gel.  Lane 1: SeeBlus Plus 2 marker, lane 2:  recombinant human 
ECD, lane 3:  recombinant mouse ECD, lane 4: A549 cell lysate and Lane 5: HC-11 cell lysate. The 
proteins were electrophoresed, turbo-blotted onto a PVDF membrane and probed with B12 antibody.  
 
Figure 4.4: Dot blot analysis of the binding of B12 and shdAb antibodies to the recombinant and native 
PTPRJ. This dot blot indicates the binding of B12 antibody to both recombinant and native mouse and 
human PTPRJ. shdAb antibody was binding strongly to the recombinant mouse and human ECDs and 
minor biding to the native PTPRJ represented by HeLa cell line was observed. His tag antibody used as a 
positive control for binding to the recombinant mouse and human ECDs. 
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4.3.1.3 Flow cytometry 
Flow cytometry was performed to characterise the binding of the isolated antibodies to the 
native PTPRJ on the surface of life cells. B12 antibody was tested against mouse HC-11 cells 
and human A549 cells. CHO cells were reported to lack the expression of PTPRJ (Takahashi 
et al., 2012), therefore, they were incorporated into the analysis to compare the level of 
antibody binding. Isotype matched human IgG1 was used as a negative control antibody on 
A549 cells. Minimal fluorescence of the non-immune control antibody was detected with 
A549 cells however the fluorescence shift resulting from B12 antibody binding was greater 
with A549 and HC-11 (Figure 4.5). There was a moderate fluorescence shift indicating 
binding of the B12 antibody to CHO cells. Although it has been published that CHO cells 
lacks the expression of PTPRJ (Takahashi et al., 2012, Takahashi et al., 2006), BLAST 
analysis of peptides from human PTPRJ against CHO cells, revealed the opposite, as some of 
the peptides showed 100% sequence homology with CHO cells and they were predicted as 
PTPRJ protein.  
shdAb antibody was also tested by flow cytometry for binding to human HeLa cells and 
mouse HC-11 cells and the level of the antibody binding was compared to B12 and to the 
isotype matched human IgG1 control antibody. There appeared to be some nonspecific 
binding of the negative control antibody to both cell lines; nevertheless, the fluorescence shift 
of both B12 and shdAb antibodies was greater (Figure 4.6).  
4.3.1.4 Immunofluorescence 
The reactivity of the B12 and shdAb antibodies with cell-associated PTPRJ was also 
investigated by immunofluorescence using HeLa cells. Cells stained with isotype matched 
human IgG1 antibody and cells with no antibody were included as negative controls. Due to 
previous reports on the involvement of PTPRJ in cytoskeletal re-arrangements (Kellie et al., 
2004), cells were exposed to the secondary goat anti-human IgG Alexa Fluor 488 antibody, 
mixed with Phalloidin-Atto 565 to assess the effect of antibodies on F-actin polymerisation. 
Fluorescence microscopy was conducted using laser confocal microscope (Carl Zeiss). 
Whilst cells treated with the isotype matched human IgG1 control antibody showed only faint 
fluorescence and the cells with no primary antibody displayed no fluorescent, 
immunostaining of HeLa cells with B12 and shdAb antibodies showed a clear punctate 
staining over the cell surface (Figure 4.7) and staining was also detected in the perinuclear 
area (arrows), which is most likely Golgi localisation within the cell. On the other hand, no 
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significant difference in F-actin staining pattern was observed between the different 
treatments.  
 
 Cells only Cells + secondary anti human IgG  Cells + B12 antibody (1, 2 and 3) 
                                                         Cells + negative control antibody (4).  
 
 
Figure 4.5: Flow cytometry of B12 antibody on HC-11, A549 and HeLa cells. Black colour indicates the 
cells with no antibody added, red colour indicates cells with the secondary anti-human IgG only and the 
blue colour indicated the cells with B12 antibody (1, 2 and 3) and the cells with the negative control 
(isotype matched human IgG1) antibody (4).  
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                 Cells only            Cells + secondary anti human IgG           Cells + negative control antibody 
                 Cells + B12 positive control antibody  Cells + shdAb antibody 
 
 
Figure 4.6: Flow cytometry of B12 antibody on HC-11 and HeLa cells. Black colour indicates the cells 
with no antibody added, red colour indicates cells with the secondary anti-human IgG. The green colour 
indicates the binding of the negative control (isotype matched human IgG1) antibody to HeLa and HC-11 
cells while the purple colour indicates the binding of the B12 antibody to the cells and the blue colour 
indicates the cells treated with shdAb antibody.  
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Figure 4.7: Immunofluorescence of B12 and shdAb antibodies on HeLa cells. Arrows indicate plasma 
membrane and perinuclear staining. No significant difference in F-actin staining pattern was observed 
between the different treatments.  
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4.3.1.5 Biacore affinity measurements. 
Another useful characterisation for the isolated antibodies is the affinity of these antibodies to 
their antigens. Measurement of the interaction kinetics was carried out using an antibody 
capture format in the surface plasmon resonance (Biacore). B12 antibody was captured by 
anti-IgG FC, which had been previously immobilised onto a CM5 sensor chip. Recombinant 
mouse and human ECDs at various concentrations were then applied to the surface to interact 
with the immobilised antibody. Association and dissociation phases of the complexes that 
resulted from the interaction of the antibody with the antigens were investigated. In the 
Biacore analysis, the simplest situation is the formation of a 1:1 complex where A is the 
analyte (ECDs) in solution, B is the ligand (the isolated antibodies) on the sensor chip surface 
and AB is the complex formed on the surface between ligand and analyte (Natsume et al., 
2000).  
Association (ka) and dissociation (kd) rates were calculated from the sensorgrams generated 
from the binding of B12 antibody to mouse and human ECDs (Figure 4.8), and the KD were 
calculated from the ka and kd values (Table 4.1). The KD for the B12 antibody interaction 
with human ECD was 2.17 x 10
-8 
M which is almost 3-fold weaker than the interaction 
between the antibody and the mouse ECD (7.45 x 10
-9
M). This means that the affinity of B12 
antibody to the mouse ECD was higher when compared to the human ECD. Taking into 
consideration that B12 antibody was isolated from a naïve human library then reformatted as 
a IgG1 whole human antibody, the affinity achieved was quite impressive.  
The shdAb antibody was immobilised directly onto a CM4 sensor chip after surface 
activation, due to difficulties with non-specific binding on the CM5 capture system. 
Recombinant human ECDs at various concentrations were applied to the surface to interact 
with the immobilised antibody. Association and dissociation phases of the complexes that 
resulted from the interaction of the antibody with the antigen were investigated using SPR. In 
the Biacore analysis, a 1:1 interaction model was used where the analyte was the human ECD 
in solution, and the ligand on the sensor chip surface was the shdAb antibody. The 
sensorgram for shdAb antibody binding to human ECD is shown in (Figure 4.9) and the ka, kd 
and KD are shown in (Table 4.2). The KD for the shdAb antibody interaction with human 
ECD was 2.86 x 10
-8 
M which is also reasonable from a phage library.  
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B12 vs hECD on anti-IgG Fc 1:1  
 
 
B12 vs mECD on anti-IgG Fc 1:1 
 
 
Figure 4.8: SPR sensorgrams for the interaction of B12 antibody with human and mouse ECDs. Analysis 
was performed on the Biacore T200 using single cycle kinetics. The antibody was captured onto an 
immobilized anti-human Fc antibody on a CM5 sensor chip, and serial two-fold increasing concentrations 
of antigen from 2 μM to 2.47 nM were injected over the surface in a single cycle at 30 μL/ minute.  The 
sensorgrams from these injections are shown as coloured lines. A 1:1 model of binding was fitted to the 
data (black lines) and the association rate (ka), dissociation rate (kd) and equilibrium dissociation constant 
(KD) were determined for these interactions using the BiaEvaluation software. 
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Antibody Analyte ka ± SE [M-1 s-1] kd ± SE [s-1] KD [M] 
B12 Ab 
h-ECD 
8833 
± 99 
1.92 x 10-4 
± 9.00 x 10-7 
2.17 x 10-8 
m-ECD 
3.75 x 10+4 
± 3.50 x 10+2 
2.79 x 10-4 
± 1.30 x 10-6 
7.45 x 10-9 
 
Table 4.1: Summary of kinetics binding data determined for B12 antibody with human and mouse ECDs.  
The KD of B12 antibody was calculated from the observed association (ka) and dissociation (kd) rates.  
 
shdAb vs hECD on CM4 1:1 
 
Figure 4.9: SPR sensorgrams for the interaction of shdAb antibody with human ECD. Analysis was 
performed on the Biacore T200 using single cycle kinetics. The antibody was immobilized on a CM4 
sensor chip and serial two-fold increasing concentrations of antigen from 0.5 μM to 0.2 nM were injected 
over the surface in a single cycle at 30 μL/min. The sensorgrams from these injections are shown as 
coloured lines. A 1:1 model of binding was fitted to the data (black lines) and the association rate (ka), 
dissociation rate  and equilibrium dissociation constant (KD) were determined for these interactions using 
the BiaEvaluation software.  
 
 
 
 
-10
0
10
20
30
40
50
60
70
80
90
-500 0 500 1000 1500 2000 2500
RU
R
e
s
p
o
n
s
e
Tim e s
138 
 
Antibody Analyte ka ± SE [M-1 s-1] kd ± SE [s-1] KD [M] 
shdAb Ab h-ECD 
2.13 x 10+4 
± 3.60 x 10+2 
6.10 x 10-4 
± 4.30 x 10-6 
2.86 x 10-8 
 
Table 4.2: Summary of kinetics binding data determined for shdAb antibody with human ECD.  The KD 
of shdAb antibody was calculated from the observed association (ka) and dissociation (kd) rates.   
 
The kinetic measurements above were calculated using a local fit of the kinetic simultaneous 
ka/kd model, assuming Langmuir (1:1) binding. The data obtained from the primary 
interaction analyses showed a relatively poor fit to the 1:1 interaction model, whereas the 
fitting to the bivalent analyte model was significantly better (Figure 4.10) and (Table 4.3). 
Although this model has been used widely for affinity studies, it is not always the true 
representation of what happens on the sensor chip surface (Drake et al., 2012, Rich et al., 
2009, Gopinath, 2010). The effects of the analysis model on the apparent affinities could be 
due to the varying structural restrictions placed on the binding domains by the adjacent Fc 
domains, which may not always allow for optimal protein positioning during the formation of 
tetrameric ligand–receptor complexes. In the case of the bivalent interaction, there might be 
fewer structural restrictions due to Fc fusion, while the 1:1 complex formation might be more 
affected by Fc fusion, leading to a reduced enhancement in the overall binding affinity 
(Pabbisetty et al., 2007b). 
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A) B12 vs hECD on anti-IgG Fc bivalent analyte fitting 
 
B) shdAb vs hECD on CM4 bivalent analyte fitting 
 
 
Figure 4.10: Affinity interaction of human ECD with B12 and shdAb antibodies fitted to the bivalent 
analyte model. SPR sensorgrams presented in Figure 4.8 and 4.9 for the interaction of recombinant 
human ECD with B12 and shdAb antibodies showed better fitting to the Bivalent analyte model. The 
association rate (ka) and dissociation rate (kd) were determined for these interactions using the evaluation 
software. 
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Antibody Analyte Ka 1± SE [M-1 s-1] Kd 1± SE [s-1] Ka 2± SE [M-1 s-1] Kd 2± SE [s-1] 
B12  h-ECD 
2654 
± 14 
0.01528 
± 1.60 x 10-4 
2.61 x 10-5 
± 1.50 x 10-7 
1.18 x 10-4 
± 5.20 x 10-7 
shdAb  h-ECD 
1.06 x 10+4 
± 34 
0.02028 
± 4.80 x 10-5 
1.24 x 10-5 
± 3.70 x 10-8 
2.13 x 10-4 
± 3.70 x 107 
Table 4.3: Summary of kinetics binding data determined for B12 and shdAb antibodies with human ECD 
using the bivalent analyte model. The observed association (ka) and dissociation (kd) rates from the 
bivalent model were calculated. 
 
4.3.2 Biological effect of the generated antibodies on in vitro bioassays. 
4.3.2.1 The effect of anti-PTPRJ antibody treatment on cell proliferation  
B12 and shdAb antibodies were tested for their biological effects in in vitro bioassays using 
cells that have been previously shown to be recognised by the antibodies (Section 4.2). First 
bioassay was to investigate the effect of the isolated antibodies on cell proliferation. HeLa, 
A549 and HC-11 cells were plated into 96 well plates and the rate of cell proliferation was 
monitored over three days post-antibody treatment. The MTT tetrazolium method was used 
as that the viable cells with active metabolism will convert MTT into a purple colored 
formazan product with an absorbance maximum near 570 nm. When cells die, they lose the 
ability to convert MTT into formazan, thus color formation serves as a useful and convenient 
marker of only the viable cells (Akagi et al., 2013). Measuring the absorbance of the MTT 
from each time point indicated that the isolated antibodies had no effect on cell proliferation 
and incubating the cells with the antibodies did not reduce the rat of cell proliferation 
compare to the non-treated cells (Figure 4.11).  However, it is worth mentioning that MTT 
reduction is a marker reflecting viable cell metabolism and not specifically cell proliferation 
(Huyck et al., 2012). 
4.3.2.2 Effect of anti-PTPRJ antibody treatment on cell differentiation 
The HC-11 cell line has been used as a model system to study the effect of the generated 
antibodies on the regulation of mammary lactogenic differentiation in vitro. HC-11 cells have 
the ability to differentiate and synthesize milk proteins in response to treatment with 
lactogenic hormones resulting in the formation of dome shaped cell structures referred to as 
mammospheres (Blatchford et al., 1995). Lactogenic differentiation of HC-11 cells was 
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induced by the addition of a combination of lactogenic hormones including dexamethasone, 
insulin, and prolactin, referred to as DIP (Morrison and Cutler, 2009). The Kellie lab has 
previously reported that modulation of the expression of PTPRJ in HC-11 cell regulated 
dome formation (Smart et al., 2012). Therefore the effect of recombinant antibodies on dome 
formation was investigated. HC11 cells induced to differentiate in the presence and absence 
of the recombinant antibodies, and the number of domes that appeared under each treatment 
was counted.  
Treatment of the cells with the antibodies had no influence on the size or the shape of the 
domes (Figure 4.12) however, by day four post induction, there was a remarkable decrease in 
the number of domes formed by the cells treated with B12 and shdAb antibodies. Although 
that both B12 and shdAb antibodies-treated cells showed a significant inhibition in the 
number of domes compared to the cells treated with the control isotype matched human IgG1 
antibody, the reduction in the number of domes was 5-7 times greater with B12 antibody 
(Table 4.4).  
4.3.2.3 The effect of anti-PTPRJ antibody on cell adhesion and spreading in vitro. 
To examine the potential effect of the isolated antibodies on cell adhesion and spreading, 8 
well slides were coated with B12, shdAb or isotype human IgG1 (negative control) 
antibodies. Cells were then added to the wells and allowed to adhere and spread for 3-4 hours 
before fixing and staining for imaging. Analysis of the images taken from both HeLa and 
HC-11 cells indicated an enhancement of cell adhesion and spreading to the walls that were 
treated with B12 antibody (Figure 4.13, A) and (Figure 4.14, A). Remarkably, fluorescence 
staining of actin showed that the cells spread and redistributed F-actin when adhering to B12-
coated wells and this pattern of cell spreading was not observed when the slide surface was 
coated with shdAb antibody or with the negative control antibody (Figure 4.13, A) and 
(Figure 4.14, A).   
To quantify and compare the number of cells that were adhering under each condition, 96 
well plates were coated with different concentration of the antibodies followed by the 
addition of HeLa or HC-11 cells in presence of the MTT reagent to allow the identification of 
the number of adherent cells by their absorbance. Results confirmed the association of cell 
adhesion with the concentration of B12 antibody used to coat the wells as the adhesion was 
greater with the highest concentration of B12 antibody and then it gradually decreased as the 
antibody concentration got lower. No change was observed in the number of cells that were 
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attached to the surfaces coated with different concentration of shdAb antibody and the 
negative control antibody (Figure 4.13, B) and (Figure 4.14, B).   
 
 
 
 
Day 0 
Day 1 
Day 2 
Day 3 
Figure 4.11: Effect of the 
recombinant antibodies on cell 
proliferation in vitro. A 
proliferation assay using MTT 
was performed using HeLa cells. 
Cells were plated in 96 well plate 
and serial dilutions of B12, shdAb 
and the negative control 
antibodies were added to the cells 
and allowed to proliferate in 
presence and absence of the 
antibodies. In each time point, 
MTT was added to the cells and 
the absorbance indicating the 
number of cells presented in each 
well was recorded. Similar results 
were obtained with A549 and HC-
11 cell lines under the same 
conditions.  
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Figure 4.12: Effect of antibody treatment on HC-11 dome formation. Panels A-D show that treatment of 
the cells with the antibodies had no influence on the size or the shape of the domes. A) shows a dome 
obtained from cells without antibody treatment, B) shows a dome obtained from cells treated with the 
isotype control human IgG1 antibody, C) shows a dome obtained from cells treated with shdAb antibody 
and D) shows a dome obtained from cells treated with B12 antibody. 
 
 
 
 
 
 
 
 
 
A B 
C D 
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Treatments n Mean Std. Deviation Std.  Error Mean 
Cells only 12 101.8 6.46 1.866 
-Co Ab 12 74.25 5.63 1.624 
shdAb 12 59.50 5.65 1.631 
B12 Ab 10 14.17 4.41 1.370 
 
 
Treatments t df Two-tailed P value Significant? 
95% confidence 
interval 
Lower Upper 
B12 Ab vs –Co Ab 28.28 22 < 0.0001 Yes -64.49 -55.68 
B12 Ab vs Cells only 37.87   22 < 0.0001 Yes -92.47  -82.87 
shdAb Ab vs -Co 6.409 22 < 0.0001 Yes -19.52 -9.977 
shdAb Ab vs Cells only 17.08 22 < 0.0001 Yes -47.47 -37.19 
 
Table 4.4: Statistical analysis of the effect of antibody treatment on dome formation. Table A) 
Quantification of the number of domes formed under each condition.  Table B) Quantitative results were 
analysed using Student’s T-test to determine the statistical significance of the addition of the antibodies 
on dome formation. 
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Figure 4.13: Effect of the anti-PTPRJ antibodies on HeLa cell adhesion and spreading. Figure (A) 
indicates the F-actin staining showing adhesion and spreading of the cells shortly after they were added to 
wells that were coated with B12 antibody, Figure (B) is quantification of the cells that were adhering as 
measured by MTT. 
Cells only Cells+ -Co Ab 
Cells+ shdAb Ab Cells+ B12 Ab 
A 
B 
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Figure 4.14: Effect of the anti-PTPRJ antibodies on HC-11 cell adhesion and spreading. Figure (A) 
indicates the F-actin staining showing adhesion and spreading of the cells shortly after they were added to 
wells that were coated with B12 antibody, Figure (B) is quantification of the cells that were adhering as 
measured by MTT. 
 
 
Cells only Cells+ -Co Ab 
Cells+ shdAb Ab Cells+ B12 Ab 
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4.3.2.4 The effect of anti-PTPRJ antibodies on in vitro wound healing 
Previous studies have indicated that changing the level of PTPRJ expression in the cells, or 
treating the cells with an anti-PTPRJ antibody, affects cell motility in in vitro bioassays 
(Dave et al., 2009, Kellie et al., 2004). In vitro wound healing assay is a simple method to 
assess cell motility by measuring cell movement and the speed by which cells migrate into 
free substratum space. After scratching HeLa and HaCaT cells to generate a ―wound‖, cells 
were incubated 24 hours with and without the antibodies to allow the closure of the gap to 
mimic wound healing followed by fixing and staining with F-actin antibody (Phalloidin-Atto) 
and imaged using the fluorescence microscopy. ImageJ Plot Profile analysis tool was used to 
measure the distance between the edges of the wound and quantitative results were analysed 
using Student‘s T-test to determine the statistical significance of the addition of the 
antibodies on wound healing. After 24 hours, the cleared area was significantly reduced in the 
presence of B12 antibody compared to control and shdAb antibodies for both HeLa and 
HaCaT cells (Figure 4.15) and (Figure 4.16). Remarkably, treatment with the B12 antibody 
resulted in almost a complete closure of the gap compared with other treatments, and this 
rapid closure was statistically significant (Table 4.5) and (Table 4.6). 
 
 
 
 
 
 
 
 
  
148 
 
 
 
 
                                                                          
 
Figure 4.15: In vitro wound healing of HeLa cells in a wound scratch test assay. Conditions include 
control cells without treatment (top panel), cells treated with the non-immune control hIgG1 (second top 
panel), cells with shdAb antibody (third top panel) and cells with B12 antibody (bottom panel). Migration 
Phalloidin staining Plot Profile analysis 
Cells only 
Cells+ -Co Ab 
Cells+ shdAb Ab 
Cells+ B12 Ab 
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of HeLa cells to the wounded (open gap) was imaged (left hand panels) and measured using ImageJ Plot 
Profile analysis tool (right hand panels). 
 
 
Analytes n Mean Std. Deviation Std.  Error Mean 
Cells only 18 374.3 89.25 21.01 
-Co Ab 18 390.8 143.1 33.70 
shdAb 18 430.7 100.0 23.56 
B12 Ab 18 70.00 46.10 10.85 
 
 
Analytes t df Two-tailed P value Significant? 
95% confidence 
interval 
Lower Upper 
B12 Ab vs –Co Ab 9.054  34 < 0.0001 Yes 248.9  392.9 
B12 Ab vs Cells only 12.85  34 < 0.0001 Yes 256.2  352.5 
shdAb Ab vs -Co 0.969  34 0.3393 No -43.75  123.5 
shdAb Ab vs Cells only 1.786  34 0.0830 No -120.7  7.776 
 
Table 4.5: Statistical analysis of wound healing with HeLa cells. A) Quantification of distance 
measurements between the edges of the wound using the Plot Profile analysis tool from ImageJ. B) 
Quantitative results were analysed using Student’s T-test to determine the statistical significance of the 
addition of the antibodies on wound healing antibody. 
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Figure 4.16: In vitro wound healing of HaCaT cells in a wound scratch test assay. Conditions include 
control cells without treatment (top panel), cells treated with the non-immune control hIgG1 (second top 
panel), cells with shdAb antibody (third top panel) and cells with B12 antibody (bottom panel). Migration 
Cells only 
Cells+ -Co Ab 
Cells+ shdAb Ab 
Cells+ B12 Ab 
Phalloidin staining Plot Profile analysis 
151 
 
of HaCaT cells to the wounded (open gap) was imaged (left hand panels) and measured using ImageJ Plot 
Profile analysis tool (right hand panels). 
 
 
Analytes n Mean Std. Deviation Std.  Error Mean 
Cells only 18 1090 196.1 46.20 
-Co Ab 18 937.7 254.0 59.82 
shdAb 18 987.2 276.6 65.14 
B12 Ab 18 96.73 50.83 11.97 
 
 
Analytes t df Two-tailed P value Significant? 
95% confidence 
interval 
Lower Upper 
B12 Ab vs –Co Ab 14.52 34 < 0.0001 Yes 762.6   1011 
B12 Ab vs Cells only 21.75 34 < 0.0001 Yes 941.9   1136 
shdAb Ab vs -Co 0.559 34 0.5797 No -130.4  229.4 
shdAb Ab vs Cells only 1.286 34 0.2072 No -59.66  265.2 
 
Table 4.6: Statistical analysis of wound healing with HaCaT cells. A) Quantification of distance 
measurements between the edges of the wound using the Plot Profile analysis tool from ImageJ. B) 
Quantitative results were analysed using Student’s T-test to determine the statistical significance of the 
addition of the antibodies on wound healing. 
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4.2 Discussion 
Two antibodies against the ECD region of mouse and human PTPRJ were successfully 
isolated, reformatted and expressed. The aim of this chapter was to characterise the binding 
and the interaction of these recombinant monoclonal antibodies with the recombinant and 
cell-derived PTPRJ, and to primary test the biological function of these antibodies in several 
in vitro bioassays.  
Various methods were used to measure the antibody-antigen interactions, such as ELISA, 
western blot, flow cytometry, immunofluorescence and immunoaffinity chromatography. 
However, many of those methodologies are only designed for detecting protein-protein 
interactions, but are not generally suitable for the quantification of binding. The ECD region 
of PTPRJ has eight to nine highly glycosylated fibronectin type III (FNIII) repeats, contains 
34 potential N-linked glycosylation sites and it was found to be glycosylated in seven 
asparagine residues by mass spectrometry (Liu et al., 2005, Chen et al., 2009). PTPRJ can 
dimerize (binding site 972-996) through the transmembrane domain, nevertheless it is unclear 
whether it can exist as dimers physiologically (Chen et al., 2009). Sedimentation velocity 
measurements show that PTPRJ along with other single-domain receptor phosphatases (e.g., 
IA2, IA2beta, GLEPP1 and STEP) is monomeric in solution (Barr et al., 2009). 
Taking the complexity of the ECD region of PTPRJ into consideration, it was not surprising 
to find differing patterns of antibody binding between the recombinant, native, denatured and 
non-denatured PTPRJ which made it more difficult to confirm the interaction and specificity 
of these antibodies to the target antigens. Therefore, the purpose of these immunoassays was 
to confirm that the isolated antibodies are able to recognise and bind to the ECD of PTPRJ.  
In ELISA, B12 antibody bound to both recombinant mouse and human ECD while the shdAb 
antibody was only specific to the human ECD. Although the B12 antibody was generated 
from panning on mouse recombinant ECD and the shdAb antibody was generated from 
panning on the human ECD, it was expected that there might be some cross reactivity of the 
antibodies between mouse and human PTPRJ due to the sequence homology in the ECD 
regions (61.0% identity and 79.8% similarity, as determent by ExPasy LALIGN tool). 
However it was also possible that the most immunogenic sequences may not be conserved, 
since T and B cells autoreactive to PTPRJ would be eliminated during development of the 
immune system. 
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To evaluate whether contiguous or conformational epitopes were recognized by the isolated 
antibodies, a Western blot and a dot blot were performed. Western blot with B12 antibody 
revealed a strong binding of the isolated antibody to the recombinant mouse ECD showing a 
broad band centred around an apparent molecular weight of ~100 kDa, with no evidence of 
positive binding to the recombinant human ECD which is possibly due to a change in the 
binding epitope upon denaturation of human ECD. It also bound to both mouse and human  
cell-derived PTPRJ with apparent bands around the molecular weight of 200 kDa that reflect 
the binding of the B12 antibody to the native full length of PTPRJ (Gaya et al., 1999, 
Autschbach et al., 1999). Thus, unless the recombinant material changes conformation 
differently to the cell-derived PTPRJ, the reason for lack of recognition of B12 with human 
recombinant PTPRJ is unknown. Recombinant B12 antibody bound to at least three other 
bands from the cell-derived PTPRJ. These other bands possibly represented PTPRJ that has 
undergone proteolytic cleavage (Mahmood and Yang, 2012) or (less likely) variant isoform 
of the actual PTPRJ (http://asia.ensembl.org/index.html, PTPRJ ENSG00000149177, splice 
variants). A clearer image may be obtained by performing a membrane preparation of the 
cells prior to PAGE separation to ensure only membrane-bound proteins are included in the 
analysis. 
shdAb antibody, on the other hand, showed no evidence of binding to the denatured 
recombinant or native PTPRJ in western blot. It is not surprising that some antibodies cannot 
be used for western blotting where the binding relies on structural integrity of the antigen‘s 
conformational epitopes (Mahmood and Yang, 2012, Kurien and Scofield, 2006). Results 
from dot blotting confirmed the binding of B12 antibody to the recombinant and native 
mouse and human PTPRJ. It also indicated the binding of the shdAb antibody to the 
recombinant mouse and human PTPRJ and some weak binding was observed with the native 
PTPRJ. Although that dot blot is a useful immunoassay for a rapid screening of protein 
interactions that require native conformation (Oprandy et al., 1988), this assays is not highly 
specific and can give false positives due to cross-reactivity of the detecting antibody with 
other proteins in the sample. Western blot has the advantage of detecting any cross-reactivity 
of the antibody with other proteins in the mixture by the known molecular weight of the 
protein of interest. 
Flow cytometry was the method used   to evaluate the binding of the isolated antibodies to 
the native PTPRJ presented in its original conformation on the cell membrane. Flow 
cytometry results indicated that B12 and shdAb antibodies are able to cross react with both 
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native mouse and human PTPRJ. The binding of the B12 and shdAb antibodies to cellular 
PTPRJ was also confirmed by immunofluorescence staining. Immunofluorescence is an 
excellent method to detect the localisation of PTPRJ protein from fluorescence images of 
B12 and shdAb antibodies binding. Localisation of proteins is frequently assessed in 
biological systems as inferences can be made regarding potential functional consequences 
(Singh et al., 2013, Roberts et al., 1989, Feracci et al., 1982). Previous immunofluorescence 
studies have demonstrated the association of PTPRJ with plasma membrane and membrane 
ruffling (Kellie et al., 2004, Dave et al., 2009). B12 and shdAb antibodies also detected 
PTPRJ on the plasma membrane in addition to the perinuclear area. The perinuclear staining 
might be due to the antibodies were detecting immature PTPRJ but it is most likely due to 
Golgi staining. However, other intracellular localisations of PTPRJ cannot be ruled out 
(Smart et al., 2012).  
The affinity of an antibody to its target antigen is an important feature that often governs the 
efficacy of the antibody. In this chapter, the affinity of B12 and shdAb antibodies was 
measured by surface plasmon resonance (Spring et al.) using BiaCore technology. Antibody 
and antigen interactions comprise 30% of all biosensor applications (Myszka, 1999, Rich and 
Myszka, 2000). SPR technology is capable of providing information about the rate of the 
kinetic and the equilibrium constants, KD, the affinity between the antigen and antibody, and 
has become the preferred technique in antibody-antigen interaction studies (Rich and 
Myszka, 2000). In Biacore analysis, the simplest situation is the formation of a 1:1 complex 
where the antigen is the analyte in solution, antibody is the ligand on the sensor chip surface 
and antigen-antibody is the complex formed on the surface between ligand and analyte (Bee 
et al., 2013, Ashish and Murthy, 2004).  
The reported KD of an antibody derived from the natural immune system is theoretically 
hypothesized to be around 10
−8
 to 10
−10
 M (Foote and Eisen, 1995, Poulsen et al., 2011). The 
binding affinity (KD) of B12 antibody was determined to be 7.45 x 10
-9 
M for mouse ECD 
and 2.17 x 10
-8 
M for human ECD which is consistent with the affinity of other antibodies 
isolated from naive libraries against a range of various antigens (Hoogenboom, 1997) and it 
is also in the range of the typical therapeutic antibodies KD of < 10-7 M (Daugherty et al., 
2000b). Therefore, if B12 showed useful biological activities, it could be used as a future 
therapeutic agent without the need for further in vitro affinity maturation. 
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shdAb antibody, in contrast, had approximately 2.86 x 10
-8 
M
 
affinity for its target antigen 
(human ECD of PTPRJ). This antibody derived from the immunized shark library and it is 
known that immunized libraries usually produce antibodies with greater affinity (Dooley et 
al., 2003b, Muyldermans and Lauwereys, 1999). The lower affinity observed for shdAb 
compared to B12 is due to the faster off-rate of the shdAb antibody. It is possible that the 
direct immobilisation of the shdAb antibody onto the CM4 chip had an influence on the 
correct estimation of the affinity of the antibody giving misleading results, compared to the 
capture system utilised for B12. There were several attempts to calculate the affinity of the 
shdAb antibody using the CM5 sensor chip, however, the affinity measurements was only 
obtained when CM4 sensor chip was used. The main difference between sensor chip CM5 
and CM4 that CM4 has a lower degree of carboxymethylation which is about 30% of that of 
Sensor Chip CM5, resulting in reduced immobilization capacity and also lower surface 
charge density. The lower immobilization capacity of this sensor ship can be advantageous 
for kinetic analysis experiments, where low ligand immobilization levels are recommended 
while the lower charge can also help to reduce non-specific binding of positively charged 
molecules to the surface (GE Healthcare,(2008)). While these seem like advantages of using 
the CM4, they might be not true for all applications, and possibly the lower charge of the chip 
results in a reduced ability of the antibody to immobilise irreversibly on the chip, or a 
reduced binding capacity of the antibody to its antigen.  
Kinetic experiments to determine the interaction between the isolated antibodies and their 
target antigens (recombinant mouse and human ECDs) were represented by a 1:1 interaction 
model. However, a better fitting of the generated data with bivalent model was quite evident. 
The effects of the analysis model on the apparent affinities could be due to the varying 
structural restrictions placed on the binding domains by the adjacent Fc domains, which 
sometimes does not allow for optimal protein positioning during the formation of the antigen-
antibody complexes. In the case of the bivalent interaction, there might be fewer structural 
restrictions due to Fc fusion, while the 1:1 complex formation is possibly more affected by Fc 
fusion, leading to a reduction in the overall binding affinity (Pabbisetty et al., 2007a). 
In summary, the binding of B12 antibody derived from the naïve human library and a shdAb 
antibody derived from the immunized shark library to recombinant and native PTPRJ was 
confirmed, and the affinity of both antibodies was relatively strong. The next task was to test 
these antibodies for their biological effect in in vitro bioassays.  
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PTPRJ is associated with the regulation of density-dependent inhibition of cell growth. 
(Ostman et al., 1994). The expression of PTPRJ in migrating and proliferating endothelial 
cells was found to be down-regulated following vascular injury (Borges et al., 1996), and 
overexpression of PTPRJ resulted in distinct morphological changes with a significant 
reduction in the ability of the cells to adhere and spread. These findings support the inhibitory 
role of PTPRJ in cell growth, signalling and propagation in non-hematopoietic cells (Kellie et 
al., 2004, Borges et al., 1996). 
B12 and shdAb antibodies were tested for their effect on the proliferation of murine and 
human cell lines however, no significant effect on the rate of cell proliferation was observed 
between the cells that were treated with anti-PTPRJ antibodies and the cells that were treated 
with the control isotype-matched antibody.  
During MTT assay, viable cells with active metabolism will convert MTT into a purple 
colored formazan product which accumulates as an insoluble precipitate inside the cells or is 
deposited near the cell surface and in the culture medium (Tada et al., 1986, Denizot and 
Lang, 1986). For cell populations in log phase of growth, the amount of formazan product is 
usually proportional to the number of metabolically active viable cells. Taking into 
considerations that cells were plated to generate the MTT results over a period of 4 days, and 
they reached the confluency of 100% during the last time point, it is likely that the cells were 
affected by the culture conditions that altered their metabolism which then affected the rate of 
MTT production into formazan. For instance, when adherent cells reach confluency and 
growth becomes contact inhibited, metabolism may possibly slow down and the amount of 
formazan production per cell will be lower (Hynes et al., 2003).  
To further explore the impact of the isolated antibodies on cell differentiation, mouse 
mammary epithelial cells (HC-11 cells), were selected as a model system to study the effect 
of B12 and shdAb antibodies on the regulation of mammary lactogenic differentiation in 
vitro, since previous work had shown that increased expression of PTPRJ inhibited 
differentiation in this cell line (Smart et al., 2012). HC-11 cells have the ability to 
differentiate and synthesize milk proteins in response to treatment with lactogenic hormones 
resulted on the formation of dome shaped cell structures referred to as mammospheres 
(Blatchford et al., 1995). Lactogenic differentiation of HC-11 cells was induced by the 
addition of a combination of lactogenic hormones including dexamethasone, insulin, and 
prolactin, referred to as DIP (Morrison and Cutler, 2009). The induction of differentiation of 
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HC-11 cells in the presence and absence of anti-PTPRJ antibodies showed a dramatic 
influence on the number of domes that were able to form in the present of the B12 antibody, 
reducing mammosphere number by almost 70%. Although that both B12 and shdAb 
antibodies-treated cells showed a significant inhibition in the number of domes, the reduction 
in the number of domes was greater with B12 antibody. It has been reported that 
overexpression of PTPRJ, reduced HC-11 dome formation in vitro (Trapasso et al., 2000, 
Keane et al., 1996, Smart et al., 2012) and this experiment also revealed that altering the 
function of PTPRJ by the addition of anti-PTPRJ antibodies, negatively affects the 
differentiation process of mammary epithelial cells. To understand the mechanism underlying 
the effect of anti-PTPRJ, it would be useful to know whether antibody-induced dimerization 
inhibits or enhanced tyrosine phosphatase activity. This question could be addressed by 
repeating the experiment to include monovalent Fab fragments in the analysis.  
Previous reports have indicated that PTPRJ regulates the actin-based cytoskeleton, and that 
an antibody against PTPRJ can also affect actin configuration in cells (Kellie et al., 2004, 
Dave et al., 2009). To address the influence of PTPRJ-mediated cytoskeletal rearrangements, 
anti-PTPRJ antibodies were coated on to multi-wall slides, and the ability of cells to spread 
and rearrange F-actin was investigated using phalloidin staining. Both HeLa and HC-11 cells 
adhered to and spread on B12-coated substrata. Phalloidin staining showed dramatic changes 
in F-actin configuration in the cells spreading on B12 antibody compared with isotype-
matched control antibody. Interestingly the cells did not spread on shdAb-coated substrata 
which is possibly due to the lower affinity of this antibody for PTPRJ. The enhancement of 
HeLa and HC-11 cell adhesion in the presence of B12 antibody confirmed the association of 
PTPRJ with the cytoskeletal rearrangement. However, it is not clear whether the actions of 
the antibody were due to the relocation/stabilization of PTPRJ on the cell surface, or due to 
the inhibition or activation of its phosphatase activity as an intracellular effect.  
In addition to the effect of PTPRJ on cytoskeletal rearrangements (Petermann et al., 2011, 
Dave et al., 2009, Luo et al., 2013), changes in the level of PTPRJ expression also found to 
have a profound effect on cell motility (Lampugnani, 2003, Kellie et al., 2004). An anti-
PTPRJ has previously been shown to inhibit monocyte chemotaxis in vitro bioassays (Dave 
et al., 2009, Petermann et al., 2011) therefore, next study was aimed at exploring the effects 
of our recombinant monoclonal antibodies on cell motility. Scratch assay is an in vitro 
correlate of ―wound healing‖ and it was established as a simpler model of cell motility since 
the attempts that were made to form monocyte chemotaxis assays showed inconsistent cell 
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motility (Al-Mansour and Kellie, data not shown). B12 and shdAb antibodies were initially 
tested on HeLa cell wound healing assay, as a cell type that forms monolayers and expresses 
PTPRJ. Surprisingly, treatment with B12 antibody significantly enhanced wound healing 
compared to the shdAb antibody and the isotype matched control antibody. In an effort to 
determine whether B12 antibody can have a potential therapeutic use, similar experiments 
were performed using HaCaT cells, a keratinocyte cell line that also expresses PTPRJ 
(Muscat, Al-Mansour and Kellie, unpublished). Similar to its effect on HeLa cells, B12 
antibody also found to enhance wound healing on HaCaT cells significantly. Wound healing 
occurs as a cellular response to injury and involves activation of endothelial cells, fibroblasts 
and macrophages (Harmon et al., 2011, Caiado et al., 2011). Since the anti-PTPRJ caused 
rapid ―wound‖ healing, and taking into consideration that these antibodies showed no effect 
on cell proliferation, it can be concluded that the B12 antibody must be enhancing cell 
migration into the cleared area causing rapid closure of the wound. It is important to note that 
the in vitro wound healing potential of anti-PTPRJ antibody or any other related bioactive 
compounds has not been reported previously and this study could leads to a new discovery of 
PTPRJ function. 
In summary, by using phage display technology, two positive scFv were successfully isolated 
from two different libraries, reformatted, expressed and purified. Characterisation of these 
two antibodies showed differential binding to recombinant mouse and human ECDs and cross 
reactivity with native mouse and human PTPRJ. The B12 antibody had bioactivity in in vitro 
bioassays of cell adhesion and wound healing suggesting a potential use of this antibody as a 
therapeutic agent. shdAb, the single domain antibody, that was generated from panning on 
the human ECD using the shark immunised library had no major effect on the few bioassays 
that were performed. However, further investigation using different cell lines and different 
approaches may reveal other as yet undiscovered biological functions of this antibody. Since 
one antibody appears to have bioactivity and another does not, epitope mapping of each may 
reveal the underlying mechanism for this differential activity. 
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CHAPTER 5 
 
Final discussion, future direction and 
conclusion. 
 
PTPRJ was the first tyrosine-specific PTP to be assigned a convincing role as a tumour 
suppressor in relation to the development of several human cancers. Positional cloning 
demonstrated that PTPRJ is the underlying mouse gene responsible for the susceptibility to 
colon cancer, and the loss of heterozygosity (Troll et al.) at the human PTPRJ locus was 
observed in 19 of the 39 human colorectal adenocarcinomas (Ruivenkamp et al., 2003, 
Ruivenkamp et al., 2002). LOH of PTPRJ was also detected in 11/76 (14.5 %) thyroid 
tumours (adenomas and carcinomas). Previous data suggested that PTPRJ polymorphisms 
can affect susceptibility to thyroid carcinomas, proposing that the presence of hemizygosity 
for these polymorphisms in the tumour facilitates tumour progression (Iuliano et al., 2003). 
LOH of the PTPRJ gene was observed in an average of 38% of human meningiomas of all 
grades (Petermann et al., 2011). Several findings implicate PTPRJ and its putative ligand in 
the development of colon, breast, thyroid and lung cancer and it was suggested that PTPRJ 
activity is potentially regulated by ectodomain-mediated oligomerization and that PTPRJ is a 
molecular target for anti-angiogenesis, anti-cancer and anti-inflammatory therapy. 
 Despite the therapeutic potential of PTPRJ, as yet no human antibodies against the 
ectodomain region of PTPRJ are available and the function of PTPRJ as a therapeutic target 
cannot be evaluated.  
The project described in this thesis endeavoured to characterise the biological function of the 
extracellular domain region of this protein tyrosine phosphatase receptor by isolating 
monoclonal antibodies that react specifically with the extracellular domains of mouse and 
human PTPRJ using phage display technology. 
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Monoclonal antibodies (mAbs) have become irreplaceable tools for a wide variety of 
applications, including biological research, diagnosis and targeted therapy (Galluzzi et al., 
2012). While mAbs were conventionally produced in murine hybridoma cell lines, several in 
vitro methods have been developed for production of antibodies (Bradbury et al., 2003a, 
Bradbury et al., 2003b) in contrast to in vivo animal-based methods. The most frequently 
used technology among other in vitro strategies is phage display technology (Hust and Dubel, 
2004) which is recognized as one of the most powerful tools for production and selection of 
recombinant antibody fragments with specific binding properties from a vast number of 
variants against a wide range of target molecules, such as proteins, glycoproteins, nucleic 
acids, oligosaccharides, toxins or low molecular weight compounds such as haptens (Willats, 
2002, Yau et al., 2003). The availability of this technique enables not only the recombinant 
expression of the original full-size antibody, but allows antibody engineering towards 
innovative diagnostic or therapeutic applications such as minibodies, Fab fragments, and 
single-chain variable fragments (scFv) (Holliger and Hudson, 2005). 
We hypothesized that PTPRJ regulates motility in monocytes and proliferation and 
differentiation in epithelial and endothelial cells. We also hypothesised that extracellular 
cross-linking of PTPRJ modulates its intracellular phosphatase activity, resulting in altered 
cell function. Both hypotheses were impossible to be tested without the availability of 
specific antibodies against the ECD region of PTPTRJ. Therefore, the overall aims of this 
project were to isolate monoclonal antibodies specific to the ECDs of mouse and human 
PTPRJ using the phage display technology and to use these antibodies as tools to investigate 
the function of PTPRJ in diverse biological functions.    
The basic plan to fulfil these aims was to clone and express the ECDs of mouse and human 
PTPRJ and to use these recombinant ECDs as antigens for the biopanning procedure. 
However, expressing the ECDs of mouse and human PTPRJ has proved to be much more 
challenging than first anticipated.  
To generate antibodies that are able to bind to the native form of PTPRJ by phage display, 
panning should be performed on antigens that represent the native protein structure, including 
disulphide bonds and glycosylation. A prokaryotic expression system has the advantages of 
high expression level, short time of expression, easy operation, low cost and easy cultivation. 
However, prokaryotic cells lack the endoplasmic reticulum and Golgi apparatus which are 
associated with glycosylation. Therefore, proteins expressed in bacteria often are non-
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functional because the cells are not equipped to accomplish the required post-translational 
modifications and molecular folding. Additionally, many proteins become insoluble as 
inclusion bodies which are very problematic to recover without harsh denaturants and 
subsequent cumbersome protein-refolding procedures (Demain and Vaishnav, 2009, Zerbs et 
al., 2009, Chen, 2012). On the other hand, protein generated by mammalian cell expression is 
almost equivalent to the native proteins in terms of structure, glycosylation style and the way 
of glycosylation (Khan, 2013, Nettleship et al., 2010, Hartley, 2012). Taking into 
consideration that the ECD sequence of PTPRJ is highly glycosylated and is predicted to 
contain approximately 37 potential protein N-glycosylation sites (Honda et al., 1994, 
Kuramochi et al., 1996, Ostman et al., 1994), the mammalian cell expression system was the 
logical method to express the ECDs as antigens for the phage panning. Different vectors and 
expression systems were used to generate the recombinant ECDs but only one method proved 
to give sufficient yield and quality of PTPRJ suitable for subsequent use as target antigens for 
phage library panning. By using the modified Gene-Switch system, comparatively high yield 
of the recombinant proteins were expressed and harvested from the culture supernatants. The 
reason that among all other expression attempts, only this modified inducible expression 
system was able to drive the expression of the recombinant ECDs, was not clearly 
understood. Further investigations of the expression of PTPRJ ECDs using another 
expression vectors with GAL4 promoter will be appropriate to detect whether it was the 
promoter that effecting the expression or another causative. The main aim of expressing the 
ECDs was to use them as antigens for the phage panning therefore; getting the required yield 
of the recombinant ECDs was the most important task rather than determining the reasons for 
the vector-dependent differences in expression 
Due to the difficulties that were encountered during the expression of the recombinant ECDs 
of mouse and human PTPRJ, BSA conjugated peptides were used as alternative panning 
antigens in the first phage panning strategy. This panning methodology enables selection of 
phage antibodies targeting specific epitopes on the surface of protein and eliminates the 
requirement of epitope mapping of the antibody binding. However, one disadvantage of using 
this method for biopanning arises from the conformational stability of the antigen; since some 
selected phage antibodies against adsorbed antigens cannot bind the antigen in its native 
conformation (Sanna et al., 1995). During panning on the BSA conjugated peptides, 
subtractive panning was performed using unconjugated BSA to eliminate the nonspecific 
binders. Nevertheless, the isolated antibodies from panning on the conjugated peptides 
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proved to be nonspecific to the target antigens. The antibodies that were generated from 
panning on conjugated peptides, could bind to the peptides when they are conjugated to the 
carrier molecule but not to the peptides or the carrier molecule alone.  This phenomenon has 
been observed before; Moghaddam et al reported that they frequently isolate antibodies from 
phage libraries which can bind to low molecular weight molecules such as amphetamine and 
steroids, but only when conjugated to a carrier molecule, and do not bind to the carrier alone  
(Moghaddam et al., 2001). In fact, subtractive panning should remove any antibody binding 
to the carrier protein, but not those antibodies binding to the bridging group linking the 
carrier protein and the peptide. As a consequence, the linkage itself is involved in the epitope, 
thereby panning antibody libraries with BSA-peptides conjugates may favour the enrichment 
of antibodies that preferentially bind the conjugated peptides rather than the peptides alone 
(Chames et al., 1998, Moghaddam et al., 2001), but this strategy can require very high 
concentration of free peptides to elute high affinity binders. 
For future consideration, when using conjugated peptides, subtractive panning should 
performed on the carrier molecular that was conjugated to an unrelated control peptide to 
eliminate the carrier and the linkage binders rather than eliminating the carrier binders only. 
This strategy will reduce the number of non-specific phage antibodies isolated and increase 
the possibility of isolating antibodies with high specificity to the desired antigens. The other 
strategy described by Moghaddam et al, is to use free peptide to elute the phage from the 
carrier protein, ensuring that the eluted phage binds to the desired soluble peptide 
(Moghaddam et al., 2001). 
When the recombinant mouse and human ECDs became available, another phage panning 
was performed using the naïve human mAbLAb library and the immunised shark library. 
Using the naïve human library, one antibody from panning on the recombinant mouse ECD 
was isolated and reformatted as a complete fully human antibody. In contrast, panning on the 
recombinant ECD of human PTPRJ using the same library was not successful. The 
enrichment of the phage binders was very poor and no positive clones were identified from 
the monoclonal ELISA following fourth and fifth rounds of panning. Taking into 
consideration that PTPRJ is widely expressed in many cell types, including epithelial and 
endothelial cells, fibroblasts, and most haematopoietic cells (Heddy, 2007, Lin et al., 2004, 
Acton, 2012), it is not surprising that attempts to isolate positive binders against human ECD 
from a naïve human library failed, as it would be expected that the immune system will 
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reduce or eliminate potentially autoimmune responses against this protein by the mechanism 
of central or peripheral tolerance (Medzhitov et al., 2012, Fenner, 1983). 
To increase the chance of isolating positive clones against the recombinant ECD of human 
PTPRJ from phage panning, another panning strategy was performed using an immunized 
shark library. According to FANTOM 5 analysis of the PTPRJ expression, it was revealed 
that dendritic cells have a high level of PTPRJ expression thus, there was a greater possibility 
that a library generated from sharks immunized with dendritic related cells would contain 
binders to human PTPRJ. One PTPRJ-binding clone that bound at a maximum absorbance 
was isolated from panning on the human ECD using the shark library, but because shark 
antibodies are composed of a heavy-chain homodimer that does not associate with light 
chains (Muyldermans et al., 1994, Greenberg et al., 1995, Dooley et al., 2003a), and due to  
the isolation of the VHH region only from selection using the shark phage library, it was 
challenging to select the best strategy for reformatting this positive clone into a humanized 
antibody. Two models have been proposed concerning the reconstruction of the isolated 
positive clone from the shark library panning.  First was to amplify the variable region from 
the phage clone and ligate it into both the heavy and light chain vectors to express a typical 
chimeric antibody (Sh4V). However, analysis of the purified Sh4V antibody revealed that the 
whole mAb structure for Sh4V was unstable, probably due to electrostatic repulsion from the 
identical sequences of the variable heavy and light chains (pI = 8.44, positively charged in 
cell culture supernatant, pH = 7.3). The second proposed plan for reformatting was to amplify 
the variable region and reformat it as a single domain antibody which would be very similar 
to the native shark antibody structure but with a human FC region (shdAb). Analysis of 
purified shdAb antibody indicated that reformatting the shark variable region into a single 
domain antibody resulted in an antibody that has better stability. 
Therapeutic monoclonal antibodies are an expanding segment in the quest for novel drugs to 
treat cancer and chronic diseases, yet only mAbs that recognize native epitopes can be 
considered as therapeutic candidates (Bee et al., 2013). Many steps in the mAb discovery 
process, such as phage display, mainly rely on the use of purified antigens, which are often 
from recombinant sources and may present non-native epitopes. While generating a mAb 
with an optimum affinity for the target antigen is an important factor in achieving a safe and 
efficacious therapeutic agent, the biophysical in vitro characterization of antigen/mAb 
interactions under physiologically relevant conditions can be challenging (Bee et al., 2013). 
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The binding of B12 antibody that was generated from the naïve human library and shdAb 
antibody that was generated from the immunized shark library to the recombinant and cell-
derived PTPRJ was confirmed. Various methods were used to measure the interaction of 
these antibodies with their antigens such as ELISA, western blot, flow cytometry, 
Immunofluorescence and immunoaffinity chromatography. Although these methods have 
confirmed the binding of our isolated antibodies, many of those methodologies are only 
designed for detecting protein-protein interactions, but are not generally suitable for the 
measurement and analysis of molecular interactions in real-time.  
The reported KD of an antibody derived from a naive immune system is theoretically 
calculated to be around 10
−8
 to 10
−10
 M (Foote and Eisen, 1995, Poulsen et al., 2011). The 
binding affinity (KD) of B12 antibody was determined to be 7.45 x 10
-9
 M for mouse ECD 
and 2.17 x 10
-8
 M for human ECD which is consistent with the affinity of other antibodies 
isolated from naive libraries against a range of various antigens (Hoogenboom, 1997), and is 
also in the range of the typical therapeutic antibodies with KD < 10
-7
 M (Daugherty et al., 
2000a). shdAb antibody had slightly lower affinity at 2.86 x 10
-8
 M for its target antigen 
(human ECD of PTPRJ). Whereas one might presume that tighter binding is always better, 
several studies have shown that very high affinities can be suboptimal for some therapeutic 
antibodies (Adams et al., 2001). Weaker binding can release antibodies from the first 
encountered antigens on the outside of a tumour permitting them to penetrate deeper into 
tissues, ultimately leading to uniform intra-distribution and higher target uptake. The right 
balance in terms of affinity will lead to efficient antigen targeting and antigen retention. Due 
to the fact that these properties depend on several factors, including internalization, antigen 
density, association and dissociation rates, the optimal affinity is not always easy to engineer 
(Chames et al., 2009). 
After it was confirmed that both isolated antibodies were able to recognise and bind to the 
recombinant and cell-derived PTPRJ, preliminary in vitro bioassays to test the biological 
effect of these antibodies were conducted. B12 antibody, derived from the naïve human 
library and which cross-reacts with human and mouse PTPRJ, significantly inhibited murine 
mammary cell differentiation and enhanced in vitro wound healing of epithelial cells and 
keratinocytes, suggesting a potential use of this antibody as a therapeutic agent. shdAb, the 
signal domain antibody, that was generated from panning on the human ECD using the shark 
immunised library had no major effect on the limited number of bioassays that were 
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performed. However, further investigation using different cell lines and different approaches 
may reveal other, as yet undiscovered, biological effects of this antibody. 
Monoclonal antibodies can have various modes of actions in vitro (Borrebaeck and Carlsson, 
2001). The simplest mode of action is when binding of the antibody interferes with the 
activity of the antigen, for example by inhibiting interaction with binding partners and 
ligands. On the other hand, the antibody may target a receptor displayed at the cell surface, as 
in the case of PTPRJ, and block its interaction with a ligand, interfere with a multimerisation 
process or trigger internalisation of receptors or apoptosis of targeted cells (Chames et al., 
2009). Although it was clear that isolated B12 antibody has important biological functions, as 
shown by the in vitro bioassays, the mode of the B12 antibody action leading to these 
significant effects is not clearly understood and requires further investigation.    
 In this project, we have demonstrated that antibodies against the ECD region of PTPRJ have 
potentials as therapeutic agents. The effect that was observed on cell adhesion and spreading 
with B12 antibody indicated that PTPRJ interacts with the cytoskeleton, either directly or 
indirectly, and that ligation of the extracellular domain of PTPRJ leads to cytoskeletal 
rearrangements thus affecting cell motility and infiltration. PTPRJ has been associated with 
autoimmune diseases and clearance of bacterial infections. Neutrophil-responses to 
Staphylococcus aureus bacterial infection have been previously investigated. It was 
confirmed that CD45 and PTPRJ have critical and redundant functions in regulating 
neutrophil adhesion, phagocytosis, superoxide release and bacterial killing. Therefore, 
deficiency in either of these RPTPs influenced neutrophil-dependent bacterial clearance (Zhu 
et al., 2011). PTPRJ has also been associated with an autoimmune disease, Cogan‘s 
syndrome, which is a chronic inflammatory disease characterized by sensorineural hearing 
loss, keratitis and vasculitis (Lunardi et al., 2002). This was demonstrated by the presence of 
autoantibodies to PTPRJ in the patients, which inhibited proliferation of PTPRJ-expressing 
cells and replicated the features of Cogan‘s disease when infused into mice (Lunardi et al., 
2002). These studies have implicated PTPRJ in inflammatory responses thus, our isolated 
antibody possibly represents a novel anti-inflammatory agent, though this remains to be 
investigated.     
In addition, the effect of B12 antibody on mammary epithelial cell differentiation indicates 
that PTPRJ may regulate differentiation of normal mammary epithelia and that dysregulation 
of protein cross-linking or localisation may be associated with tumorigenesis (Smart et al., 
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2012). Induction of PTPRJ expression also found to inhibit breast cancer cell growth by 5-10-
fold in vitro identifying PTPRJ as a regulator and an inhibitor of breast cancer cell growth 
and differentiation (Keane et al., 1996). A reduction in the proliferation, survival and 
tumorigenicity of several cell types upon ectopic expression of PTPRJ further suggests a 
tumor suppressor role for this protein (Jandt et al., 2003, Keane et al., 1996, Zhang et al., 
1997). The inhibitory activity of B12 antibody on mammary cell differentiation may not lead 
to the development of an anti-PTPRJ based anticancer therapeutic, but it shows proof of 
principle that ligation of PTPRJ in epithelial cells can modulate cells differentiation. A 
common aspect of many tumours is dedifferentiation thus it would be interesting to test 
whether monovalent antibodies (as opposed to the bivalent antibodies used here) might have 
the opposite effect and encourage cell differentiation. In addition, identification of the epitope 
that had an effect on cell differentiation when it bond to B12 antibody, might lead to the 
development of different ligands that could enhance cell differentiation. 
Due to the reported association of PTPRJ with cell proliferation (Lampugnani, 2003, Kellie et 
al., 2004), motility and migration (Petermann et al., 2011, Dave et al., 2009, Luo et al., 2013),  
adhesion and cytoskeletal re-arrangement (Dave et al., 2009, Petermann et al., 2011), and due 
to the observation that keratinocytes express detectable levels of PTPRJ (Muscat, Al-MAnour 
and Kellie, unpublished), the potential in vitro wound healing effect of the isolated antibodies 
was also explored. Significant enhancement of in vitro wound healing was observed in both 
HeLa cells and HaCaT keratinocyte cell line. This is possibly due to the ability of anti-PTPRJ 
to stimulate fibroblast migration as it previously reported that fibroblast cell migration and 
proliferation are essential events for tissue repair and wound healing (Hakkinen et al., 2000, 
Basso et al., 2012). These findings added a new therapeutic potential to our isolated antibody 
as a bioactive agent that enhances wound healing and subsequently tissue repair.  
Several challenges were confronted during the progress of this thesis. Attempts to clone and 
express the complete ECD region of PTPRJ were more difficult than initially planned 
delaying the progress towards antibody discovery. A variety of different methods and 
expression vectors were tried before we successfully expressed and purified a satisfactory 
level of the recombinant proteins using the pGene vector. Although smaller parts of the ECD 
of PTPRJ have previously been cloned and expressed (Paduano et al., 2012, Iuliano et al., 
2009, Sorby et al., 2001, Takahashi et al., 2006), an attempt to express the complete ECD 
region has not been reported previously. Due to time limitations and because the aim of 
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expressing the ECDs was to use them as antigens for the phage panning, further 
troubleshooting of the problems associated with the previous attempts to express the ECDs 
was not developed. However, the observed dependence of the vector system used should be 
further investigated to help guide other investigators looking to express large and complex 
extracellular domains as soluble protein. 
Another major problem was the isolation, reformatting, expression and purification of four 
recombinant monoclonal antibodies from panning using the BSA-conjugated peptides. 
Unfortunately, it was confirmed that the generated antibodies were not specific to the targeted 
antigens and they were binding to a common part on the conjugated peptides. Although 
binders to the BSA carrier were eliminated during negative selection on BSA, the phage 
binders to the junction between the BSA protein and the acetylated N-terminal cysteine 
remained present during panning and they were likely enriched in the absence of other 
positive binders. This problem caused significant delays since work towards reformatting and 
characterisation of the antibodies binding to cells was undertaken before realising that they 
were not specific to the PTPRJ peptides. 
The main drawback of this thesis is the lack of tools such as control monoclonal antibodies 
that can be used for comparison. Our isolated antibodies are the first fully human and 
humanised monoclonal antibodies against the ECD sequence of PTPRJ and it was difficult to 
find an equivalent positive control antibody for our characterisation and bioassays. 
Previously, the lab has used mouse antibodies generously provided by Prof Art Weiss 
(UCSF), however only limited amounts of these antibodies were available and their use was 
restricted. 
During early stage of the project, attempts were made to obtain positive control antibodies 
from commercial custom antibody providers. This backup plan (not reported in this thesis) 
was initiated by contracting Abmart (Shanghai, China) to raise the development of traditional 
murine monoclonal antibodies against PTPRJ peptides. By the use of Surface Epitope 
Antibody Library (SEAL technology), ten monoclonal antibodies from six predicted surface 
peptide antigens were delivered using the traditional immunization method in mice. I then 
characterized the binding and the specificity of these MAbs by flow cytometry, western 
blotting and immunofluorescence. Although these were mouse monoclonal antibodies and 
possibly binding to different epitopes than our isolated antibodies, we planned to use them 
alongside our generated antibodies by the phage technology to compare the affinity and the 
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specificity of the antibodies generated by these two different techniques, especially after they 
showed robust binding and specificity to the native PTPRJ. Unfortunately this line of 
research had to be terminated because of legal problems derived from the lack of appropriate 
export licences to export biologicals such as MAbs out of China by the contracted company. 
This was only discovered towards the end of this part of the project when we attempted to 
purchase and import the hybridomas (data not shown).  
For the negative control, there is no cell line known to be PTPRJ deficient to use it as a 
negative control for the characterization of the binding specificity of our generated 
antibodies. It was reported that CHO cells lack the expression of PTPRJ (Takahashi et al., 
2012) however, BLAST analysis of PTPRJ peptides and the use of these cells with our 
isolated antibodies confirmed that CHO cells do express a variant level of PTPRJ. Generating 
PTPRJ knockdown cells would be the best method to confirm the specificity of our isolated 
antibodies, however previous attempts in the lab to knock down PTPRJ using RNA 
interference were unsuccessful (Dave et al 2009; Smart et al 2012). It may have been possible 
to obtain tissues from PTPRJ knockout animals (Lin and Weiss, 2003, Trapasso et al., 2000), 
however that would preclude the use of these antibodies on viable cells.  
Despite all these difficulties and complications, this thesis has achieved all the aims and 
objectives that were anticipated to accomplish. Successful isolation of two recombinant 
monoclonal antibodies against the ECD sequence of mouse and human PTPRJ is the 
highlight of the research reported in this thesis. The preliminary experiments open up exciting 
possibilities for other associated projects that will expand our understanding of the 
mechanism of PTPRJ function, associated ligands, pathways and more therapeutic potentials. 
Future characterization of these isolated antibodies should focus on identifying the precise 
epitopes bound by the antibodies. Epitope mapping of the antibodies binding site will also 
benefit in identifying the part of the ECD of PTPRJ that was responsible for the observed in 
vitro cell adhesion, spreading, inhibition of cell differentiation and enhancement of wound 
healing. While both isolated antibodies were confirmed to bind to the native PTPRJ, 
significant effect in in vitro bioassays was observed only with B12 antibody but not with the 
shdAb antibody. This might be due to the different epitopes recognised by the antibodies. 
Determining where are these antibodies binding will help to identify the biologically active 
sites of the ECD region of PTPRJ.  Additionally, the fact that these antibodies have different 
effects leads to their use in different applications.  The shdAb antibody binds PTPRJ with no 
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biological effect, meaning it could be used as a diagnostic imaging reagent, whereas B12 
could be used as a therapeutic agent possibly in wound healing. 
To conclude, this thesis pioneered the use of the phage display technology to isolate 
antibodies against the ECDs of mouse and human PTPRJ in an effort to analyse the function 
of PTPRJ. We successfully isolated, reformatted, expressed, purified and characterised two 
monoclonal antibodies against mouse and human ECDs using naïve and immunized shark 
libraries. These antibodies lay the foundation for future studies that will elucidate the function 
of PTPRJ in various biological processes and will provide further insight into its role as a 
therapeutic target. 
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